Without Fauci, you wouldn’t have now either AIDS, Covid or gay/pedophile propaganda in kindergartens.
Later, maybe, but not so fast.

Also see

AIDS AND COVID ARE TWO COMMERCIAL BRANDS AND ONE BUSINESS MODEL BY FAUCI

PUPPIES?! FAUCI TORTURED ORPHAN BABIES AND CHILDREN IN HIS AIDS DRUG EXPERIMENTS

By Diane Bernard

May 20, 2020 at 4:40 p.m. EDT

“Act Up, Fight Back, Fight AIDS!” The angry chanting grew louder as hundreds of protesters wove through the usually placid campus of the National Institutes of Health in Bethesda on May 21, 1990.

With signs that read “Red Tape Kills Us” and “NIH — Negligence, Incompetence and Horror,” members of the AIDS Coalition to Unleash Power, or ACT UP, marched toward a row of police officers in riot gear guarding Building One. Suddenly, the pack parted and a small group of protesters ran through the middle of the crowd, right to the police line, bearing torches spewing rainbow-colored smoke. Chaos erupted between the screaming crowd and police, each pushing and shoving back and forth.

ACT UP’s “Storm the NIH” had begun.

“It was spectacular,” Mark Harrington, a leading member of the group, remembered in a phone interview.

As confused NIH scientists and administrators looked out of their windows, the 1,000-strong demonstration then marched to Building 31, which housed the offices of the protests’ target: Anthony S. Fauci, then and now the chief of the National Institute of Allergy and Infectious Diseases (NIAID).

For months, ACT UP had been formally urging Fauci to include their members in the government’s development process for AIDS drugs. Fauci, now under attack by some Trump supporters for his response to the coronavirus pandemic, was in favor of the group’s participation.

“I was trying to get them into all the planning meetings for the clinical trials,” Fauci said last week, taking time out from the coronavirus fight to look back at another deadly disease he managed 30 years ago. But he met increasing resistance from the scientific community, who were put off by ACT UP’s tactics.

“We were putting Tony in a tough spot,” acknowledged Peter Staley, the ACT UP leader who spearheaded the protest.

ACT UP had formed in New York City in 1987 as an angry response to government inaction on finding drugs and treatments for AIDS patients. The group was motivated by rage, helplessness and grief, Harrington said, as they stood by and watched thousands of friends and lovers die of the human immunodeficiency virus that led to AIDS — what was then called a “gay plague.”

As more and more gay men died in the mid-1980s, and homophobia flourished, ACT UP staged theatrical protests at the Food and Drug Administration, on Wall Street and at New York’s City Hall. The most famous was a 1989 die-in at St. Patrick’s Cathedral in New York to protest then-Cardinal John O’Connor’s opposition to teaching safe sex and distributing condoms.

The “Storm the NIH” protest was the culmination of the group’s public demonstrations about the deadly disease.

“We wanted a seat at the table,” Staley said, and for months before the protest pushed to have ACT UP organizers become voting members on all the scientific committees that set the research agenda at NIAID.

“One of the things that people in ACT UP said is that we are the people who are experiencing this novel disease, and we are the experts, not just the scientists and doctors,” said Garance Ruta, executive director of GEN magazine and an ACT UP member who was at the NIH protest.

The NIH demonstration also advocated for the group’s quest to reduce the dose and price of the only AIDS-fighting drug approved by the FDA at the time, AZT, made by Burroughs Wellcome Co.

“At $8,000 a year for users, AZT is said to be the most expensive prescription drug in history,” read a New York Times column in August 1989. The column also pointed out that about 35 percent of AIDS patients had either no health insurance or policies that did not pay for drugs.

Fauci was one of the younger scientists working on AIDS research at NIAID at the time, and Staley said ACT UP members began to get to know him. “All the older scientists thought we were crazy,” he said. “But Fauci wanted to hear what we had to say.”

“We liked Tony personally. He’s a brilliant scientist, a brilliant fighter of epidemics,” Staley said.

“I was becoming friends with some of them, like Peter Staley and Mark Harrington,” Fauci agreed. “I felt very strongly that we needed to get them into the planning process because they weren’t always right, but they had very, very good input.”

Fauci attended an ACT UP meeting in October 1989. After that, some of the group’s leaders on its Treatment and Data Committee would meet the NIAID chief and his deputy, Jim Hill, for dinner at Hill’s townhouse on Capitol Hill.

Fauci said he urged the scientific community and his own staff to include ACT UP members in the drug trial process. “I was pushing and pulling these people and screaming, ‘Hey, we have to deal with them,’ ” he said. “I was in a difficult position because I was trying to convince the establishment that ACT UP had something to offer.”

Fauci promised NIAID would become more inclusive, but after months with no action, ACT UP decided the only choice they had was a protest, Harrington said.

At a dinner with Fauci in March, Staley said, “Tony, we’ve got some bad news for you. We know you’ve been advocating for us on this. But we’ve decided to do a gigantic demonstration at the NIH, and it will be in front of your building.”

Fauci tried to talk them out of it, but Staley vowed not just to demonstrate, but to get arrested, too, according to Fauci.

Between March and May, ACT UP spread the word about “Storm the NIH” to its chapters across the country. The group took out full-page ads in The Washington Post.

ACT UP was renowned for creating what Staley called a six-ring circus at its demonstrations, and the NIH protest was no different. Gathering at the NIH gates that Monday morning in May, chapters were divided into “affinity groups,” each of which organized its own presentation, skit or protest focus.

“All the affinity groups gave themselves campy names, like CHER!, the Juicers or the Marys,” Staley explained. “I was in charge of a group called the Power Tools.”

A movie he saw featuring military pyrotechnics made him think about using colored smoke. He looked through a military magazine and learned smoke bombs in the shape of grenades were available in different colors. “I ordered all the colors of the rainbow, thinking, ‘That will make a statement,’ ” he said.

The day of the demonstration, he and Power Tools members taped the canisters to poles and hid them behind posters to get on campus.

Staley’s group stayed behind the bulk of the protesters, who marched ahead to confront about 200 police officers, some on horseback, who were clubbing some activists. Others set up a mock graveyard in front of Building 31, with tombstones describing deaths from “drug profiteers” or “AZT poisoning.”

Chanting, “NIH, you can’t hide, we charge you with genocide,” according to United Press International, affinity groups carried banners, posters, mock coffins, and effigies — including one of Fauci. One group staged a die-in. Another formed a human snake that slid its way through the raucous crowd, each section labeled with a different opportunistic AIDS infection.

“One guy even had Fauci’s head on a stick,” Staley said.

It might have seemed otherwise, “but this was not a protest against research,” Ruta said. “It was a protest on behalf of research.”

Staley and his crew lit the smoke bombs and ran through the parting crowd. A roar went up from protesters as billows of red, yellow, blue, purple and green smoke filled the air. An Associated Press photo of screaming activists under a cloud of rainbow smoke eventually made it onto the cover of newspapers across the country.

Meanwhile, Fauci, looking out his office window, grew frustrated. “I didn’t like that degree of disruption on campus,” he said, concerned the rowdy action would further alienate scientists from including ACT UP in the drug development process.

Then Fauci noticed a protester climbing onto the building’s front overhang. It was Peter Staley. Police officers pulled Staley off the roof, lowering him into a band of officers who immediately handcuffed him. Fauci said he raced down to the first floor to make sure Peter was okay.

“I didn’t want him to get hurt because there were mounted police and that could be dangerous,” he said.

“A big, burly African American cop dragged me through the first floor of the building, and who should I run into, but Tony Fauci,” Staley said.

“Peter?” Fauci said.

“Hey, Tony,” Staley responded with a grin.

“Are you guys okay?” Fauci asked.

Staley laughed. “See — I told you I’d get arrested,” he said, adding, “I’m just doing my job,” surprising the officer that his perpetrator knew the head of the institute.

Staley was the first arrest of the day, he said, with about 80 more arrests following, according to The Post.

In The Post story, Fauci was critical of the protest, expressing concern that it could hurt AIDS researchers’ morale.

“It was interesting theater,” Fauci said at the time, “but it was not helpful.”

The next day, The Post’s editorial page accused the group of harassing NIH scientists.

The next month, however, ACT UP could definitively declare victory. At the International Conference on AIDS in San Francisco, Fauci gave Harrington the good news: Activists, journalists and people with AIDS would be let into the AIDS Clinical Trials Group, Harrington said, and the trials would expand to include women of color, drug users and children.

It was a turning point — for both ACT UP and biomedical research, Harrington said.

All drug testing committees at NIH now have patient advocates, he noted, including NIH’s trial to test hydroxychloroquine and azythromicin.

Staley points out that community activists are now involved in coordinating efforts to combat covid-19, an outgrowth of ACT UP. Activists “are now in lockstep with scientists,” he said.

“Ever since the 1990 demonstration, we’ve been partners in fighting illnesses and diseases, and our enemies now are hesitant politicians and anti-science radio hosts,” he said. “We are now Fauci’s great defenders against the anti-science. And the world is better for it.” – WASHINGTON POST

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

In case you doubted the latest Project Veritas viral, you can stop doing that now.

SOMEONE PASS THIS TO RAND PAUL! 

… aaand the video is finally up!

Dr. Vladimir Zelenko (Zelenko Protocol):

THE UNITED STATES GOVERNMENT
CREATED THE COVID-19 BIOWEAPON, THE ANTIDOTE, THE POISONOUS DRUG REMDESIVIR, AND FUNDED THE POISON DEATH SHOT VACCINE.

The antidote was and is intentionally hidden from the public.

CONCLUSION:

Our government is the enemy of the people. Don’t listen to the demented puppet in the White House. Don’t listen to the murderous cdc, fda, nih.

-Our government made a weapon of mass murder

-Our government created an antidote that only the privileged have access to

-Our government is blocking access to the antidote to American citizens

-Our government is pushing a failed and deadly drug remdesivir.

———————————————————

Dr. Ralph Baric with funding from the NIH, NIAID created a weapon of mass destruction and murder.

Dr. Ralph Baric developed the antidote for the weapon using zinc/zinc Ionophores which is the basis of the Zelenko Protocol.

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1001176

In 1999 at the University of NC at Chapel Hill Baric figured out how to take a bat Corona virus and make it infect humans

In 2015 in Wuhan-funded
By NIH-Baric and Zengli figured out how to augment the lethality of this virus to lungs and cause blood clots.

https://news.yahoo.com/nih-admits-funding-gain-function-125103852.html

Raplh Baric also help develop The killer drug remdesivir for covid.

https://journals.asm.org/doi/abs/10.1128/mBio.00221-18

Ignore the fear rhetoric from the government.

Joe Biden warns of ‘winter of death’ for the unvaccinated, with Omicron ‘here now and spreading’

https://news.yahoo.com/joe-biden-warns-winter-death-070719247.html

Joe Biden should be in a diaper in a nursing 
home and not spreading fear.

Vladimir Zev Zelenko MD

journals.plos.org

Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses…

Author Summary Positive-stranded RNA (+RNA) viruses include many important pathogens. They have evolved a variety of replication strategies, but are unified in the fact that an RNA-dependent RNA polymerase (RdRp) functions as the core enzyme of their RNA…

t.me/zelenkoprotocol/2359

76.0KviewsZev Zelenko, 

Full text: Coronavirus Research Conducted by Dr. Ralph Baric’s Team at University of North Carolina2021-11-09 10:45

The full text of the non-paper entitled “Coronavirus Research Conducted by Dr. Ralph Baric’s Team at University of North Carolina.”

Dr. Ralph Baric and his team from the UNC have been systematically working on coronavirus-related researches for a long time, including Gain-of-Function (GOF) research. They possess synthetic biology techniques used for manipulation and modification of coronavirus genome and have applied for multiple patents related to coronavirus research.

In the aftermath of the SARS outbreak in 2003, the Baric team collaborated with the United States Army Medical Research Institute of Infectious Disease (USAMRIID) and developed a novel reverse genetic system for synthesis of a full-length cDNA of the SARS-CoV, which was published in a paper in 2003. The paper claimed that within two months after obtaining the RNA of the SARS virus, the full-length cDNA of the virus was successfully synthesized, which shows that as early as 2003, these institutes already had advanced capabilities to synthesize and modify SARS-related coronavirus.

In December 2008, Dr. Baric co-authored another paper on the successful reconstitution of a chimeric virus with the genome backbone from a bat SARS-like coronavirus and the receptor binding domain (RBD) from SARS-CoV using similar synthetic biology techniques, arguing that the design and synthesis of various SARS-related coronaviruses are important steps to prevent similar outbreaks in the future.

It is worth noting that the Baric team has close collaboration with the USAMRIID, and they co-own the patent related to manipulation of coronavirus genome and have published multiple papers together. The scope of this cooperative relationship was further expanded after Lisa Hensley, one of Dr. Baric’s students, joined the USAMRIID.

In November 2015, the Baric team published a paper titled “A SARS-like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence”. According to the paper, a chimeric coronavirus was made with the genome backbone from a mouse-adapted SARS-CoV virus provided by the U.S. team and the RBD from a bat SARS-related CoV SHC014 discovered by Zhengli Shi’s team from the Wuhan Institute of Virology. Dr. Baric’s lab tested the pathogenesis of the chimeric virus in mice and even reconstituted the full length SHC014 virus. In this study, both the virus modification and the experiment on mouse infection were conducted at the UNC and the chimeric virus was not provided to Shi’s team.

Some people in the United States claim that GOF researches by the Wuhan Institute of Virology have caused bat coronaviruses to mutate into SARS-CoV-2 and a lab leak led to the COVID-19 pandemic. As a matter of fact, the United States have sponsored and carried out more such researches than any other country. In particular, the Baric team leads the world in researches in this field. A thorough investigation into Dr. Baric’s lab will help clarify whether such researches have led to or can lead to SARS-CoV-2. 

Sure, Dr. Didntdonuffin, wanna investigate yourself on this?

This rabbit hole is really deep, so I will probably add more documents soon.

EPILOGUE?

+

AAAND BACK TO MAGNETOGENETICS AS US ARMY ANNOUNCES FERRITIN NANOPARTICLE VACCINE AGAINST ALL SARS VARIANTS!

Remember when ferritin in Covid bioweapons was a conspiracy theory and we were getting our YouTube channels and socials wiped out for exposing it? That was fun!

Close the circle with this essential reading:

THE MILITARY BIOTECH COMPLEX FROM ORIGINS TO THE DARK WINTER AND COVID

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

The Internets got agitated recently at the news that Moderna’s CEO, Stephane Bancel, dumped $400Million in Moderna stocks and nuked his Twitter account. Here’s why this shouldn’t surprise you and you should expect the worst any moment now.

Developing story, to be updated

Have you watched the former Blackrock director that went on Bannon’s War Room and prophesied that the Covid vaccines are a bubble that’s about to pop? Everything I’ve learned lately stands to support his claim.

This is him on Twitter:

If the dumping were a sudden and unusual move, this would indicate a recent event that shook the system, possibly rats leaving a sinking ship, a near threat for the business, as in:

That’s the case only partly, due to the stock crash overlapped with the incoming financial report, but a constant behavior over the span of months and years rather indicate a strategy and it’s associated with insider trading more often than not.

Surprisingly, it’s NPR of all the fakestream media who came in support of my suspicions, with a pretty merciless analysis of Moderna’s leadership financial behavior. And you know what’s funny? The piece dates all the way back to September 2020. I recommend reading the whole piece, I added the bolding and highlights :

Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs.

“On a scale of one to 10, one being less concerned and 10 being the most concerned,” said Daniel Taylor, an associate professor of accounting at the Wharton School, “this is an 11.”

Taylor said Moderna’s stock-selling practices appear well outside the norm, and raise questions about the company’s internal controls to prevent insider trading.

Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock held by himself or associated investment funds; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million.

Stéphane Bancel, chief executive officer of Moderna, has sold roughly $40 million worth of stock in the company since the beginning of this year.

The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May [2020 – S.m.]. At that point, the company’s share price jumped and official disclosures showed executives cashing in their shares for millions of dollars.

“As long as stocks are sold after public announcements – and not before – one might conclude that for an executive with significant net worth tied up in the company, it’s a prudent thing to do,” said Marc Fagel, a former longtime enforcement official with the Securities And Exchange Commission (SEC). “But the optics aren’t great.”

The Moderna vaccine was quick to reach a phase 3 trial, and is seen as a promising contender. But, in some ways, the executives’ stock sales have overshadowed the company’s progress.

Advocates have questioned whether it’s appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company’s vaccine development and manufacture.

Here’s what NPR’s examination found:

  • Stock Sales Worth Tens Of Millions: Since June 1, NPR has found, company executives have sold roughly $90 million worth of Moderna stock. Rather than put a hold on the trades after facing intense criticism in May, company executives continued to sell.
  • Questionable Modifications To Stock Sale Plans: Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules – known as 10b5-1 plans – can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company’s vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.
  • Selling To Zero: Generally, corporate best practices suggest that a company’s leadership should hold on to at least some stock in their company to have “skin in the game.” That way, the thinking goes, an executive has an incentive to improve the company’s performance. As Moderna has been developing its coronavirus vaccine, two executives, including the Chief Medical Officer, have sold all their stock holdings in the company. The General Counsel has sold nearly all of her holdings.

In an interview with NPR, Ray Jordan, Moderna’s Chief Corporate Affairs Officer, said the company has strict internal policies in place to prevent illegal insider trading. For example, Jordan said, the company only allows employees to make changes to their stock sale schedules when they don’t have confidential inside information that could affect the company’s share price.

NPR asked Jordan why Moderna executives modified their 10b5-1 plans just before major announcements. Initially, Jordan said by email, “I believe you must have your dates wrong.”

NPR then provided documentation of those dates from the company’s official disclosures to the government, which Jordan did not dispute.

Jordan then said that even though multiple Moderna executives changed their 10b5-1 plans within one business day of announcements, the company had determined that those executives did not have “material nonpublic information” – a key term for insider trading – when they made those changes.

A spokesperson for the SEC declined to comment for this story.

From a relative unknown, to a key player in the vaccine race

Moderna launched in 2010 with a headquarters based in Cambridge, Mass., focused on using a technology called messenger RNA (or mRNA) to develop vaccines and therapeutics. The mRNA technology has been widely considered innovative, but remains largely unproven. The company has never brought a product to market. In early January, Moderna was trading for under $20 per share, and was valued at around six billion dollars.

Then Moderna announced that it had started collaborating on a coronavirus vaccine with scientists from the National Institute of Allergy and Infectious Diseases, which is led by Dr. Anthony Fauci.

By April, the government had committed half a billion dollars to the Moderna vaccine project as part of Operation Warp Speed.

Since then, the company’s stock price has exploded. Press releases suggesting positive news from the scientific trials, or announcing additional commitments of taxpayer funding sent the share price to a peak of around $95, before dropping to between $60-$70 in recent months. The company is now valued at around $25 billion.

As a result, shares owned by Moderna executives suddenly became much more valuable. And those executives have cashed in tens of millions of dollars worth of stock, according to filings with the SEC.

The bad press and critical comments did not deter continued sales. Since June 1, NPR found, executives sold around $90 million worth of stock.

Public money, private gain

The U.S. government is making massive financial bets on several vaccine candidates. In all likelihood, only some of those vaccine candidates will prove sufficiently safe and effective.

“If the vaccine doesn’t work, you lost a lot of money,” Fauci has said. “But we feel this is serious enough that it’s worth the financial risk.”

But even if taxpayers lose money betting on Moderna, the company’s executives have already made millions.

“The insiders are making plenty of profit and they’re mostly doing it with our money,” said Margarida Jorge, a campaign director with the group Lower Drug Prices Now. “I’m absolutely for deploying public money in the interests of public health and the public good. But we don’t have any commitment from the administration that any of this investment is ultimately going to benefit real people.”

Moderna has argued that the company was only in a position to work with the government on a coronavirus vaccine, because it had spent a decade developing its mRNA technology with the support of private investors.

“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”

[But they locked in the Government and its funding for mRNA technology years before SARS-COV2, as shown below, so this was a deliberate lie – S.m]
Trying to resuscitate the company with some archive work?

“Set it and forget it” stock plans

Moderna has offered another defense of those stock sales: the sales, representatives and executives say, were scheduled well in advance, and were unrelated to the market-moving announcements about the coronavirus vaccine. An NPR examination of the company’s financial filings tells a more complicated story.

The schedules are known as 10b5-1 plans. If your stock trades are on autopilot, the idea goes, then you can’t be accused of insider trading. But these “set it and forget it” plans have to be adopted when executives do not have “material nonpublic information,” to use the legal term.

In an interview with CNBC in July, CEO Bancel said he and other executives set up their 10b5-1 plans “a long time ago” – in December 2018 – and “obviously, when we set up those plans, none of us had any idea what was going to happen in 2020.”

In fact, NPR has found, Moderna executives, including Bancel himself, implemented new plans or modified older plans at multiple points in 2020, and right around key announcements related to the company’s vaccine.

On Jan. 21, 2020, for example, Chief Medical Officer Dr. Tal Zaks amended his 10b5-1 plan. (It’s unclear what changes he made.)

Then, on Jan. 22, Moderna first widely confirmed that it was working with the government on a coronavirus vaccine. The following day, Jan. 23, the company announced it had received additional funding to support its coronavirus vaccine development.

NPR asked Moderna whether Zaks might have been aware of the collaboration with the government when he changed his stock trading plan.

“What was known on that particular day or not known, I couldn’t specifically talk to,” Moderna’s Jordan told NPR. But he said that the Moderna legal team only allows employees to change their 10b5-1 plans if they do not possess inside information that could affect the company’s share price.

Later, on Friday, March 13, three Moderna executives adopted new 10b5-1 plans, according to records reviewed by NPR: Zaks, Chief Technical Operations and Quality Officer Juan Andres, and then-Chief Financial Officer Lorence H. Kim. (Kim left the company in August 2020.)

On Monday, March 16 – one business day later – the company announced that it had given a participant the first dose of their vaccine as part of its phase 1 trial. The stock ended that day up 24% compared to the previous day’s close. Moderna was “bucking the trend” of the broader market, which was panicking over coronavirus fears, one CNBC host said at the time.

Timing Of Changes To Pre-Scheduled Stock Sales Raises Questions

Jan. 21 – Chief Medical Officer Dr. Tal Zaks amends his schedule of stock sales, known as a 10b5-1 plan.

Jan. 22 – Moderna widely confirms that it is working on a coronavirus vaccine with the National Institutes of Health. The company’s share price rises nearly 5% over the previous day’s close.

Jan. 23 – Moderna announces new funding from the Coalition for Epidemic Preparedness Innovations.

Mar. 13 – Chief Technical Operations Officer Juan Andres, Chief Financial Officer Lorence Kim, and Zaks adopt new 10b5-1 trading plans.

Mar. 16 – Moderna announces that it provided the first dose of its coronavirus vaccine to a participant in a phase 1 trial. Moderna stock climbs 24% over the previous day’s close.

May 18 – Moderna reports early positive data from its phase 1 trial. The company’s stock ends the day up 20% over the previous day’s close.

May 21 – CEO Stéphane Bancel adopts and amends multiple 10b5-1 trading plans.

May 29 – Moderna announces another milestone in its phase 2 coronavirus vaccine trial.

June 1 – President Stephen Hoge amends his 10b5-1 plan.

Despite the close timing, Jordan told NPR, “by the judgment of the legal team, there would not have been material, nonpublic information known” when executives entered into the new plans.

“Every company and individual is entitled to the presumption of innocence. That said, from the public’s perspective, this trading behavior looks very problematic,” said Taylor of the Wharton School, who first pointed out the timing of these changes to NPR.

“If I put on my SEC enforcement hat, I would certainly be asking, ‘What caused you to change the plan on a Friday?'” said Kurt Wolfe, who works as a defense attorney in securities cases for the firm Troutman Pepper. “I don’t think it’s a good fact pattern.”

On May 21 – in between announcements of major vaccine trial milestones on May 18 and May 29 – CEO Bancel amended and adopted 10b5-1 plans. And on June 1, President Hoge amended his trading plan.

“Amending a trading plan after a positive announcement, like trading after a positive announcement, is only problematic if the executive possesses material, nonpublic information at the time,” said Fagel. “Though repeated or questionably-timed changes to a trading plan will reduce its value as a defense to insider trading.”

Selling to zero

Using these 10b5-1 plans, two Moderna executives – Zaks and Andres – have sold all of their shares in the company. General Counsel Lori Henderson has sold nearly all of her shares.

In fact, roughly every week since June, Zaks has exercised stock options (meaning, he bought stock at a price set by the company as part of his compensation), and then immediately sold all of his shares for a significant profit.

[Isn’t this a great explanation for Bancel’s sales too?! – S.m]


On Aug. 24, for example, Zaks exercised stock options and bought 25,000 shares at bargain prices of between $12 to $21. He then immediately sold all of those shares for around $65 per share. Zaks ended up with a profit of nearly $1.2 million.

SEC filings indicate these trades are made under the 10b5-1 plan he adopted in March.

Selling so much stock can also raise concerns for investors – and the public – about why company leaders would sell now if they expected their vaccine to succeed later. After all, a safe and effective vaccine could send Moderna’s stock to even greater heights.

“It perhaps draws questions about how much they believe in it,” said Wolfe.

If the company does develop a safe and effective coronavirus vaccine, and its stock keeps rising, then “these trades will be water under the bridge,” said Fagel, the former SEC enforcement official.

But, Fagel warns, if the vaccine fails, then SEC regulators and angry investors may come looking for answers. In that case, he said, “both class action litigation and an SEC investigation would seem inevitable.”

NPR revelations end here, we’re actually just starting

So what we’ve learned is that Moderna looks like a stock market operation more than a medical one. The chiefs create momentums and then trade. And they use public money to bet and make billions, but more about that shortly.

This news is actually pretext to get you to know the real history of Moderna, a crux point in modern history in the widest sense. The stock dumping is not really news, it’s been happening for quite a while, indicating a long term strategy and business model, rather than a sudden or impulse move.

The next two older reports from Pharma’s own media – STAT, will cement the certainty that Moderna turned into a stock market bubble long ago, under the helms of Stephan Bancel. They don’t mind having some science to show, but that’s just the bait.

Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups

By Damian Garde for STAT, Sept. 13, 2016

At first glance, Moderna Therapeutics looks like the most enviable biotech startup in the world. It has smashed fundraising records and teamed up with pharmaceutical giants as it pursues a radical plan to revolutionize medicine by transforming human cells into drug factories.

But the reality is more complicated.

A STAT investigation found that the company’s caustic work environment has for years driven away top talent and that behind its obsession with secrecy, there are signs Moderna has run into roadblocks with its most ambitious projects.

At the center of it all is Stéphane Bancel, a first-time biotech CEO with an unwavering belief that Moderna’s science will work — and that employees who don’t “live the mission” have no place in the company. Confident and intense, Bancel told STAT that Moderna’s science is on track and, when it is finally made public, that it will meet the brash goal he himself has set: The new drugs will change the world.

But interviews with more than 20 current and former employees and associates suggest Bancel has hampered progress at Moderna because of his ego, his need to assert control and his impatience with the setbacks that are an inevitable part of scienceModerna is worth more than any other private biotech in the US, and former employees said they felt that Bancel prized the company’s ever-increasing valuation, now approaching $5 billion, over its science.

As he pursued a complex and risky strategy for drug development, Bancel built a culture of recrimination at Moderna, former employees said. Failed experiments have been met with reprimands and even on-the-spot firings. They recalled abusive emails, dressings down at company meetings, exceedingly long hours, and unexplained terminations.

At least a dozen highly placed executives have quit in the past four years, including heads of finance, technology, manufacturing, and science. In just the past 12 months, respected leaders of Moderna’s cancer and rare disease programs both resigned, even though the company’s remarkable fundraising had put ample resources at their disposal. Each had been at the company less than 18 months, and the positions have yet to be filled.

Lower-ranking employees, meanwhile, said they’ve been disappointed and confused by Moderna’s pivot to less ambitious — and less transformative — treatments. Moderna has pushed off projects meant to upend the drug industry to focus first on the less daunting (and most likely, far less lucrative) field of vaccines — though it is years behind competitors in that arena.

The company has published no data supporting its vaunted technology, and it’s so secretive that some job candidates have to sign nondisclosure agreements before they come in to interview. Outside venture capitalists said Moderna has so many investors clamoring to get in that it can afford to turn away any who ask too many questions. Some small players have been given only a peek at Moderna’s data before committing millions to the company, according to people familiar with the matter.

“It’s a case of the emperor’s new clothes,” said a former Moderna scientist. “They’re running an investment firm, and then hopefully it also develops a drug that’s successful.”

Like many employees and former employees, the scientist requested anonymity because of a nondisclosure agreement. Others would not permit their names to be published out of fear that speaking candidly about big players in the industry would hurt their job prospects down the road.

Moderna just moved its first two potential treatments — both vaccines — into human trials. In keeping with the culture of secrecy, though, executives won’t say which diseases the vaccines target, and they have not listed the studies on the public federal registry, ClinicalTrials.gov. Listing is optional for Phase 1 trials, which are meant to determine if a drug is safe, but most companies voluntarily disclose their work.

Investors say it’ll be worth the wait when the company finally lifts the veil.

“We think that when the world does get to see Moderna, they’re going to see something far larger in its scope than anybody’s seen before,” said Peter Kolchinsky, whose RA Capital Management owns a stake in the company.

Moderna
The Moderna offices in Cambridge, Mass.ARAM BOGHOSIAN FOR STAT

Bancel, meanwhile, said he is aware of the criticism of him and has taken some steps to address it. After scathing anonymous comments about Moderna’s management began showing up online, Bancel went to Silicon Valley to get tips on employee retention from the human resources departments of Facebook, Google, and Netflix. But he makes no apologies for tumult past or present, pointing to the thousands of patients who might be saved by Moderna’s technology.

“You want to be the guy who’s going to fail them? I don’t,” he said in an interview from his glassy third-floor office. “So was it an intense place? It was. And do I feel sorry about it? No.”

An ambitious CEO dreams big

Bancel, 44, had no experience running a drug development operation when one of biotech’s most successful venture capitalists tapped him to lead Moderna. He’d spent most of his career in sales and operations, not science.

But he had made no secret of his ambition.

A native of France, Bancel earned a master’s in chemical engineering from the University of Minnesota and an MBA from Harvard in 2000. As Harvard Business School classmates rushed to cash in on the dot-com boom, Bancel laid out a plan to play “chess, not checkers.”

“I was always thinking, one day, somebody will have to make a decision about me getting a CEO job,” he told an audience at his alma mater in April. “… How do I make sure I’m not the bridesmaid? How do I make sure that I’m not always the person who’s almost selected but doesn’t get the role?”

He went into sales and rose through the operational ranks at pharmaceutical giant Eli Lilly, eventually leading the company’s Belgian operation. And in 2007, at just 34, he achieved his goal, stepping in as CEO of the French diagnostics firm bioMérieux, which employs roughly 6,000 people.

The company improved its margins under Bancel’s tenure, and he developed a reputation as a stern manager who got results, according to an equities analyst who covered bioMérieux at the time.

“He doesn’t suffer fools lightly,” the analyst said, speaking on condition of anonymity to comply with company policy. “I think if you’re underperforming, you’ll probably find yourself looking for another job.”

Bancel’s rise caught the eye of the biotech investment firm Flagship Ventures, based here in Cambridge. Flagship CEO Noubar Afeyan repeatedly tried to entice him to take over one of the firm’s many startups, Bancel said. But he rejected one prospect after another because the startups seemed too narrow in scope.

Moderna was different.

The company’s core idea was seductively simple: cut out the middleman in biotech.

For decades, companies have endeavored to craft better and better protein therapies, leading to new treatments for cancer, autoimmune disorders, and rare diseases. Such therapies are costly to produce and have many limitations, but they’ve given rise to a multibillion-dollar industry. The anti-inflammatory Humira, the world’s top drug at $14 billion in sales a year, is a shining example of protein therapy.

Moderna’s technology promised to subvert the whole field, creating therapeutic proteins inside the body instead of in manufacturing plants. The key: harnessing messenger RNA, or mRNA.

In nature, mRNA molecules function like recipe books, directing cellular machinery to make specific proteins. Moderna believes it can play that system to its advantage by using synthetic mRNA to compel cells to produce whichever proteins it chooses. In effect, the mRNA would turn cells into tiny drug factories.

It’s highly risky. Big pharma companies had tried similar work and abandoned it because it’s exceedingly hard to get RNA into cells without triggering nasty side effects. But if Moderna can get it to work, the process could be used to treat scores of diseases, including cancers and rare diseases that can be death sentences for children.

Bancel was intrigued. He knew it was a gamble, he told STAT, “but if I don’t do it, and it works, I’m just going to kick myself every morning.”

And so he became the company’s CEO — and soon developed an almost messianic reverence for the mRNA technology.

Despite having never worked with RNA before, Bancel said he sat around the table with his core team in the early days of the company, dreaming up experiments. As a result, he is listed as a co-inventor on more than 100 of Moderna’s early patent applications, unusual for a CEO who is not a PhD scientist.

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

By Damian Garde, STAT, Jan. 10, 2017

SAN FRANCISCO — Moderna Therapeutics, the most highly valued private company in biotech, has run into troubling safety problems with its most ambitious therapy, STAT has learned — and is now banking on a mysterious new technology to keep afloat its brash promise of reinventing modern medicine.

Exactly one year ago, Moderna CEO Stéphane Bancel talked up his company’s “unbelievable” future before a standing-room-only crowd at the annual J.P. Morgan Healthcare Conference here. He promised that Moderna’s treatment for a rare and debilitating disease known as Crigler-Najjar syndrome, developed alongside biotech giant Alexion Pharmaceuticals, would enter human trials in 2016.

It was to be the first therapy using audacious new technology that Bancel promised would yield dozens of drugs in the coming decade.

But the Crigler-Najjar treatment has been indefinitely delayed, an Alexion spokeswoman told STAT. It never proved safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project. Unable to press forward with that technology, Moderna has had to focus instead on developing a handful of vaccines, turning to a less lucrative field that might not justify the company’s nearly $5 billion valuation.

“It’s all vaccines right now, and vaccines are a loss-leader,” said one former Moderna manager. “Moderna right now is a multibillion-dollar vaccines company, and I don’t see how that holds up.”

Bancel made no mention of the Crigler-Najjar drug when he spoke Monday before a similarly packed room at this year’s J.P. Morgan conference.

His presentation instead focused on four vaccines that the company is moving through the first phase of clinical trials: two target strains of influenza, a third is for Zika virus, and the fourth remains a secret. Bancel clicked through graphs of data from animal studies before hurrying on to tout Moderna’s balance sheet and discuss the company’s cancer vaccines, slated for clinical testing later this year.

When STAT asked Bancel after the presentation about Crigler-Najjar, he deferred to Alexion.

In need of a Hail Mary

Founded in 2012, Moderna reached unicorn status — a $1 billion valuation — in just two years, faster than Uber, Dropbox, and Lyft, according to CB Insights. The company’s premise: Using custom-built strands of messenger RNA, known as mRNA, it aims to turn the body’s cells into ad hoc drug factories, compelling them to produce the proteins needed to treat a wide variety of diseases.

But mRNA is a tricky technology. Several major pharmaceutical companies have tried and abandoned the idea, struggling to get mRNA into cells without triggering nasty side effects.

Bancel has repeatedly promised that Moderna’s new therapies will change the world, but the company has refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists and a chiding from the editors of Nature.

The indefinite delay on the Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be delivered in multiple doses, covering almost everything that isn’t a vaccine, former employees and collaborators said.

The company did disclose a new technology on Monday that it says will more safely deliver mRNA. It’s called V1GL. Last month, Bancel told Forbes about another new technology, N1GL.

But in neither case has the company provided any details. And that lack of specificity has inevitably raised questions.

Three former employees and collaborators close to the process said Moderna was always toiling away on new delivery technologies in hopes of hitting on something safer than what it had. (Even Bancel has acknowledged, in an interview with Forbes, that the delivery method used in Moderna’s first vaccines “was not very good.”)

Are N1GL and V1GL better? The company has produced no data to answer that question. When STAT asked about new technologies, Bancel referred questions to the company’s patent filings.

The three former employees and collaborators said they believe N1GL and V1GL are either very recent discoveries, just in the earliest stages of testing — or else new names slapped on technologies Moderna has owned for years.

“[The technology] would have to be a miraculous, Hail Mary sort of save for them to get to where they need to be on their timelines,” one former employee said. “Either [Bancel] is extremely confident that it’s going to work, or he’s getting kind of jittery that with a lack of progress he needs to put something out there.”

Former employees and collaborators who spoke with STAT requested anonymity because they had signed nondisclosure agreements — which the highly secretive Moderna requires even some job candidates to sign.

STAT investigation last year found that Bancel had driven away top talent from Moderna with a culture of recrimination and a caustic work environment, including on-the-spot firings for failed experiments.

The company, based in Cambridge, Mass., seems to have repaired its reputation among many rank-and-file employees, winning workplace accolades from Science Magazine and the Boston Globe, but Moderna has lost more than a dozen top scientists and managers in the past four years, despite its vast financial resources.

A bug in the software

Bancel, a first-time biotech CEO, has dismissed questions about Moderna’s potential. He describes mRNA as a simple way to develop treatments for scores of ailments. As he told STAT over the summer, “mRNA is like software: You can just turn the crank and get a lot of products going into development.”

Related: SOFTWARE OF LIFE™ IS A MODERNA TRADE MARK FOR MRNA. LITERALLY. AND THEY MAKE APPS

It seems clear, however, that the software has run into bugs.

Patients with Crigler-Najjar are missing a key liver enzyme needed to break down bilirubin, a yellowish substance that crops up in the body as old red blood cells break down. Without that enzyme, bilirubin proliferates in the blood, leading to jaundice, muscle degeneration, and even brain damage.

In Moderna’s eyes, the one-in-million disease looked like an ideal candidate for mRNA therapy. The company crafted a string of mRNA that would encode for the missing enzyme, believing it had hit upon an excellent starting point to prove technology could be used to treat rare diseases.

But things gradually came apart last year.

Every drug has what’s called a therapeutic window, the scientific sweet spot where a treatment is powerful enough to have an effect on a disease but not so strong as to put patients at too much risk. For mRNA, that has proved elusive.

STAT
mRNA jabs are “rewriting the Genetic Code” we call it “information therapy” – Tal Zaks (Ted 2017)

Before COVID-19, the company’s secretive nature, and its failure to deliver a functional product, was drawing comparisons to the infamous biotech startup Theranos. Similar to Moderna, Theranos rarely published any peer-reviewed material. Like Moderna, Theranos mastered the networking game, and recruited high profile individuals to its board in order to vouch for the company’s “revolutionary technologies.” Once valued at well over $10 Billion, Theranos collapsed after it was revealed that the company was running a massive fraud scheme, in addition to its failure to implement its promised blood testing technology.

Jordan Schachtel @JordanSchachtelIn 2015, Dr John Ioannidis published a paper calling attention to Theranos & the shady biotech unicorn industry. Moderna is mentioned as a company that is following the Theranos path of zero disclosures, & publishing zero papers on their “innovative” tech. onlinelibrary.wiley.com/doi/epdf/10.11…
April 15th 2021113 Retweets281 Likes

Moderna’s Mysterious Medicines

FORBES EDITORS’ PICK |Dec 14, 2016

Excerpts:

“Now an obscure lawsuit filed in British Columbia in October sheds light on one of Moderna’s key partners, and through it FORBES can reveal details on Moderna’s amazing but still untested technology.

It appears that the first two products Moderna has entered into clinical trials rely on technology from a small outfit in Vancouver, British Columbia, called Acuitas Therapeutics. (Acuitas is so small, in fact, that its worldwide headquarters are in its CEO’s single-family home.)

Almost all medicines either block proteins–the building blocks of life–or, in the case of expensive biotech drugs, are proteins themselves. But Moderna has been promising to hack an entirely different part of life’s cookbook. In order to turn genetic information encoded in DNA into the cellular machines that actually are proteins, living things use a messenger chemical called mRNA.

Creating these mRNA drugs is a big challenge on many levels. For them to work, Moderna needs to deliver mRNA to the body’s cells. By itself mRNA breaks down in the bloodstream. Tiny Acuitas specializes in one method: lipid-nanoparticle delivery systems. Its technology essentially wraps the mRNA into balls of fat that disguise the drug so that the target cells will readily ingest it.

“Although we are small,” says Thomas Madden, chief executive of Acuitas, “I believe the technology we have developed is highly effective.”

The problem for Madden and Moderna is that Acuitas doesn’t actually own the technology it has licensed to Moderna. The tech belongs to a third company, publicly traded Arbutus, which recently decided to terminate the license for the tech that it had granted to Acuitas. That’s why Acuitas filed the lawsuit in British Columbia, to protect the deal it had. Arbutus immediately countersued, claiming its deal with Acuitas didn’t cover Moderna’s medicines.

The legal mess has its roots in Moderna’s 2011 start, when Robert Langer, an MIT professor, Moderna board member and founder of dozens of biotech companies, told Bancel that Moderna was too underfunded and small to create its own delivery system. So Moderna vetted over a dozen external delivery methods for mRNA and settled on at least three. One belonged to Arbutus, but Moderna turned to tiny Acuitas to get access to it.

Acuitas was formed in 2009 by Madden after a merger eliminated his position at Arbutus’ predecessor, Tekmira Pharmaceuticals. After a contentious lawsuit Madden was able to license from his former employer the novel tech he had helped develop, and Bancel claims Moderna chose to work with Acuitas because it had “the people and the capabilities.”

But that doesn’t explain why Moderna–flush with capital–didn’t make sure that sublicensing through Acuitas would be okay with Arbutus before advancing its new drugs into human studies.

Bancel met with FORBES at a Brooklyn coffee shop on a recent Saturday to dispel the implications of the lawsuit. He is dismissive of Acuitas’ technology. “We knew it was not very good,” he says. “It was just okay.”

He further explains that Moderna is in the process of producing its own nanoparticle lipids. One such lipid, N1GEL (called “Nigel” internally), appears to cause less inflammation than Acuitas’ version. Another is being licensed from Merck. Bancel says Moderna has stopped using the Acuitas tech for new drugs.

That still leaves a somewhat messy situation for any Moderna vaccines that are being developed using Acuitas’ tech.

Data from one vaccine is expected early next year. If results are good, it could lead to a sizzling-hot initial public offering, even if the Canadian lawsuit ultimately affords Arbutus bigger royalty payments from Moderna.”

Well, the two tiny Canadian companies mentioned above bring royalties to the Canada’s treasury (should I say The British Crown?), so don’t expect Trudeau to backpedal too soon

AND IF ONLY THEY HUSSLED WITH PRIVATE FUNDS, AS THEY CLAIMED…

Moderna chief keep claiming that they started to use public funds only as a patch on infrastructure, science and funding they’ve built for years.

Wrong!

It’s known that NIH + NIAID have long been one of their main sources for the “lavish funding” mentioned earlier and when they locked in the government support, they actually started to leverage it and attract even more private funds, in an self-feeding loop that created today’s monster-bubble.

Very few people know they even got money from BARDA and DARPA. As in “military funds”.

Remember this lie from earlier?
“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”
Watch this claim getting nuked:

Taken from:

This grid above looks familiar to you? It does to me, but it’s not blood from people who underwent Covid genetic therapies, just something similar. Taken from:

KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents

  by  Knowledge Ecology International (KEI)

Luis Gil Abinader has taken a deep dive into Moderna’s surprising practice of never declaring government funding in its 126 patents and 154 patent applications, despite having had funding from multiple federal agencies.

One outcome of his research is a 25 page report (RN-2020-3) on Moderna’s failure to report funding from DARPA, and a request by KEI to DOD and DARPA to remedy this, including by taking title to patents where disclosures should have been made. (Text of letter below, and PDF version here).

KEI will also send a letter to BARDA. The letter below was addressed to DOD and DARPA, and focuses on their funding.

Context

The obligation to disclose federal funding in patent applications has been subject to presidential executive orders, statutes, regulations and contracts, including those cited and quoted in Abinader’s report. The disclosure clarifies the public’s rights in the inventions and the obligations on the entity getting the money, on everything from the government’s worldwide royalty free license to the public’s march-in rights, obligations to make inventions available to the public on reasonable terms, and additional safeguards that can be exercised by a government inclined to do so.

Secondly, the disclosure changes the narrative about who has financed the inventive activity, often the most risky part of development.

One of the earlier norms on this was Franklin Roosevelt’s Executive Order 9424, on the Establishment of a Register of Government interests in patents.

In 2018, the regulations on disclosure were modified by NIST (see 83 FR 15954), where, among other things, the government gave itself unlimited time to remedy a failure to disclose federal funding, to eliminate one loophole that created an incentive ignore the disclosure requirement.

In the past, the US Department of Defense has taken title to patents where federal funding was not disclosed. See: Campbell Plastics v. Brownlee, 389 F.3d 1243 (Fed. Cir. 2004).

There is more on the broader issue of disclosure of government funding in patents here: https://www.keionline.org/bayh-dole/failure-to-disclose

The research on the Moderna/DARPA funding is outlined in a 25 page August 27, 2020 report by Luis Gil Abinader, titled: “Moderna failures to disclose DARPA funding in patented inventions.” RN-2020-3

Below is the text of the KEI letter to Dr. Mark T. Esper, Secretary of Defense, and Dr. Amy Jenkins, of the Pandemic Prevention Platform for the Defense Advanced Research Projects Agency (DARPA), regarding the apparent failure by Moderna to disclose DARPA funding in patent applications.
PDF copy here:

2020. September 18. DARPA letter to KEI confirming investigation of Moderna for failure to report government funding in patent applications. https://www.keionline.org/33970

2020. September 4. BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications. https://www.keionline.org/33907

2020. September 2. KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications. https://www.keionline.org/33892

2020. August 30. DARPA announces investigation into Moderna’s apparent failures to disclose mRNA vaccine patents. https://www.keionline.org/33832

2020. August 28. KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents. https://www.keionline.org/33763

2020. August 27. 2020:3 KEI Research Note: Moderna failures to disclose DARPA funding in patented inventions. https://www.keionline.org/rn-2020-3

2020. August 5. BARDA Responds to KEI, Public Citizen Letter Asking BARDA to Enforce Moderna Contract. https://www.keionline.org/33633

2020. August 4. KEI and Public Citizen request BARDA to address Moderna’s noncompliance with COVID-19 vaccine contract term. https://www.keionline.org/33618

2020. July 1. KEI receives seven new contracts for COVID 19 research from BARDA and DOD, including five using “Other Transactions Authority” that weaken or eliminate Bayh-Dole and FAR Safeguards. https://www.keionline.org/covid19-ota-contracts

2020. May 21. Moderna and US Government Funding of its COVID-19 Vaccine Candidate. https://www.keionline.org/33150

MORE Press Coverage

Washington Post
2020. August 28. “Moderna failed to disclose federal support in vaccine patents, researchers say: The company with a leading coronavirus vaccine candidate did not adhere to a law designed to protect public investment.” Washington Post. Christopher Rowland.
https://www.washingtonpost.com/business/2020/08/28/moderna-vaccine-patents-darpa-funding/

Bloomberg
2020. August 29. “Moderna’s Patents Probed by U.S. Defense Department, FT Says.” Bloomberg. Chiara Vasarri. https://www.bloomberg.com/news/articles/2020-08-29/u-s-government-s-darpa-probes-patents-filed-by-moderna-ft

Axios
2020. August 5. “Moderna skirts disclosures of coronavirus vaccine costs.” Axios. Bob Herman. https://www.axios.com/moderna-barda-coronavirus-funding-disclosure-2775a517-a775-485a-a509-b6906c8535a9.html

STAT
2020. September 4. “A second U.S. agency will review if Moderna disclosed federal funding in vaccine patents.” STAT. Ed Silverman. https://www.statnews.com/pharmalot/2020/09/04/moderna-vaccine-darpa-barda-patents-covid19/

2020. August 8. “Moderna failed to disclose federal funding for vaccine patent applications, advocates say.” STAT. Ed Silverman. https://www.statnews.com/pharmalot/2020/08/28/moderna-covid19-vaccine-coronavirus-patents-darpa/

2020. August 4. “BARDA faces pressure to force Moderna to disclose cost details from its Covid-19 contract.” Ed Silverman. https://www.statnews.com/pharmalot/2020/08/04/covid19-coronavirus-pandemic-barda-moderna-vaccine-transparency/

Financial Times
2020. August 29. “US government’s Darpa probes Moderna’s vaccine patents: Researchers accuse biotech company of failing to disclose federal grants in patents which also cover Covid-19 candidate.” Financial Times. Donato Paolo Mancini. https://www.ft.com/content/2be1f87e-9e96-4e23-9cc5-33ba35e50586

National Public Radio (NPR)
2020. August 4. “Prices For COVID-19 Vaccines Are Starting To Come Into Focus.” NPR. Sydney Lupkin. https://www.statnews.com/pharmalot/2020/08/04/covid19-coronavirus-pandemic-barda-moderna-vaccine-transparency/

Health Policy Watch
2020. September 3. “US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding.” Health Policy Watch. Grace Ren.
https://healthpolicy-watch.news/pharma-watchdog-requests-further-inquiries-into-modernas-us-patents/

2020. September 1. “US Department Of Defense Is Investigating Moderna’s Patents For Allegedly Failing To Disclose Federal Support.” Health Policy Watch. Grace Ren. https://healthpolicy-watch.news/usagency-investigating-moderna-for-allegedly/

The Pharma Letter
2020. September 4. “Non-profit says Moderna hid federal funding from patent office.” The Pharma Letter. https://www.thepharmaletter.com/article/nonprofit-says-moderna-hid-federal-funding-from-patent-office

Life Sciences Intellectual Property Review
2020. September 8. “Moderna’s COVID-19 and Zika patent applications to be investigated.” Life Sciences Intellectual Property Review. Muireann Bolger. https://www.lifesciencesipreview.com/news/moderna-s-covid-19-and-zika-patent-applications-to-be-investigated-4183

Law360
2020. September 4. “HHS Unit Probes Funding For Moderna’s Patented Vaccines.” Law360. Kevin Stawicki. https://www.law360.com/articles/1307690/hhs-unit-probes-funding-for-moderna-s-patented-vaccines

2020. August 31. “DOD Investigating Moderna’s Vaccine Patents.” Law360. Kevin Stawicki. https://www.law360.com/compliance/articles/1305849/dod-investigating-moderna-s-vaccine-patents

2020. August 28. “Activists Say Moderna Hid Gov’t Support For Vaccine Patents.” Law360. Kevin Stawicki. https://www.law360.com/articles/1305474

Moderna’s vaccine was developed with support from the NIAID, and, as covered in a past fact check, analysis from Axios found that the National Institutes of Health, of which the NIAID is part, may own intellectual property used in producing Moderna’s vaccine. Dr. Francis Collins, director of NIH, has also said that NIH has a stake in intellectual property used in the vaccine, though what exactly this means in practical terms is unclear. 

The Dispatch Fact-check

Also…

All the documents Glenn Beck is creaming about and more can be found below:

Nipah virus as in…?

READ: URGENT! DEBUNKING THE NEXT ENGINEERED PANDEMIC: HEMORRHAGIC FEVER (NIPAH, MARBURG, EBOLA)

Well, yeah, no coincidence here either, more proof to that below.

SO WE HAVE A FINACIER WHO TOOK OVER A WELL FUNDED PHARMA START-UP AND BROUGHT IN HUGE FUNDS, IGNITING THE MOTHER OF ALL ENRONS. WHO’S THIS GUY?!

Buckle up, friends, this so far was jus the prelude.

Bancel came to Moderna from the French Merieux Institute.

Merieux happens to be the French billionaire who helped China build the infamous P4 Lab in Wuhan.

Merieux also happens to be an old friend of Xi’s.

That Xi visit at the Merieux HQ in France happened in 2014, not long after this:

Obama & Xi working together on a pandemic playbook in 2012

And then, in 2018..

2017

Bancel maintained a top role in the Merieux Foundation long after leaving the BioMerieux division for Moderna.

CA Merieux Foundation

Therefore no surprise that Moderna was allegedly the first to get the SARS-COV2 genetic code and start working on the mRNA injection.

CONFIDENTIAL DOCUMENTS: MODERNA SENT A MRNA CORONAVIRUS VACCINE CANDIDATE TO UNIVERSITIES WEEKS BEFORE EMERGENCE OF COVID-19

MORE COINCIDENCE THEORIES

In 2017, Moncef Slaoui, the brain behind GSK, also took a seat on the board of Moderna,

Trump awarded Moderna almost $0.5Billion from public money a few days before nominating Slaoui as Warp Speed co-chief. in May 2020.

Trump’s Moroccan “vaccine czar”: worked for Bill Gates, Google, GSK. Worked in China. Transhumanist. Lockdown fanatic

“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.

In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News

To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus.
He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:

“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest.
Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.”
The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine.
Slaoui could not immediately be reached for comment on the matter.”

Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation

Gates, Fauci and Slaoui have long been making and selling scandalous vaccines together. It’s a cartel

So we should add Bancel to this cover graphic
DAVOS 2022: BANCEL AND FAUCI MEET AGAIN TO WHINE ABOUT THE ANNOYANCE WE ARE TO THEM. MORE TO COME, SCUMBAGS!

LAST MINUTE:

The circle has just closed.
Unless China faked another interview to prop up another myth.

So this has never been about health, just a global scale racketeering operation that’s coming to light about about to go bust. You can speed up this process simply by spreading this expose far and wide!

UPDATE MARCH 21, 2022: VOILA!

Via our ex-BlackRock friend Edward Dowd. I rest my case, but I bet they will “unrest” it soon.

BONUS: MODERNA DIDN’T EVEN CREATE THE SCAM THEY’RE RUNNING

The story of the first BIOTECH INVESTMENT BUBBLE told by BBC

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

For my mother, who has just buried my father, passed away from a very suspicious heart event involving some clots. She had to bury him in my absence, because the Military BioTech Complex holds us prisoners on two different continents. I had to bury myself in work to keep it together.

Work in progress, I will keep adding pieces to the Tetris until it goes away.
Please return regularly for updates, this is a very long and fascinating story that should change the worldview for most people.

This is to request that the current retention allowance [(b)(6) redaction] for Dr. Anthony S. Fauci be converted to a permanent pay adjustment in the amount [(b)(6) redaction] over his base pay of [(b)(6) redaction] in order to appropriately compensate him for the level of responsibility in his current position of Director, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), especially as it relates to his work on biodefense research activities.”

GW BUSH

Key points

First, in the US, Military and an emerging petrochemical industry with strong roots in agriculture but expanding into health, among others. The Rockefellers were the main force driving this expansion in the US and bridging over the ocean to Germany, the most advanced country in terms of chemical industrialization.
But it was mostly Crown-controlled and Rothschild-controlled from the City of London, through their many henchmen.

After a few good collaborative experiences, the Military and Pharmafia decided they have a future together, and they bought up the Academia to help with the labs and the brains, as both industries already had a foot in the door there.

Two world wars demonstrated there’s hardly any limit to what they can achieve together.

The Cold War is then used as an excuse to develop more surveillance and population control tools. From these efforts spring1 out Silicon Valley and the Internet.

Before the end of 20th century, Big Pharma and Big Tech are fused by all means: capital, gear, agenda.

The Great Military BioTech Complex is born to be the main Operating System of the system.

9/11 is the launch of the new control grid.

Many of the following events were just test runs.

Covid is a forced upgrade of this operating system.

Weapons trade is disguised as “defense”, bioweapons trade as “biodefense”. And the latter is booming.

Transhumanism Airlines depart from Humanism and are set to land in lifeless soulless material existence.

The Military Biotech Complex Origins

After 1865, American inventiveness turned away from war and toward commerce and industry. Development of the lands of the West did promote some agencies to investigate natural resources. The Department of Agriculture, the Department of Commerce and Labor, and the National Park Service appeared during this period. While government research tended toward the applied end of the research spectrum, newly-created private foundations, such as the Rockefeller Foundation and the Carnegie Institute of Washington, supported much of the nation's basic scientific research.- Daniel Else, "Origins of the Military-Industrial Complex", 2017 
This is the official history, not whistleblowing. It’s redacted by a system critter to make crimes palatable to the normies. Still a good starting point

Summary

Daniel Else explored the results of his year-long inquiry into the organizational underpinnings of that military technological revolution of the 1940s and 1950s. By mining the Library’s resources, Else traced the evolving relationship between science and the federal government leading to the creation of the Office of Scientific Research and Development (OSRD) in 1941. A temporary wartime agency, OSRD mobilized the nation’s academic and industrial technological resources in support of the war effort, and in so doing profoundly altered the linkages between science and engineering, industry, and government. Else explored those wartime changes and outline their impact, still seen and felt today more than seven decades after V-J Day.

Event Date September 21, 2017

Notes-  Daniel Else was a specialist in national defense in the Congressional Research Service in the Library of Congress and the 2016 Kluge Staff Fellow at the Library’s John W. Kluge Center.

Finally in 1950, the Air Force created a larger organization, the Air Research and Development Command. The House finally passed the Senate bill that had been passed the year before, and the president signed the bill, establishing the National Science Foundation. So in that five-year gap, what we saw was the creation of a number of military, Department of Defense organizations for science and scientific research, and the final NSF bill contained no mandate for military research for the National Science Foundation. 

So, what are its legacy organizations? A number of federal agencies can trace their origins back to the OSRD. National Science Foundation, of course, the Office of Naval Research, the Army Research Development and Engineering, or, and Evaluation Command, Air Force Office of Scientific Research, DTRA, the Defense Threat Reduction Agency, DARPA, of course, and in the Department of Energy, the National Nuclear Security Administration, which is the custodian of atomic stockpile. - Daniel Else, "Origins of the Military-Industrial Complex", 2017 
Some of Vannevar Bush’s greatest official honors

One of Vannevar Bush’s PhD students at MIT was Frederick Terman, who was later instrumental in the development of “Silicon Valley”.

Wikipedia
CIA’s Senate Hearing on the Heart Attack Gun and the Bioweapons Developed in Fort Derrick (1975)

MEANWHILE, IN EUROPE

AND FROM THERE TO ALL THE QUEEN’S TERRITORIES

MIT is basically MBTC’s main civilian lab
Rockefeller Medicine – James Corbett
One of the most essential videos on Internet. Source

From Dark Winter to the coming winter – how biodefense drills have altered society

DR. HEIKO SCHÖNING: THE STAGE FOR THE DARK WINTER HAS BEEN SET WITH THE ANTHRAX ATTACKS FROM 2001. There was even an Event201 for the Anthrax attacks. It was called “The Dark Winter”

The Dark Winter exercise was the collaborative effort of 4 organizations. John Hamre of the Center for Strategic and International Studies (CSIS) initiated and conceived of an exercise wherein senior former officials would respond to a bioterrorist induced national security crisis. Tara O’Toole and Tom Inglesby of the Johns Hopkins Center for Civilian Biodefense Studies and Randy Larsen and Mark DeMier of Analytic Services, Inc., (ANSER) were the principal designers, authors, and controllers of Dark Winter. Sue Reingold of CSIS managed administrative and logistical arrangements. General Dennis Reimer of the Memorial Institute for the Prevention of Terrorism (MIPT) provided funding for Dark Winter.

DARK WINTER Official page

Deleted article, now ARCHIVED HERE

Simulations and Tabletop Exercises

Part of the: Homeland Security Archived Projects

Preparing homeland security professionals through scenario-based simulations and exercises on key issues.

Steadfast Resolve

The Steadfast Resolve exercise was planned to address the concern that poorly designed government response to the next terrorist attack could disrupt America’s economy and society as much or more than the attack itself. This concern is particularly relevant in the context of an attack that may be harmful, but not catastrophic.

In the event of a next attack, government officials will be under enormous pressure to respond swiftly, more than likely with limited information about the status of the attack or what to expect next. In today’s news cycle, the public – and the situation – will demand a swift and decisive response perhaps before exactly what is happening becomes clear. Confusion, indecision, or false starts at government’s highest levels will be magnified and may have long-lasting ramifications. Getting it wrong will be easier than getting it right. As the Hurricane Katrina experience has demonstrated, a lack of situational awareness, understanding of current plans, and an absence of effective decisionmaking tools can lead to disaster. 

Dark Winter: Bioterrorism Simulation Exercise

In the summer of 2001, a group of senior-level officials, including Gov. Frank Keating of Oklahoma, David Gergen, and James Woolsey, participated in an executive level simulation. Dark Winter simulated a U.S. National Security Council meeting at which senior officials were confronted with a smallpox attack on the United States. The exercise illustrated the issues to be addressed in the event of a bioterrorism crisis, including the challenges facing state and local governments, the role and responsiveness of the federal government, and the likely friction spots between federal- and state-level responders and responses.

Coming as it did before the September 11 terrorist attacks and the subsequent anthrax attacks, Dark Winter generated an enormous amount of interest in both the public policy community and the media. CSIS briefed Vice President Dick Cheney, then National Security Advisor Condoleeza Rice, then FEMA Director Joe Allbaugh, over 80 members of Congress, senior government officials and leaders, including approximately 20 ambassadors to the United States, and senior government officials from Asia, Latin America, and Europe. Besides raising public awareness of the bioterrorism threat, these briefings contributed to the Bush administration’s decision to manufacture 300 million doses of the smallpox vaccine.

Silent Vector: A Critical Energy Infrastructure Simulation Exercise

The events of September 11 and additional intelligence on al Qaeda demonstrate the potential for an attack against the infrastructure of the United States. To face this challenge, CSIS developed an executive-level simulation focusing on U.S. critical energy infrastructure. The exercise took place in October 2002 and employed a simulated National Security Council of senior policymakers with former senator Sam Nunn, now chairman of CSIS’s Board of Trustees, serving as scenario president.

Silent Vector was designed to simulate possible U.S. reaction to a credible threat of terrorist attack when there is not sufficient information for effective protection. The overall purpose of the exercise was to assist the administration and Congress in their attempts to improve the effectiveness of response during the pre-attack phase of a major terrorist incident. Silent Vector challenged current and former senior government leaders to respond to increasingly credible and specific intelligence indicating the possibility of a large-scale attack against critical energy and energy-related infrastructure on the East Coast of the United States.
 

Black Dawn: A Scenario-Based Exercise on Catastrophic Terrorism

Organized under the auspices of the Strengthening the Global Partnership project by CSIS and the Nuclear Threat Initiative, Black Dawn gathered approximately 55 current and former senior officials and experts from the European Council, the European Commission, NATO, 15 member states, and various international organizations to grapple with the challenges associated with preventing the use of weapons of mass destruction (WMD) by terrorists.

The exercise aimed to develop a set of actionable recommendations for the EU, NATO and individual European governments to prevent terrorists from acquiring and using WMD. The exercise was designed to energize discussion and debate as various European countries and institutions entered into their policy and budget deliberations. The central question animating the exercise was this: In hindsight, what could we have done to prevent terrorists from acquiring WMD and conducting such an attack? And what more can and should we do now?

The exercise concluded with several lessons learned: the threat of WMD terrorism is real; it could happen in Europe; prevention is the best option; we can take concrete steps to significantly reduce the risk of terrorists acquiring nuclear, biological, and chemical weapons; Europe has a leadership role to play; and we need to act now.

  • Simon Chair BlogCommentaries on U.S. relations with countries in the Western Hemisphere – focusing on international political economy, trade, investment, energy, and other current events.

A “Dark Winter” for Public Health: Meet Homeland Security’s New Bioterror Czarina

by Tom Burghardt / August 24th, 2009

In the wake of the 2001 anthrax attacks, successive U.S. administrations have pumped some $57 billion across 11 federal agencies and departments into what is euphemistically called “biodefense.” Speaking at the World Economic Forum in Davos, Switzerland in January 2005, former U.S. Senate Majority Leader William Frist, a Bushist acolyte, baldly stated that “The greatest existential threat we have in the world today is biological” and predicted that “an inevitable bioterror attack” would come “at some time in the next 10 years.”

Later that year, Frist and former House Speaker Dennis Hastert (R-IL) covertly inserted language into the 2006 Defense Appropriations bill (H.R. 2863) that granted legal immunity to vaccine manufacturers, even in cases of willful misconduct. It was signed into law by President Bush.

According to Public Citizen and The New York Times, Frist and Hastert benefited financially from their actions; the pair, as well as 41 other congressmen and senators owned as much as $16 million in pharmaceutical stock. revealed that “the Biotechnology Industry Organization (BIO) is purported to be the key author of the language additions. This trade association represents virtually all major vaccine manufacturers.”

The Senate Majority Leader’s alarmist jeremiad at Davos was seconded by Dr. Tara O’Toole who added, “This [bioterrorism] is one of the most pressing problems we have on the planet today.”

Really? Not grinding poverty, global warming or the lack of access by hundreds of millions of impoverished workers and farmers to clean water, an adequate diet, health care or relief from epidemic levels of preventable diseases such as malaria, tuberculosis or diarrhea, but “bioterrorism” as narrowly defined by securocrats and their academic accomplices.

But Dr. Victor W. Sidel, a founder of Physicians for Social Responsibility (PSR) and an outspoken critic of the Bioweapons-Industrial-Complex challenged O’Toole’s hysterical paradigm.

Sidel made the point that there is a fundamental conflict between the state’s national security goals and health care providers’ professional responsibilities to patients. He wrote in 2003 that “military, intelligence, and law enforcement agencies and personnel have long histories of secrecy and deception that are contrary to the fundamental health principles of transparency and truthfulness. They may therefore be unsuitable partners for public health agencies that need to justify receiving the public’s trust.”

In this context, the choice of O’Toole as the Department of Homeland Security’s (DHS) Undersecretary of Science and Technology is troubling to say the least. As former CEO and Director of UPMC’s Center for Biosecurity, critics charge that O’Toole’s appointment will be nothing short of a disaster.

No ordinary policy wonk with an impressive résumé and years as a government insider, O’Toole is a key player advocating for the expansion of dual-use biological weapons programs rebranded as biodefense.

Subverting the Biological Weapons Convention

The resuscitation of American bioweapons programs are facilitated by their secretive and highly-classified nature. Under cover of academic freedom or intellectual property rights, the U.S. Bioweapons-Industrial-Complex has largely been outsourced by the state to private companies and contractors at top American corporations and universities.

Efforts to strengthen the Biological Weapons Convention (BWC) by the inclusion of verification language into the treaty and regular inspection of suspect facilities by international experts have been shot-down since 2001 by the Bush and now, the Obama administrations. Why?

Primarily because the United States view onsite measures as a threat to the commercial proprietary information of multinational pharmaceutical and biotechnology companies as well as to America’s reputedly “defensive” biological programs; initiatives that continue to work with nature’s most dangerous and deadly pathogens.

In fact, the problem of the dual-use nature of such research is a conundrum facing critics who challenge the break-neck expansion of concealed weapons programs. Simply put, military activities can be disguised as commercial research to develop medical countermeasures without anyone, least of all the American people, being any the wiser.

Highly-trained microbiologists deployed across a spectrum of low-key companies, trained for academic, public health, or commercial employment are part of the dual-use problem. Who’s to say whether scientists who genetically-manipulate pathogens or create Frankenstein-like chimera disease organisms (say, synthesized Marburg or Ebola virus as has already been done with poliovirus in a U.S. lab) are engaged in treaty-busting weapons research or the development of life-saving measures.

And what about the accidental, or more sinisterly, the deliberate release of some horrific new plague by a scientist who’s “gone rogue”? As researcher Edward Hammond pointed out:

British researchers pled guilty in 2001 to charges that they improperly handled a genetically engineered hybrid of the viruses causing hepatitis C and dengue fever. British authorities characterized the virus as “more lethal than HIV”. ‘Dengatitis’ was deliberately created by researchers who wanted to use fewer laboratory animals in a search for a vaccine for Hepatitis C. Under unsafe laboratory conditions, the researchers created and nearly accidentally released a new hybrid human disease whose effects, fortunately, remain unknown; but which may have displayed different symptoms than its parents and thus been difficult to diagnose, and have required a new, unknown treatment regime. (Emerging Technologies: Genetic Engineering and Biological Weapons, The Sunshine Project, Background Paper No. 12, November 2003)

A new report by the Center for Arms Control and Nonproliferation has charged that despite restrictions under the BWC prohibiting the development, production, stockpiling and use of weaponized disease agents such as anthrax, smallpox or plague, as well as equipment and delivery systems intended for offensive use, the rapid growth of “biodefense and research programs over the last decade” has placed “new pressure” on efforts to curb the development of banned weapons listed in the treaty.

In an interview with Global Security Newswire Gerald Epstein, a senior fellow with the hawkish Center for Security and International Studies (CSIS) told the publication, “When one is doing bioresearch and biodefense, one has to be careful to not overstep the treaty itself.”

He cited the U.S biodefense effort Project Bacchus–an investigation by the Defense Threat Reduction Agency to determine whether it was possible to build a bioweapons production facility using readily available equipment–as an instance where questions were raised if the treaty had been violated.

The type of biodefense activity that is most likely to raise questions regarding treaty compliance is “threat assessment,” the process of determining what type of biological attacks are most likely to occur, he told Global Security Newswire. A dangerous biological agent could inadvertently be developed during such research, Epstein said. (Martin Matishak, “Biodefense Research Could Violate Weapons Convention, Report Warns,” Global Security Newswire, August 20, 2009)

But Pentagon bioweaponeers did more than build “a bioweapons productions facility using readily available equipment.” They built banned weapons. According to Jeanne Guillemin, author of Biological Weapons: From the Invention of State-Sponsored Programs to Contemporary Bioterrorism, the Pentagon and CIA made and tested a model of a Soviet anthrax bomb and created an antibiotic-resistant strain of anthrax.

After consulting with scientists who strongly suggested that the CIA anthrax bomb project would violate the BWC, “CIA lawyers decided the project was within the allowed realm of defensive research,” Guillemin revealed. Project Clear Vision, a joint investigation by the CIA and the Battelle Memorial Institute, under contract to the Agency, reconstructed and tested a Soviet-era anthrax bomblet in order to test its dissemination characteristics. The Agency “decided the same” for the small, fully functional bioweapons facility built under the rubric of Project Bacchus.

The third initiative, Project Jefferson, led to the development of an antibiotic-resistant strain of anthrax based on a Soviet model. After the outgoing Clinton administration hesitated to give the CIA the go-ahead for the project, the Bush regime’s National Security Council gave the Pentagon permission. “They believed” Guillemin wrote, “the Pentagon had the right to investigate genetically altered pathogens in the name of biodefense, ‘to save American lives’.”

Shortly thereafter, the Pentagon authorized the Defense Intelligence Agency (DIA), one of the most secretive and heavily-outsourced Defense Department branches, to re-create the deadly anthrax strain.

What the scope of these programs are today is currently unknown. We do know however, that based on available evidence the Department of Homeland Security, the Defense Department and the oxymoronic Intelligence Community, using the Department of Health and Human Services (HHS) and the U.S. Department of Agriculture (USDA) as a cover, continue to investigate the feasibility of transforming nature’s most deadly pathogens into weapons.

In close coordination, the United States government and their outsourced corporate partners are spending billions of dollars on research and simulation exercises, dubbed “disaster drills” by a compliant media, to facilitate this grisly trade.

Secrecy and Deceit

That the official bioterror narrative is a preposterous fiction and swindle as even the FBI was forced to admit during its much-maligned Amerithrax investigation, is hardly worth a second glance by corporate media beholden to the pharmaceutical industry for advertising revenue; call it business as usual here in the heimat.

As we now know, the finely-milled anthrax powder which killed five people and shut down representative government didn’t come from the Afghan-Arab database of disposable Western intelligence assets known as al Qaeda, but rather from deep within America’s own Bioweapons-Industrial-Complex, to wit, from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Ft. Detrick in Maryland. But such troublesome and inconvenient truths are barely worth a mention by “respectable” media, e.g. the corporate stenographers who sold two imperialist military adventures to the American people.

Indeed, a credible case can be made that without the anthrax attacks, the fear levels gripping the country in the wake of the 9/11 terrorist events–and the subsequent clamp-down that followed, from the USA Patriot Act to the indefinite detention and torture of “terrorism” suspects, and from warrantless wiretapping to the demonization of dissent–may very well have been impossible.

It is difficult not to conclude that from the beginning of the affair, there was a clear intent on the part of the anthrax terrorist(s) to draw a straight line between 9/11 and the anthrax mailings. From there, it was but a short step to stitching-up a case for “regime change” in Iraq. The media’s role in this criminal enterprise was indispensable for what Salon’s Glenn Greenwald has called“the single greatest, unresolved media scandal of this decade.” As Greenwald points out,

During the last week of October, 2001, ABC News, led by Brian Ross, continuously trumpeted the claim as their top news story that government tests conducted on the anthrax–tests conducted at Ft. Detrick–revealed that the anthrax sent to [former Senator Tom] Daschle contained the chemical additive known as bentonite. ABC News, including Peter Jennings, repeatedly claimed that the presence of bentonite in the anthrax was compelling evidence that Iraq was responsible for the attacks, since–as ABC variously claimed–bentonite “is a trademark of Iraqi leader Saddam Hussein’s biological weapons program” and “only one country, Iraq, has used bentonite to produce biological weapons.” (Glenn Greenwald, “Vital unresolved anthrax questions and ABC News,” Salon, August 1, 2008)

Despite ABC News’ claims that their information came from “four well-placed and separate sources,” they were fed information that was patently false; as Greenwald avers, “No tests ever found or even suggested the presence of bentonite. The claim was just concocted from the start. It just never happened.”

And as we will shortly explore below, the dubious “Dark Winter” and “Atlantic Storm” bioterror exercises designed by Dr. Tara O’Toole freely drew from the neocon’s sinister playbook, right down to the weaponized smallpox supplied to al Qaeda by Saddam.

Whether or not one buys the current permutation of the “lone nut” theory, this one alleges that Dr. Bruce Ivins, a vaccine specialist employed by USAMRIID, was the anthrax mailer; the fact is, when all is said and done the attacks, to use a much over-hyped phrase, were an inside job.

And like other “lone nuts” who have entered the parapolitical frame at their own peril, Ivins isn’t around to refute the charges.

The Alliance for Biosecurity: Insiders with a Mission and (Very) Deep Pockets

Before being pegged by the Obama administration to head DHS’s Science and Technology division where she will oversee the department’s billion dollar budget, with some 45 percent of it going towards chemical and bioweapons defense, O’Toole, as previously mentioned, was the CEO and Director of UPMC’s Center for Biosecurity, a satrapy which describes itself as “an independent organization dedicated to improving the country’s resilience to major biological threats.”

How “independent”? You make the call!

According to their web site The Alliance for Biosecurity is “a collaboration among the Center for Biosecurity and 13 pharmaceutical and biotechnology companies whose mission is to work in the public interest to improve prevention and treatment of severe infectious diseases–particularly those diseases that present global security challenges.”

Alliance partners include the usual suspects: Bavarian Nordic; Center for Biosecurity of UPMC; Cangene Corporation; DOR BioPharma, Inc.; DynPort Vaccine Company LLC, a CSC company; Elusys Therapeutics, Inc.; Emergent BioSolutions; Hematech, Inc., a subsidiary of Kyowa Kirin; Human Genome Sciences, Inc.; NanoViricides, Inc.; Pfizer Inc.; PharmAthene; Siga Technologies, Inc.; Unither Virology LLC, a subsidiary of United Therapeutics Corporation. Rounding out this rogues gallery are associate members, the spooky Battelle Medical Research and Evaluation Facility and the Lovelace Respiratory Research Institute.

Among the chief activities of the Alliance is lobbying Congress for increased funding for the development of new drugs deemed “countermeasures” under the Project BioShield Act of 2004, previously described by Antifascist Calling as a particularly grotesque piece of Bushist legislative flotsam.

The Alliance avers that “the United States faces unprecedented risks to national security … by the clear and growing danger of bioterrorism or a destabilizing infectious disease pandemic,” and that “our nation’s vulnerability to biothreats is so severe” due to the fact that “most of the vaccines and medicines that will be needed to protect our citizens do not now exist.” Therefore, countermeasures needed to mitigate nebulous biothreats never spelled out once in the group’s literature “will likely require several years and several hundred million dollars each to successfully develop and produce.” (emphasis added)

An Alliance report, The State of Biosecurity in 2008 and Proposals for a Public/Private Pathway Forward, charts a course for “improving and accelerating” efforts to “develop medical countermeasures (MCMs) for the nation’s Strategic National Stockpile (SNS).”

Under the Project Bioshield Act of 2004, Congress authorized $5.6 billion over ten years “to purchase MCMs for the SNS.” Funds were allocated for the procurement of the anthrax vaccine as well as for “therapeutic antibodies for inhalational anthrax, a botulism heptavalent antitoxin, a smallpox vaccine, and several products for radiological and nuclear threats, obligating a total of about $1.9 billion of the $5.6 billion BioShield fund.”

In 2006 as I noted previously, Congress created the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services (HHS). BARDA was authorized to spend some $1.07 billion over three years for MCMs, “only $201 million has been provided by Congress through FY 2008″ noted the Alliance, “approximately one-fifth of the authorized level.”

According to an “independent economic analysis” carried out by (who else!) the Alliance’s academic partner, the Center for Biosecurity, “it would require $3.4 billion in FY 2009 to support one year of advanced development.”

“Similarly” according to the organization, “the original appropriation of $5.6 billion for Project BioShield is equally insufficient to ensure that once MCMs are developed there will be funds available to procure them and maintain the stockpile.” Indeed, “this level of funding would need to be sustained for many years.” You can bet however, that Alliance lobbyists are busy as proverbial bees in pressuring Congress to fork over the dough!

The report state’s that Alliance goals necessarily entail instilling “a sense of urgency … with Congress” by hyping the “bioterror threat.” But there’s much more here than a simple cynical exercise at preparing the “public diplomacy” ground through academic and industry “message force multipliers” that will enable Congress to shower Big Pharma with a veritable tsunami of cash. A “risk-tolerant culture” should be promoted within BARDA, one that “understands the realities, risks, timelines, and costs of drug development.”

The “risks” to whom and for what purpose are not enumerated, but one can be certain that a “risk-tolerant culture” crafted by industry insiders will come at the expense of the health and safety of the American people, one that pushes potential legal liability should things head south onto the taxpaying public.

The stealth nature of Alliance recommendations are clearly spelled out when they aver that “stakeholders” should “focus more on the potential biothreats and the corresponding countermeasures, rather than the price tag” and that BARDA, ostensibly a public agency, should be packed with insiders “who have drug development and manufacturing experience.” This will lead to the development of “a culture that is focused on partnering with industry and academia.”

But the bottom line as always, is the corporatist bottom line for Alliance shareholders! How else can one interpret their statement that emerging “biothreats” are all the more dire today now that “interest of the public and private capital markets in biodefense has declined over the last 2-3 years.” What better way then, to beef-up those sagging capital markets than to install an industry-friendly individual at DHS with a documented track record of overplaying the “bioterror threat.”

Dark Winter

O’Toole was the principal designer of two “tabletop” bioterror preparedness drills, the 2001 Dark Winter exercise and the 2005 Atlantic Storm run-through; both were criticized by scientific experts as fabrications of an alleged threat of a smallpox attack mounted by al Qaeda.

Reviewing Milton Leitenberg’s 2005 report, Assessing the Biological Weapons and Bioterrorism Threat, published the U.S. Army War College’s Strategic Studies Institute, protein chemist Dr. Eric Smith wrote the following:

Of note is Leitenberg’s dissection of the process of assessment as practiced through bioterrorism threat scenarios conducted by the US government and private think tanks. Exercises like Dark Winter, which modeled an “aerosolized” smallpox attack, Top Off 2 and 3, both on pneumonic plague strikes, and Atlantic Storm, an exercise that purported to show an al Qaida group manufacturing a dry powder smallpox weapon, were rigged. In the cases of Dark Winter and the Top Offs, transmission rates of disease were sexed up beyond historical averages so that “a disastrous outcome was assured” no matter any steps taken to contain outbreaks. Eight pages are reserved to pointedly condemn the Atlantic Storm exercise on a host of sins which can generally be described as a bundle of frank lies and misinformation coupled with a claimed terrorist facility for making smallpox into a weapon that even state run biological warfare operations did not possess. And once again, juiced transmission rates of disease were employed to grease theoretical calamity. The reader comes to recognize the deus ex machina–a concoction or intervention added to dictate an outcome, in these cases very bad ones–as a regular feature of the exercises. However, the results of the same assessments–the alleged lessons learned–have never been reported with much, if any, skepticism in the media. (Eric Smith, “A Vaccine for the Hype: Milton Leitenberg’s new ‘Assessing the Biological Weapons and Bioterrorism Threat,” Global Security, National Security Notes, March 31, 2006)

In criticizing “the fancy that such attacks are easy and one of the most catastrophic threats faced by the American people,” Smith denounces the alarmist scenarios of Dark Winter and Atlantic Storm’s designers–people like Dr. Tara O’Toole and the coterie of industry insiders and other well-paid “experts”–as guilty of perpetrating a massive “fraud … and a substantial one” on the American people.

While one of Atlantic Storm’s architects proclaimed “this is not science fiction” and that “the age of Bioterror is now…” Leitenberg and Smith denounce O’Toole’s spurious claims as “not the least bit plausible.”

Leitenberg wrote that “well before October-November 2001, the spectre of ‘bioterrorism’ benefitted from an extremely successful sales campaign.” Indeed, hyped-up scenarios such as Dark Winter and Atlantic Storm that place “weapons of mass destruction” in the hands of shadowy, intelligence-linked terror outfits like al Qaeda provided “inflated predictions that … were certainly not realistic. Much worse, in addition to being wrong, inflated predictions were counterproductive. They induced interest in BW in the wrong audiences.”

But the implausible nature of the scenarios deployed in national exercises hardly prohibited the Bioweapons-Industrial-Complex from concocting scarecrow-like straw men designed to sow terror amongst the American people while extracting regular infusions of cash from Congress.

Among the eight exercises analyzed by Leitenberg between 1998-2005, he found that each and every one were fraudulently designed and the threat of bioterrorism had been framed as a rationalization for “political action, the expenditure of public funds for bioterrorism prevention and response programs,” that could “not occur without it.” This is “not benign,” Leitenberg concludes.

A second consequence of sexed-up “bioterror” drills have even more ominous implications for the immediate future. Because of national security state perceptions that mitigation of catastrophic bioterrorism is of supreme importance for national survival–perceptions reinforced by academic, corporate and militarist peddlers of crisis–”the US biodefense research program appears to be drifting into violation” of the Biological Weapons Convention. This is a menacing development and has happened, I would argue precisely because the evaluation process which justifies research into biological weapons threat capabilities and scenarios, are repackaged to conceal the offensive thrust of this research as wholly defensive in nature, which it certainly is not.

How else would one explain ongoing research funded by the National Institutes of Health to study botulism toxin, “with the added qualification” Smith points out, that because the protein toxin is “unstable, therefore there will be collaboration with other researchers to stabilize it.” The NIH grant “means preparing a much more effective botulinum toxin than had been available before.”

Smith goes on to cite “another problematical breakout” offered by two scientists to study the “aerobiological” characteristics of the lethal Marburg and Ebola viruses. How this is “defensive” in nature, in keeping with research restrictions under the Biological Weapons Convention, is another instance of a backdoor move to kick-start illicit bioweapons development.

According to Smith, the study “looks to define how the organisms can be aerosolized, an instance of research into examining vulnerability in the complete absence of a verified threat.” But I would argue that showering taxpayers dollars into such dark and troubling research tributaries deploy hyped-up threats as cover for the development of illegal weapons.

When her nomination was announced in May, Rutgers University and homeland security critic Richard Ebright told Wired,

“This is a disastrous nomination. O’Toole supported every flawed decision and counterproductive policy on biodefense, biosafety, and biosecurity during the Bush Administration. O’Toole is as out of touch with reality, and as paranoiac, as former Vice President Cheney. It would be hard to think of a person less well suited for the position.”

“She was the single most extreme person, either in or out of government, advocating for a massive biodefense expansion and relaxation of provisions for safety and security,” he adds. “She makes Dr. Strangelove look sane.” (Noah Shachtman, “DHS’ New Geek Chief is a Bioterror ‘Disaster,’ Critics Charge,” Wired, May 6, 2009)

And Dr. Smith told Wired that exercises designed by O’Toole and her colleagues show her to be “the top academic/salesperson for the coming of apocalyptic bioterrorism which has never quite arrived.”

As noted above, “[She’s] most prominent for always lobbying for more money for biodefense, conducting tabletop exercises on bioterrorism for easily overawed public officials, exercises tweaked to be horrifying,” Smith told Wired.

But Smith goes even further and denounces O’Toole as an industry shill who “has never obviously appeared to examine what current terrorist capabilities have been… in favor of extrapolating how easy it would be to launch bioterror attacks if one had potentially unlimited resources and scientific know-how.” It’s a “superb appointment if you’re in the biodefense industry and interested in further opportunity and growth.”

“Alternatively” Smith avers, O’Toole’s appointment is “a disaster if threat assessment and prevention” has “some basis in reality.”

Not that any of this matters in Washington. The Senate Homeland Security and Governmental Affairs Committee led by “independent Democrat” and arch neocon Sen. Joseph Lieberman, voted to send her nomination to the full Senate July 29.

Never mind that the deadly weaponized pathogen employed in the attacks didn’t originate in some desolate Afghan cave or secret underground bunker controlled by Saddam.

And never mind that the principal cheerleaders for expanding state-funded programs are Pentagon bioweaponeers, private corporations and a shadowy nexus of biosecurity apparatchiks who stand to make a bundle under current and future federal initiatives.

Leading the charge for increased funding is the Alliance for Biosecurity, a collaborative venture between the Center for Biosecurity of the University of Pittsburgh Medical Center (UPMC) and Big Pharma.

Tom Burghardt is a researcher and activist based in the San Francisco Bay Area. His articles are published in many venues. He is the editor of Police State America: U.S. Military “Civil Disturbance” Planning

Bioweapon manufacturing and trading is ‘biodefense’. Guess who does the bioterrorism that sells the ‘biodefense’.
Deleted article ARCHIVED HERE

 Soviet scientists reportedly used newly developed genetic engineering techniques to create vaccine-subverting and antibiotic-resistant strains of anthrax, plague, tularemia, and smallpox for attacks against military forces and civilian populations (Bozheyeva et al. 1999Alibek and Handelman 2000)

More info: BBC / GRUNGE / THE GUARDIAN
Sure
Is that US bill ‘military’ for the same reason the Defence Force is involved in this act?
SOURCE
TRUMP: WE’RE MOBILIZING THE MILITARY TO DELIVER THE CORONAVIRUS VACCINE END OF 2020
Dr Sharad S. Chauhan is a decorated Indian Police Service (IPS) officer awarded the Prime Minister’s baton and the Home Minister’s Revolver. He is also a Gold Medallist MBBS Doctor from Delhi University with a PhD in Bioterrorism. He also authored the book Biological Weapons.
SOURCE

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Alexeter Technologies LLC, Alnylam Pharmaceuticals Inc., Altimmune Inc., ANP Technologies Inc., Bavarian Nordic AS, Cleveland BioLabs Inc., Elusys Therapeutics Inc., Emergent BioSolutions Inc., General Dynamics Corp., and GlaxoSmithKline Plc are some of the major market participants. Although the rising prevalence of infectious disease and rapid increase in government funding in R&D will offer immense growth opportunities, to leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments, while maintaining their positions in the slow-growing segments.

TECHNAVIO BIODEFENSSE MARKET REPORT

GERMAN & UK DEFENSE WORK ON MASSIVE “HUMAN AUGUMENTATION” PROJECT FOR CIVILIAN POPULATION

In an exclusive interview, Dr. Boyle touches upon GreatGameIndia‘s exclusive report Coronavirus Bioweapon – where we reported in detail how Chinese Biowarfare agents working at the Canadian lab in Winnipeg were involved in the smuggling of Coronavirus to Wuhan’s lab from where it is believed to have been leaked.

In this bombshell interview (full transcript below), Boyle talks about:

  • The bioweapons origins of the coronavirus
  • How the Deep State deployed anthrax on US soil to whip up publicity about biological weapons and increase funding for bioweapons labs
  • Why the WHO and CDC are both criminal organizations which are complicit in the covert development of biological weapons
  • The “death science” industry and why the US government has spent over $100 billion developing self-replicating weapons
  • Details about the Pirbright Institute and its ties to bioweapons, depopulation, vaccines and coronavirus patents. (It’s partially funded by Bill & Melinda Gates)
  • Why all BSL-3 and BSL-4 labs in the world should be banned and shut down.

Full transcript


Geopolitics and Empire: Geopolitics & Empire is joined by Dr. Francis Boyle, who is international law professor at the University of Illinois. We’ll be discussing the Wuhan coronavirus and biological warfare. He’s served as counsel to numerous governments such as Bosnia and Herzegovina and the Palestinian authority. He’s represented numerous national international bodies in the areas of human rights, war crimes and genocide, nuclear policy, and biowarfare. He’s written numerous books, one of my favorites being “Destroying Libya and World Order”, which I assigned as mandatory reading material for my own students when I taught at the Monterrey Institute of Technology.

But most important for this interview, he’s written a book called “Biowarfare and Terrorism”, and drafted the US domestic implementing legislation for the biological weapons convention, known as the Biological Weapons Anti-Terrorism Act of 1989 that was approved unanimously by both houses of the US Congress and signed into law by President Bush. Thanks for joining us, Dr. Boyle.

Dr. Francis Boyle: Wow. Thank you so much for having me on and thanks for that kind introduction.

Geopolitics and Empire:  Now let’s get to what’s been on the news recently. This coronavirus in Wuhan. There have been some reports recently, there’s a really interesting website called GreatGameIndia that has been reporting on this. They’ve been talking about China, which they say has been complying with biological weapons convention in recent years.

But then there are some people in the US and experts that have been saying that in reality, China isn’t complying with the weapons convention. And I think neither, perhaps the US as well. I’m wondering if China is developing its own biosafety level four lab in Wuhan and elsewhere, as you know, as a type of deterrence. Is it a type of a biological arms race that we have going on?

You told me in an email that you suspect China was developing the coronavirus as a dual use of biowarfare weapons agent. Also, what do you make of reports that Chinese scientists have been stealing research and viruses, including the coronavirus from a Canadian bio lab this past December?

And as well, Chinese nationals have been charged with smuggling vials of biological research to China from the US with the aid of Charles Lieber who was the chair of Harvard’s chemistry department. And he also happens to be in 2011 a strategic scientist at Wuhan University. So, can you tell us what’s going on with this recent outbreak in Wuhan?

Dr. Francis Boyle: Well, that’s a lot of questions. I guess we can take them one at a time, but if you just do a very simple Google search on “Does China have a BSL-4 laboratory?”, Wuhan comes up right away. It’s at the top of the list. That’s all with the moment this type of thing happened I began to do that. So a BSL-4 is the most serious type. And basically BSL-4 labs, we have many of them here in the United States, are used to develop offensive biological warfare weapons with DNA genetic engineering.

So it does seem to me that the Wuhan BSL-4 is the source of the coronavirus. My guess is that they were researching SARS, and they weaponize it further by giving it a gain of function properties, which means it could be more lethal.

Indeed, the latest report now is it’s a 15% fatality rate, which is more than SARS at 83% infection rate. A typical gain of function travels in the air so it could reach out maybe six feet or more from someone emitting a sneeze or a cough. Likewise, this is a specially designated WHO research lab. The WHO was in on it and they knew full well what was going on there.

Yes. It’s also been reported that Chinese scientists stole coronavirus materials from the Canadian lab at Winnipeg. Winnipeg is Canada’s formal center for research, developing, testing, biological warfare weapons. It’s along the lines of Fort Detrick here in the United States of America. I have three degrees from Harvard. It would not surprise me if something was being stolen out of Harvard to turn over to China. I read that report. I don’t know what was in those vials one way or the other.

But the bottom line is I drafted the US domestic implementing legislation for the Biological Weapons Convention that was approved unanimously by both Houses in the United States Congress signed into law by President Bush Sr. that it appears the coronavirus that we’re dealing with here is an offensive biological warfare weapon that leaped out of Wuhan BSL-4. I’m not saying it was done deliberately. But there had been previous reports of problems with that lab and things leaking out of it. I’m afraid that is what we are dealing with today.

Geopolitics and Empire: We’ll be talking about the Wuhan and the coronavirus and China, but can you give us kind of like a bigger context. I know you’ve, previously, in interviews said that since 9/11, you think that the US has spent $100 billion on biological warfare research. We know the Soviet Union, if I’m not mistaken, developed anthrax as a bioweapon. And you’ve also mentioned that UK, France, Israel and China are all involved in biological warfare weapons research.

And something interesting, I believe one or two years ago a Bulgarian journalist and the Russian government shared their concern of the discovery of a US bioweapons lab in the country of Georgia. You’ve commented how in Africa, US has set up bioweapons labs to work on Ebola, which I think is illegal under international law. But they were allowed somehow to put those in Africa. Can you give us like a bigger picture? What’s going on with these different countries and what’s the purpose of this research?

Dr. Francis Boyle: All these BSL-4 labs are by United States, Europe, Russia, China, Israel are all there to research, develop, test biological warfare agents. There’s really no legitimate scientific reason to have BSL-4 labs. That figure I gave $100 billion, that was about 2015 I believe. I had crunched the numbers and came up with that figure the United States since 9/11.

To give you an idea that’s as much in constant dollars as the US spent to develop the Manhattan Project and the atom bomb. So it’s clearly all weapons related. We have well over 13,000 alleged life science scientists involved in research developed testing biological weapons here in the United States. Actually this goes back it even precedes 9/11 2001.

I have another book, The Future of International Law and American Foreign Policy, tracing that all the way back to the Reagan administration under the influence of the neocons and they got very heavily involved in research development testing of biological weapons with DNA genetic engineers. It was because of that I issued my plea in 1985 in a Congressional briefing sponsored by the Council for Responsible Genetics, I’m a lawyer for them. They’re headquartered in Cambridge, Mass. All the MIT, Harvard people are involved in that, the principal ones. And then they asked me to draft the implementing legislation.

The implementing legislation that I drafted was originally designed to stop this type of work. “Death science work”, I call it, “by the United States government”. After 9/11, 2001, it just completely accelerated. My current figure, that last figure a 100 billion. I haven’t had a chance to re-crunch the numbers because I just started classes. But you have to add in about another 5 billion per year.

Basically, this is offensive biological weapons raised by the United States government and with its assistance in Canada and Britain. And so other States, the world have responded accordingly including Russia and China. They were going to set up a whole series of BSL-4 facilities as well. And you know Wuhan was the first. It backfired on them.

Geopolitics and Empire: Would you basically consider what happened and Wuhan and just boil it down to ineptitude or incompetence on the Chinese part?

Dr. Francis Boyle: Well, it’s criminality. It does appear they stole something there from Winnipeg. This activity that they engaged in clearly violates the Biological Weapons Convention. Research development of biological weapons these days is an international crime, the use of it would be. That was criminal.

I’m not saying they deliberately inflicted this on their own people, but it leaked out of there and all these BSL-4 facilities leak. Everyone knows that who studies this. So this was a catastrophe waiting to happen. Unfortunately, it happened. The Chinese government under Xi and his comrades there have been covering this up from the get-go. The first reported case was December 1, so they’d been sitting on this until they couldn’t anymore. And everything they’re telling you is a lie. It’s propaganda.

The WHO still refuses to declare a global health emergency. It said Tedros was over there shaking hands with Xi and smiling and yanking it up. The WHO was in on it. They’ve approved many of these BSL-4 labs., they know exactly what’s going on and that is a WHO research-approved laboratory. They know what’s going on too. You can’t really believe anything the WHO is telling you about this, either they’re up to their eyeballs in it, in my opinion.

Geopolitics and Empire: I’d probably agree with you that this outbreak in Wuhan was an accidental leak from the laboratory. But just your thoughts, it’s happening at quite an opportune time because namely we’re smack in the middle of a US-China new Cold War, which is currently characterized by economic warfare such as the trade war among other forms of hybrid and technological warfare. And it seems the Wuhan outbreak will likely hit the Chinese economy hard. The Chinese are flat out dismissing any idea that the US is involved in. Like I said, it’s probably they made the mistakes in the Wuhan lab. What are your thoughts of any seemingly, this would benefit the US…

Dr. Francis Boyle: When the outbreak occurred, of course I considered that alternative too. When you have an outbreak, you’re never quite sure who or what is behind it. It certainly isn’t bats, that’s ridiculous. They made the same argument on Ebola in West Africa. I demolished that online. You can check it out. So I kept competing theories about this.

But right now, when you originally contacted me, I said I wasn’t prepared to comment because I was weighing the evidence. I’m a law professor and a lawyer,  I try to do the best I can to weigh the evidence. But right now, the Wuhan BSL-4 in my opinion is the most likely source, apply Occam’s razor, the simplest explanation. I’m not ruling out some type of sabotage. But right now, I believe that is the source here.

Geopolitics and Empire: And you mentioned WHO. I’d like to just get your thoughts on the WHO and the Big Pharma. There’s also some analysts who are downplaying this news media hype of the coronavirus. You’ve just said that it seems to be lethal, but if we go back a decade to the 2009 swine flu, which I believe didn’t have too many casualties, but I think profited greatly the pharmaceutical companies. If I recall that back in 2009, many countries purchased great stocks of the vaccines and they ended up not using anywhere from 50 to 80% of the vaccines that they purchased.

You’ve previously stated in an interview that the World Health Organization is a front for Big Pharma if I’m not mistaken. Robert F. Kennedy Jr. also agrees and he says, you know, 50% of WHO funding comes from pharmaceutical companies. And that the CDC itself is also severely compromised. What are your thoughts on the WHO? The CDC?

Dr. Francis Boyle: Can’t trust anything the WHO says because they’re all bought and paid for by Big Pharma and when they work in cahoots with the CDC, which is the United States government, they work in cahoots with Fort Detrick, so you can’t trust any of it.

However, the swine flu and yes, I agree pharma made a lot of money, but that swine flu which I looked at it, it did seem to me to be a genetically modified biological warfare weapon. It was a chimera of three different types of genetic strains that someone put it together in a cocktail. Fortunately, it was not as lethal as all of us fear. So fine. But as I said, this figure I just gave to you was Saturday from Lancet, which is a medical publication, saying it’s a 15% fatality rate and an 83% infection rate. So it’s quite serious, I think, far more serious than the swine flu.

As for big pharma, sure they’re all trying to profit off this today as we speak. There was a big article yesterday in the Wall Street Journal, all big pharma trying to peddle whatever they can over there in China even if it’s worthless and won’t help. We do know, if you read the mainstream news media they say there isn’t a vaccine.

Well, there is, it’s by the Pirbright Institute in Britain that’s tied into their biological warfare program over there. They were behind the hoof and mouth disease outbreak over there that wiped out their cattle herd and it leaked out of there. So it’s clear they’re working on a hoof and mouth biological warfare weapon, but the vaccine is there. I have the patent for it here, I haven’t had a chance to read the patent it’s about 25 pages long and my classes just resume. So eventually, I get some free time and I’ll read the patent.

You can’t patent a vaccine with the United States patent office unless the science is there. So there is a vaccine. Everyone’s lying about that, no one’s pointing this out – there’s a vaccine but instead big pharma wants to make money and the researchers say, well, it’ll take three months and we’re racing forward, you know. Everyone’s gonna make a buck off of this, that’s for sure. But there is a vaccine, I have the patent here. It’s been patented by the United States government.

So obviously, I don’t know exactly how workable it is, but it’s a vaccine. I don’t know why it isn’t out there now? Why isn’t someone saying there is a vaccine? Perhaps political leaders have already been vaccinated for all I know, I really don’t know.  But there is a vaccine, Pirbright is well known there in Britain and it’s tied into Fort Detrick and CDC is tied into Fort Detrick too. So they all know there’s a patented vaccine.

Geopolitics and Empire:  And just to get your comment on, I mean, something to related to this, which was my next question. So I think, I’m not sure if it’s that same Institute that you just mentioned that has the patent.  I read somewhere that the Bill & Melinda Gates foundation maybe funds or has some connection to that Institute that has the patent.

Dr. Francis Boyle:  I think they do. The Bill & Melinda Gates information, they fund this type of DNA genetically engineered biological warfare work. That’s correct. So you can’t trust anything they’re telling you that somehow they’re out there trying to make the world a better place.  I mean, we have Bill Gates publicly admitting that the world be a better place if there were a lot less people. So the Bill & Melinda Gates foundation, they are wolves in sheep’s clothing and they are funding this type of stuff. Sure.

Geopolitics and Empire: And just your comment, there was also the report that I guess it was a consortium of companies which included the Gates foundation that back in just two or three months ago in October of 2019 they held a pandemic exercise simulating an outbreak. I mean, what are the chances specifically of a coronavirus and it was called events 201. People can find this online online and they gave a list of seven recommendations for governments and international organizations to take. I also find that kind of interesting how they had this simulation.

Dr. Francis Boyle:  That’s correct. It raises that question,  the origins of what happened here.  But right now, I’m just looking at the evidence I have and applying Occam’s razor and we know that Wuhan BSL-4 was research developing, testing, SARS as a biological warfare agent. So it could have been, they gave it this DNA genetic engineering enhanced properties gain of function which we do here in the West, in the United States all the time. We have  all sorts of research that is clearly a bio warfare research that has been  approved by the National Institutes of Health, it’s a joke. They know full well they are proving all kinds of biological warfare research and it gets funded by the United States government.

Geopolitics and Empire:  And you’ve also mentioned in the email to me that what happened in the biosafety lab level 4 in Wuhan calls into question the safety of all of these level 3and 4four labs around the world.

Dr. Francis Boyle:  They’re complete unsafe. BSL-3 and BSL-4 lab are only designed for research development testing of offense of biological warfare agents.  In my opinion, they serve no legitimate purpose at all. They should all be shut down, every one of them. Even assuming, they’re simply too dangerous. If you want, there’s an excellent  documentary called Anthrax Wars by Nadler and Coen and I’m in there.  Repeatedly at the end, I say with respect to these labs, three and four, this is a catastrophe waiting to happen. Well, I’m afraid the catastrophe is now happened. So there it is.

Geopolitics and Empire:  Yeah, I was just watching that documentary before we connected and I recommend the listeners go check that out. Do you see, in the future, any countries,  if we come to a conflict between US, EU, Israel, Saudi Arabia, Iran, China, Russia,  I mean you name it. Do you see any of these countries actually utilizing these biological weapons?  I mean, it’s illegal under international law but we know like in the past that international law isn’t followed. Do you think that there’s a real danger of this escalating?

Dr. Francis Boyle: For sure. That’s the only reason they develop these biological weapons to eventually be used, sure.  I mean, it’s like the Manhattan project, we put all that money into developing an atom bomb and even though it was not needed to end world war II they still knew Hiroshima and Nagasaki. So, yes,  I think that’s correct.  And also these can be used covertly. Anytime you see an unexplained  sudden outbreak of a disease like this anywhere in the world, both for human beings and or animals, I always suspect the bio warfare agent is at work.  I monitor the situation like I did at Wuhan until I can reach a conclusion. Yes, they can be used as the eyes for the United States government, today they are fully prepared, armed, equipped, supplied to wage a biological warfare with anthrax.

These other more exotic things I don’t know, but they have the weapons, there are stockpiles. We have to understand if you read Seymour Martin Hersh’s book published about 1968, he won the Pulitzer prize, he had the whole offensive US biological warfare industry in there back before it was illegal and criminal. Basically after 9/11, 2001, that entire industry – offensive biological warfare industry has been reconstituted here in the United States with all these BSL-4 BSL-3 labs, well over 13,000, alleged scientists sort of like Dr. Mengele working on these things. Other countries have responded in kind like Russia, like China, France is involved, Britain’s involved. Sure.

Geopolitics and Empire: I just wanted to get your thoughts on, in the last few years there was the Russian double agent spy Sergei Skripal who had been allegedly poisoned with Novichok out in Britain and  I thought it was funny. It just so happened where he was allegedly poisoned, he was right in Porton down the British bio weapons lab, I guess the world’s first bio weapons lab that was created in 1916. I mean,  I don’t know if you have thoughts on that whole incident.

Dr. Francis Boyle: Yeah, I was right down the street from Porton Down, so applying Occam’s razor who you think might’ve been behind this and it was not a nerve agent. A nerve agent would have killed him immediately. This is Novichok. It was something else like DX or something like that. So fine. But, I would just say that I don’t think that was a coincidence, but, you know, there you go. There’s the, obviously there’s a lot of speculation on that.

Geopolitics and Empire: Something else that’s kind of interesting. You’ve written in bio warfare and terrorism in your book and there’s also Graeme Macqueen, I think your colleague who wrote the anthrax deception the case for domestic conspiracy…

Dr. Francis Boyle:  Everything you said in there. That’s correct.

Geopolitics and Empire:  I’m wondering also if this new war for biotechnological dominance, whatever you want to call it, if it can also be used kind of as a pretext for the centralization of political power and the initiation of wars like I guess it did in the 2003 Iraq war. I mean, is this another danger that we get these events like now this coronavirus and then governments will call for a centralization of greater power and taking away some of our civil liberties?

Dr. Francis Boyle:  Sure. If you look at the October, 2001 anthrax attacks here in the United States, that was clearly by elements of the United States government that was behind that. That was a super weapons grade anthrax with a trillion spores per gram and it floated in the air solely a very sophisticated biological weapons lab like Fort Detrick could produce that. And they use that anthrax attack including on Congress to brand through the USA Patriot act which basically turned the United States to a police state which is what we have now. You have to understand the Pentagon, Fort Dietrich made the dugway proving ground still has a stockpile of that super weapons grade anthrax that we saw in October of 2001 that they can use the next time they want to do something like that to further develop the American police thing. Right.

Geopolitics and Empire:  Is there anything else you feel important to mention regarding this Wuhan Coronavirus outbreak or biological warfare or any other thoughts you’d like to leave us with?

Dr. Francis Boyle:  Well, you just can’t believe anything the Chinese government, the WHO,  the CDC are telling. They’re all lies because they know what’s going on here  and so you’re going to have to figure it out as fast as you can. But in my opinion, as of this time and I’m fully prepared to consider further evidence on this, it does seem to me that this was  a DNA genetically engineered biological warfare agent leaking out of Wuhan that has gain-of-function properties which can make it more lethal.  I think they are probably doing something with SARS to make it a lot more lethal and more infectious. And so for that reason,  you have to take extreme precautions and they’re now finally admitted anyone within six feet can be infected, whereas with SARS that was about two feet. Well, that’s gaining a function right there and that should be a tip off.

So, I guess you’re gonna have to protect yourself.  Laurie Garrett had a pretty good essay in a foreign policy yesterday and she was over there covering the SARS and she has very good advice in there except that she took the SARS figure out two to three feet and said  well, you gotta stay to two to three. I think you’ve got to stay at least six feet away because this is gained function. It can flow through the air and infect and it can get you in the eyes. Any orifice, the mouth, maybe the ears, we’re not sure at this point.

Geopolitics and Empire: I’m here on the border of China in Kazakhstan and I was just reading yesterday – today that they’re no longer allowing Chinese citizens into Kazakhstan without a medical paper, a medical check to get their visas to enter Kazakhstan

Dr. Francis Boyle:  Those medical checks are worthless because this is just public relations by all the governments involved because there is a 14 day incubation period where people can still be infected. So someone could walk right through a medical inspection and passing a gate into your country and then they come down with the coronavirus.  So that’s all public relations in my opinion by governments and they know it and they’re just sending people out there with temperatures and things like that. It’s not like SARS, this is more dangerous than SARS.  As I said, I think that Wuhan lab, we know they had SARS in there that they were dealing with and I think they enhanced it at and  I’m afraid that’s what we’re dealing with. But you know, I’m keeping an open mind as to what other sources that might have and I wasn’t prepared to say anything until that Wuhan lab is right there and it’s dealing with coronavirus. So again, apply Occam’s razor. It seems to me that’s the simplest explanation here.

Geopolitics and Empire: I guess my, one of my final question would be in the months ahead, apart of what you say staying six feet away from people.  I’ve read taking high doses of vitamin C and other things like this can help you. But, if they come out as the situation develops and if it gets worse and they come out with a coronavirus vaccine,  should people take it or not? What are your thoughts?

Dr. Francis Boyle:  Well, what I would say is this. Right now, if you look at the article at the Wall Street Journal, big pharma is trying to sell all sorts of – they’re taking all their drugs off the shelf and say well let’s see if it works. Which is preposterous. Okay. The scientists are saying, well, we can get you a vaccine maybe two to three months but they’re not tested.  So what we do know, however, is that Pirbright vaccine has been patented. So all I can assume is that that might work. But I don’t think I’d be taking any of these other vaccines. No, you have no idea what’s in there. You’ll be the Guinea pig for big pharma and everyone figures they’re gonna make a lot of money here. So I’ll keep my eye open on this  and how it develop but I wouldn’t trust anything they’re trying to sell right now. They’re just pulling these things off the shelf.

If they do come up with something in two to three months, even that’s not going to be tested in accordance with normal scientific protocol. So it’s going to be a crap shoot. If it’s going to help you, indeed it might not help you because they’ll be using for this vaccines (these DNA genetic engineered vaccines) they’ll be using live coronavirus probably and sticking it in there and giving you some live coronavirus on the theory you’ll develop an immunityThat’s the way a lot of these vaccines worked out, that’s what happened with the Ebola vaccine that created the Ebola pandemic there in West Africa. They were testing out a vaccine on poor black Africans, as usual, and  this vaccine had live Ebola in it so it gave them Ebola. So again, I’d be very careful even if they do come up with these vaccines two to three months from now, very careful. Why would you want to inject the live coronavirus in you?

Geopolitics and Empire: All right. I don’t believe you have a strong online presence. How can people best follow your work? I suppose to search for interviews as well as get your books.

Dr. Francis Boyle: Well, basically I’m blackballed and blacklisted off all the mainstream news media here on purpose. As far as I can figure out, the US government gave an order that I should not be interviewed by anyone, so I’m not.  I guess you could just put my name in there under Google, Google alert, and some interviews might come up. What happened was, right after the anthrax attacks of 9/11 2001, I was giving a lecture out at Harvard m Alma Mater.  I was running a panel on biological warfare for the council for responsible genetics and it was at Harvard Divinity School and as I was going in, there was a Fox camera crew there from Boston and I said it looks to me like this has come out of the US government lab. We know they do research and testing on anthrax. Then I said the same thing there at Harvard then I gave an interview to a radio station in Washington, D C then I gave an interview on that to the BBC. So the whole world saw it and at that point I was completely cut off and I’ve been cut off  ever since. So you  probably not going to hear too many  interviews from me here. As for my book. Biowarfare & Terrorism, you can just get it at amazon.com. That picks up the story pretty much from 9/11 2001 and until it went to press and then there are interviews I’d given to an investigative reporter, Sherwood Ross and a big one I just sent you and you might want to put that on your web page. That was pretty comprehensive.

Geopolitics and Empire: Yeah,  I read that as well and I’ll include the link in the description of this interview so people can go check that out. You’re not the only academic I know and have heard of others that similar things have happened and that’s just I guess the price we pay for telling the truth. Again, for listeners, if people wanted to have a broader context and deeper understanding of what’s happening today especially with biological warfare as well as us foreign policy and international affairs, I urge you to get Dr. Francis Boyle’s books and listen to his interviews as well as his colleagues book. Graeme Macqueen, The Anthrax Deception, The Case For Domestic Conspiracy. Thank you for being with us, Dr. Boyle.

Dr. Francis Boyle: Well, thank you and again, please understand these are my current opinions.  I could change my opinion here based on more evidence. So  I’m just looking at the evidence out there as I see it and you have to understand there is so much disinformation, lies and propaganda that it’s kind of very difficult to distinguish truth from fact.  I’m doing the best job I can here.

— end interview —


Originally published (greatgameindia.com)


A message from a former US Army psyops officer
VINCE JAMES DOES A GREAT JOB EXPLORING THE COMPLEX FROM THE CIA ANGLE AND ARRIVING TO THE SAME BIG PICTRE AND ALL THE GOOD CONCLUSIONS, MUST WATCH ENTIRELY!

UPDATE SEPTEMBER 23, 2022:

The Pentagon has ordered a sweeping audit of how it conducts clandestine information warfare after major social media companies identified and took offline fake accounts suspected of being run by the U.S. military in violation of the platforms’ rules.

Colin Kahl, the undersecretary of defense for policy, last weekinstructed the military commands that engage in psychological operations online to provide a full accounting of their activities by next month after the White House and somefederal agencies expressed mounting concerns over the Defense Department’s attempted manipulation of audiences overseas, according to several defense and administration officials familiar with the matter.

The takedowns in recent years by Twitter and Facebook of more than 150 bogus personas and media sites created in the United States was disclosed last month by internet researchers Graphika and the Stanford Internet Observatory. While the researchers did not attribute the sham accounts to the U.S. military, two officials familiar with the matter said that U.S. Central Command is among those whose activities are facing scrutiny. Like others interviewed for this report, they spoke on the condition of anonymity to discuss sensitive military operations.

The researchers did not specify when the takedowns occurred, but those familiar with the matter said they were within the pasttwo or three years. Some were recent, they said, and involved posts from the summer that advanced anti-Russia narratives citing the Kremlin’s “imperialist” war in Ukraine and warning of the conflict’s direct impact on Central Asian countries. Significantly, they found that the pretend personas — employing tactics used by countries such as Russia and China — did not gain much traction, and that overt accounts actually attracted more followers.

Centcom, headquartered in Tampa, has purview over military operations across 21 countries in the Middle East, North Africa and Central and South Asia. A spokesman declined to comment.

Air Force Brig. Gen. Patrick Ryder, the Pentagon press secretary, said in a statement that the military’s information operations “support our national security priorities” and must be conducted in compliance with relevant laws and policies. “We are committed to enforcing those safeguards,” he said.

Spokespersons for Facebook and Twitter declined to comment.

According to the researchers’ report, the accounts taken down included a made-up Persian-language media site that shared content reposted from the U.S.-funded Voice of America Farsi and Radio Free Europe. Another, it said, was linked to a Twitter handle that in the past had claimed to operate on behalf of Centcom.

One fake account posted an inflammatory tweet claiming that relatives of deceased Afghan refugees had reported bodies being returned from Iran with missing organs, according to the report. The tweet linked to a video that was part of an article posted on a U.S.-military affiliated website.

Centcom has not commented on whether these accounts were created by its personnel or contractors. If the organ-harvesting tweet is shown to be Centcom’s, one defense official said, it would “absolutely be a violation of doctrine and training practices.”

Independent of the report, The Washington Post has learned that in 2020 Facebook disabled fictitious personas created by Centcom to counter disinformation spread by China suggesting the coronavirus responsible for covid-19 was created at a U.S. Army lab in Fort Detrick, Md., according to officials familiar with the matter. The pseudo profiles — active in Facebook groups that conversed in Arabic, Farsi and Urdu, the officials said — were used to amplify truthful information from the U.S. Centers for Disease Control and Prevention about the virus’s origination in China.

The U.S. government’suse of ersatz social mediaaccounts, though authorized by law and policy, has stirred controversy inside the Biden administration, with the White House pressing the Pentagon to clarify and justify its policies. The White House, agencies such as the State Department and even some officials within the Defense Department have been concerned that the policies are too broad, allowing leeway for tactics that even if used to spread truthful information, risk eroding U.S. credibility, several U.S. officials said.

“Our adversaries are absolutely operating in the information domain,” said a second senior defense official. “There are some who think we shouldn’t do anything clandestine in that space. Ceding an entire domain to an adversary would be unwise. But we need stronger policy guardrails.”

A spokeswoman for the National Security Council, which is part of the White House, declined to comment.

Kahl disclosed his review at a virtual meeting convened by the National Security Council on Tuesday, saying he wants to know what types of operations have been carried out, who they’re targeting, what tools are being used and why military commanders have chosen those tactics, and how effective they have been, several officials said.

The message was essentially, “You have to justify to me why you’re doing these types of things,” the first defense official said.

Pentagon policy and doctrine discourage the military from peddling falsehoods, but there are no specific rules mandating the use of truthful information for psychological operations. For instance, the military sometimes employs fiction and satire for persuasion purposes, but generally the messages are supposed to stick to facts, officials said.

In 2020, officers at Facebook and Twitter contacted the Pentagon to raise concerns about the phony accounts they were having to remove, suspicious they were associated with the military. That summer, David Agranovich, Facebook’s director for global threat disruption, spoke to Christopher C. Miller, then assistant director for Special Operations/Low Intensity Conflict, which oversees influence operations policy, warning him that if Facebook could sniff them out, so could U.S. adversaries, several people familiar with the conversation said.

“His point‚” one person said, “was ‘Guys, you got caught. That’s a problem.’ ”

Before Miller could take action, he was tapped to head a different agency — the National Counterterrorism Center. Then the November election happened and time ran out for the Trump administration to address the matter, although Miller did spend the last few weeks of Donald Trump’s presidency serving as acting defense secretary.

With the rise of Russia and China as strategic competitors, military commanders have wanted to fight back, including online. And Congress supported that. Frustrated with perceived legal obstacles to the Defense Department’s ability to conduct clandestine activities in cyberspace, Congress in late 2019 passed a law affirming that the military could conduct operations in the “information environment” to defend the United States and to push back against foreign disinformation aimed at undermining its interests. The measure, known as Section 1631, allows the military to carry out clandestine psychologic operations without crossing what the CIA has claimed as its covert authority, alleviating some of the friction that had hindered such operations previously.

“Combatant commanders got really excited,” recalled the first defense official. “They were very eager to utilize these new authorities. The defense contractors were equally eager to land lucrative classified contracts to enable clandestine influence operations.”

At the same time, the official said, military leaders were not trained to oversee “technically complex operations conducted by contractors” or coordinate such activities with other stakeholders elsewhere in the U.S. government.

President Biden, right, Defense Secretary Lloyd Austin, left, and Chairman of the Joint Chiefs of Staff Gen. Mark A. Milley attend a Pentagon ceremony to remember the victims of 9/11. (Leigh Vogel/Bloomberg)

Last year, with a new administration in place, Facebook’s Agranovich tried again. This time he took his complaint to President Biden’s deputy national security adviser for cyber, Anne Neuberger. Agranovich, who had worked at the NSC under Trump, told Neuberger that Facebook was taking down fake accounts because they violated the company’s terms of service, according to people familiar with the exchange.

The accounts were easily detected by Facebook, which since Russia’s campaign to interfere in the 2016 presidential election has enhanced its ability to identify mock personas and sites. In some cases, the company had removed profiles, which appeared to be associated with the military, that promoted information deemed by fact-checkers to be false, said a person familiar with the matter.

Agranovich alsospoke to officials at the Pentagon. His messagewas: “We know what DOD is doing. It violates our policies. We will enforce our policies” and so “DOD should knock it off,” said aU.S. official briefed on the matter.

In response to White House concerns, Kahl ordered a review of Military Information Support Operations, or MISO, the Pentagon’s moniker for psychological operations. A draft concluded that policies, training and oversight all needed tightening, and that coordination with other agencies, such as the State Department and the CIA, needed strengthening, according to officials.

The review also found that while there were cases in which fictitious information was pushed by the military, they were the result of inadequate oversight of contractors and personnel training — not systemic problems, officials said.

Pentagon leadership did little with the review, two officials said, before Graphika and Stanford published their report on Aug. 24, which elicited a flurry of news coverage and questions for the military.

Army psyop graduates receive pins at the end of a field exercise reading “Persuade, Change, Influence.” (Cynthia McIntyre/Fort Hunter Liggett Public Affairs)

The State Department and CIA have been perturbed by the military’s use of clandestine tactics. Officers at State have admonished the Defense Department, “Hey don’t amplify our policies using fake personas, because we don’t want to be seen as creating false grass roots efforts,” the first defense official said.

One diplomat put it this way: “Generally speaking, we shouldn’t be employing the same kind of tactics that our adversaries are using because the bottom line is we have the moral high ground. We are a society that is built on a certain set of values. We promote those values around the world and when we use tactics like those, it just undermines our argument about who we are.”

Psychological operations to promote U.S. narratives overseas is nothing new in the military, but the popularity of western social media across the globehas led to an expansion of tactics, including the use of artificial personas and images — sometimes called “deep fakes.” The logic is that views expressed by what appears to be, say, an Afghan woman or an Iranian student might be more persuasive than if they were openly pushed by the U.S. government.

The majority of the military’s influence operations are overt, promoting U.S. policies in the Middle East, Asia and elsewhere under its own name, officials said. And there are valid reasons to use clandestine tactics, such as trying to infiltrate a closed terrorist chat group, they said.

A key issue for senior policymakers now is determining whether the military’s execution of clandestine influence operations is delivering results. “Is the juice worth the squeeze? Does our approach really have the potential for the return on investment we hoped or is it just causing more challenges?” one person familiar with the debate said.

The report by Graphika and Stanford suggests that the clandestine activity did not have much impact. It noted that the “vast majority of posts and tweets” reviewed received “no more than a handful of likes or retweets,” and only 19 percent of the concocted accounts had more than 1,000 followers. “Tellingly,” the report stated, “the two most-followed assets in the data provided by Twitter were overt accounts that publicly declared a connection to the U.S. military.”

Clandestine influence operations have a role in support of military operations, but it should be a narrow one with “intrusive oversight” by military and civilian leadership, said Michael Lumpkin, a former senior Pentagon official handling information operations policy and a former head of the State Department’s Global Engagement Center. “Otherwise, we risk making more enemies than friends.”

Excerpt from the article sourced above:

A LONG PATTERN OF INFILTRATION

45 years ago, legendary journalist Carl Bernstein released an investigation documenting how the CIA had managed to infiltrate U.S. and global media. The CIA had placed hundreds of agents into newsrooms and had convinced hundreds more reporters to collaborate with them. These included individuals at some of the most influential outlets, including The New York Times. The CIA needed to do this clandestinely because any attempt to do so openly would harm the effectiveness of the operation and provoke stiff public resistance. But by 2015, there was barely a murmur of disapproval when Reuters announced that it was hiring 33-year veteran CIA manager and director Dawn Scalici as a global director, even when the company announced that her primary responsibility was to “advanc[e] Thomson Reuters’ ability to meet the disparate needs of the U.S. government.”

Facebook, however, is vastly more influential than the New York Times or Reuters, reaching billions of people daily. In that sense, it stands to reason that it would be a prime target of any intelligence organization. It has become so big and ubiquitous that many consider it a de facto public commons and believe it should no longer be treated as a private company. Considering who is making many of the decisions on the platform, that distinction between public and private entities is even more blurry than many presume.

BONUS:

I’ve just brought to light insider information that confirms a very similar model has been pursued in USSR / Russia. I wonder if the two are eventually merging at the top, like Coca-Cola and Pepsi, seeing that Putin is a former Klaus Schwab disciple and a Davos regular.

Bottom line…

‘It’s warfare, not science’ – Dr. Nancy T. Banks – the legendary 2012 interview on vaccines & pharma

FOLLOW UPS

THIS SUBSTACK AND RESEARCHER DESERVE A SEPARATE POST O THEIR OWN!

Discussion with Sam Dube and Lara Logan (after 15 min) on DoD Vax Ownership and FDA Theatrics

The role of the US DoD (and their co-investors) in “covid countermeasures” enterprise.

Intelligence is never artificial.

By Sasha Latypova, Dec 28, 2022

I asked the AI Chat Bot “What was the role of the DoD in covid-countermeasures?” Here is what it wrote:

“The Department of Defense (DoD) played a significant role in the development of countermeasures against COVID-19, the disease caused by the novel coronavirus. The DoD worked closely with other federal agencies, such as the Department of Health and Human Services (HHS), to respond to the pandemic.

One of the main roles of the DoD in the COVID-19 response was to provide logistical support and medical resources to help healthcare workers and first responders on the front lines of the pandemic. The DoD also worked to develop and distribute personal protective equipment (PPE) and other supplies to support the response efforts.

In addition, the DoD provided funding and resources to support the development of vaccines and treatments for COVID-19. The Defense Advanced Research Projects Agency (DARPA), a research arm of the DoD, played a key role in this effort by funding and supporting the development of treatments and vaccines through its “Rapid Response Research” program.

Overall, the DoD played a vital role in the response to the COVID-19 pandemic by providing logistical support, medical resources, and funding for research and development efforts to combat the disease.”

AI Chat Bot gets a “F” – for a highly controlled narrative answer, which was fed to all MSM sources, while the “alternative” media did not examine it very much, with some exceptions. It wasn’t just logistics or even just lots of funding, and certainly nobody was “combatting disease”.

INTENT TO HARM – EVIDENCE OF THE CONSPIRACY TO COMMIT MASS MURDER BY THE US DOD, HHS, PHARMA CARTEL

DOD contracts for “covid countermeasures” can be found here: https://www.keionline.org/covid-contracts

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

ORDER

! Articles can always be subject of later editing as a way of perfecting them

THERE’S NO BETTER PREVENTION THAN SHARING THE KNOWLEDGE FASTER THAN THEY SHARE THEIR PROPAGANDA!

The original title of this article was URGENT! DEBUNKING THE NEXT ENGINEERED PANDEMIC: NIPAH VIRUS. I expanded the scope because in the meantime I learned they are ramping up propaganda for all three. These viruses have more things in common, as you will find out below.

You should actually begin with this earlier report:

‘OBSCENE’ PANDEMIC BONDS ISSUED IN 2017 BY WORLD BANK FOR CORONAVIRUSES, MARBURG, EBOLA. DESIGNED TO FAIL

UPDATE 7, JAN 10 2022: Dr. Robert Malone Warns Of ‘Ebola-Like Hemorrhagic Fever’ Super Virus In China Caused By Mutations Due To Mass Vaccination

UPDATE 6: NOVEMBER 9, 2021:

To further develop the ChAd3 Ebola and Marburg vaccines, Sabin has entered into a Research Collaboration Agreement with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.
The Sabin Vaccine Institute, a non-profit organization founded in 1993, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Sabin received more than $110 million for vaccine R&D programs from public and philanthropic funding sources, including the Bill & Melinda Gates Foundation, European Commission, Dutch Ministry of Foreign Affairs, Global Health Innovative Technology Fund and the Michelson Medical Research Foundation.

SABIN VACCINE INSTITUTE, August 6, 2019

Washington DC, Oct. 21, 2021 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the third contract option, valued at $34.5 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.  

In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million. This third contract option will enable continued nonclinical efficacy and safety studies, Phase 2 clinical trials in Africa, and vaccine manufacturing processes to ensure quality and safety.

In August, a case of Marburg disease was confirmed in the West African country of Guinea where the Ministry of Health officially declared an outbreak of Marburg.1 This recent case, as well as Marburg’s history of outbreaks and their potential for future devastating outbreaks, demonstrates that preventative measures are overdue to protect civilian populations, military personnel, first responders, health care workers and laboratory workers, both in the United States and abroad, against these emerging infectious diseases.

Ebola Sudan and Marburg viruses are closely related to Ebola Zaire virus, which has caused more than 2,200 deaths since 2018, leading the World Health Organization (WHO) to declare it a Public Health Emergency of International Concern. Like Ebola Zaire, Ebola Sudan and Marburg are among the world’s deadliest viruses, causing hemorrhagic fever with subsequent death in an average of 50 percent of cases.2,3

“Even as the world struggles with the COVID-19 pandemic, disease caused by Ebola Sudan and Marburg viruses continue to be a serious threat, as we have seen with the recent outbreak of Marburg in Guinea. We are grateful for BARDA’s continued support of Sabin’s efforts to advance vaccines against these deadly viruses,” said Sabin Chief Executive Officer Amy Finan. “We also thank our partners at the Vaccine Research Center of the NIH National Institute of Allergy and Infectious Diseases for their continued collaboration, and GSK for their earlier work on the candidates.” 

The two candidate vaccines, based on GSK’s proprietary ChAd3 platform, were exclusively licensed to the Sabin Vaccine Institute from GSK in 2019.

This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C00055.

Learn more about Sabin’s Ebola Sudan and Marburg program.

This above is the official Sabin Inst. press release, this below isn’t:

November 4, 2021 – The U.S. CDC published a Level Three Travel Advisory for the recent Ebola outbreak in the Beni Health Zone of the Democratic Republic of the Congo.

November 3, 2021 – The U.S. CDC vaccine advisory committee reviewed previous recommendation preexposure vaccination with Ervebo for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus species Zaire ebolavirus because they are: responding to an outbreak of Ebola Virus Disease (EVD), or work as health care personnel at federally designated Ebola treatment centers in the U.S., or work as laboratorians or other staff at biosafety level 4 facilities in the U.S.

November 2, 2021 – The WHO reported additional cases and deaths confirmed in the Ebola virus disease outbreak in the Democratic Republic of the Congo with two new health areas affected. A total of 394 people (67 primary care providers including nine high-risk contacts, nine contacts of contacts, and 49 probable contacts) have been vaccinated including 182 contacts of contacts, 125 probable contacts, and 87 high-risk contacts.

October 29, 2021 – A Research Article – Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomized, placebo-controlled Phase II clinical trial in Africa – was published by the journal PLOS Medicine. Conclusion – The Ad26.ZEBOV and MVA-BN-Filo combo vaccination were well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and an Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These data supported the approval by the European Union for prophylaxis against EBOV disease in adults and children ≥1 year of age.

October 27, 2021 – IAVI announced an award of up to US$126 million from the Biomedical Advanced Research and Development Authority to develop two recombinant vesicular stomatitis virus (rVSV)-vectored filovirus vaccine candidates. This award supports preclinical activities and includes options for clinical development up to and inclusive of a Phase II clinical trial of IAVI’s rVSV Sudan ebolavirus vaccine candidate (rVSVΔG-SUDV-GP). Optional work that would continue the development of IAVI’s Marburg virus vaccine candidate (rVSVΔG-MARV-GP) that is currently supported by the Defense Threat Reduction Agency of the U.S. Department of Defense could be funded at a later date.

“Vectored” means, most likely, mRNA or some other genetic / nanotech targeting technology.

October 20, 2021 – The WHO African Region reported 5 Ebola cases, and over 27,000 travelers have been screened in the DRC. Furthermore, over 116 people have been vaccinated.

October 17, 2021 – Africa News reported Ebola vaccinations started in Beni, DRC, after at least two people died due to the virus in October 2021. The WHO African Region Tweeted DRC Situation Report (17/10/21) 5 confirmed cases, three deaths, 369 contacts identified, and 308 contacts monitored.

October 13, 2021 – Democratic Republic of the Congo (DRC) health officials confirmed an Ebola vaccination campaign had launched in the North Kivu province where one confirmed Ebola case, plus three related suspected deaths, were recently reported. About 1,000 doses of the rVSV-ZEBOV Ebola vaccine and other medical supplies were delivered from the capital Kinshasa to Goma city in North Kivu. The DRC has more than 12,000 vaccine doses in Kinshasa that can be deployed if necessary.

October 10, 2021 – The WHO reported additional Ebola cases related to the recent DRC case of a 3-year-old boy. A cluster of three deaths (two children and their father) who were neighbors of the case. These three patients died on 14, 19, and 29 September 2021 after developing symptoms consistent with Ebola. However, none were tested for the virus. As of October 9th, a total of 148 contacts have been identified and are under follow-up by the local response team.

October 8, 2021 – A case of Ebola has been confirmed in the eastern Democratic Republic of the Congo, five months after the end of the most recent Ebola outbreak there. The child died on October 6th. It was not immediately known if the Ebola case was related to the 2018-20 outbreak that killed more than 2,200 people in eastern Congo or the flare-up that killed six people in 2021.

September 13, 2021 – A new study based in Sierra Leone concluded the Ebola vaccine regimen from Janssen – J&J. It was found well tolerated with no safety concerns in children aged 1–17 years and induced robust humoral immune responses, suggesting the suitability of this regimen for Ebola virus disease prevention in children.

August 31, 2021 – The government of Cote d’Ivoire has informed the WHO that a second laboratory has tested samples from a patient suspected of having Ebola and has found no evidence of the virus. Around a dozen WHO experts were mobilized to support the country’s efforts, and 5,000 Ebola vaccine doses which WHO had helped Guinea procure were sent from Guinea to Cote d’Ivoire.

August 23, 2021 – The WHO African region reported Ebola booster dose vaccinations in Sierra Leone following administration of the prime dose of the Johnson & Johnson Ebola vaccine in May 2021. Frontline health workers, practitioners of traditional medicines or traditional healers, and commercial motorbike riders who received the first dose are now given their second jab to maximize their protection against the disease. 

August 17, 2021 – The WHO confirmed Cote d’Ivoire deployed 2,000 vaccine doses from Merck and around 3,000 vaccine doses manufactured by Johnson & Johnson – Janssen.

August 14, 2021 – The WHO Africa reported the Ministry of Health of Cote d’Ivoire today confirmed the country’s first case of Ebola since 1994. This came after the Institut Pasteur in Cote d’Ivoire confirmed the Ebola Virus Disease in samples collected from a patient hospitalized in Abidjan’s commercial capital after arriving from Guinea.

August 9, 2021 – The WHO confirmed ‘Marburg virus disease (MVD) is a highly virulent, epidemic-prone disease associated with high case fatality rates (CFR 24-90%). In the early course of the disease, the clinical diagnosis of MVD is difficult to distinguish from other tropical febrile illnesses because of the similarities in the clinical symptoms. Differential diagnoses to be excluded include Ebola virus disease, as well as malaria, typhoid fever, leptospirosis, rickettsial infection, and plague.’

June 15, 2021 – The Southwest National Primate Research Center at Texas Biomedical Research Institute (Texas Biomed) has been awarded more than $37 million from the U.S. National Institutes of Health to continue operations into 2026. The P51 grant, given by the NIH Office of Research Infrastructure Programs, provides essential funding to house and care for nearly 2,500 non-human primates that are part of life-science research programs at Texas Biomed and partners around the globe.

June 4, 2021 – Johnson & Johnson welcomed a new recommendation by the Strategic Advisory Group of Experts on Immunization for the WHO that supports the use of the Johnson & Johnson Ebola vaccine regimen both during outbreaks for individuals at some risk of Ebola exposure and preventively, in the absence of an outbreak, for national and international first responders in neighboring areas or countries where an outbreak might spread.

June 4, 2021 – J&J confirmed about 235,000 people had received at least the first dose of the Janssen two-dose Ebola vaccine regimen.

April 10, 2021 – The government of Sierra Leone and the WHO announced Johnson & Johnson had donated about 4,500 Zabdeno and Mvabea Ebola vaccines to Sierra Leone to help prevent any Ebola outbreak. The last Ebola outbreak in Sierra Leone was in 2016.

March 25, 2021 – Ohio Gov. Mike DeWine revealed health officials are monitoring 44 people who have returned from areas of Africa with active outbreaks of Ebola.

March 25, 2021 – Oregon public health officials announced they are monitoring four people who recently visited the West African countries of Guinea and the Democratic Republic of the Congo. Regions in each of these countries are currently experiencing outbreaks of Ebola virus disease. The Oregon Health Authority and local public health departments have been in contact with these individuals, considered “persons under monitoring” since they arrived in the state earlier in March 2021.

March 23, 2021 – The WHO African Region Tweeted Guinea Ebola outbreak Situation Report (22/03/21) 18 cases, nine deaths, 78 contacts, 82% monitored. And 3,905 people have been vaccinated.

March 13, 2021 – After a request from the Guinean authorities, Russia is considering supplying a domestic vaccine against the Ebola virus to the African country, reported TASS.

May 13, 2020 – BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines

The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at $20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials. In September 2019, BARDA awarded Sabin a development contract, valued at $128 million, and provided the initial funding award of $20.5 million. This second $20 million award will enable the manufacture and release of clinical vaccine material developed by ReiThera, a specialist in the development and cGMP manufacture of adenoviral vector vaccines. The funding will also support non-clinical studies to evaluate efficacy and immune response.

UPDATE 5: NOVEMBER 7, 2021: MARBURG GOES VIRAL ON INTERNET ONLY, YET. I’m happy awareness increases, it’s crucial. I’ve addressed this virus below, but not many had the patience to go through all text, and I kind of understand them, but there’s no easier way than reading.
Here’s another angle to keep in sight when computing all this info:

UPDATE 4: OCTOBER 19 2021: THE FEARPORN CAMPAIGN TAKES SPEED AS IF THEY ARE TO RELEASE THIS SOON. IF YOU FALL FOR THEIR BRAINWASH, THEY HAVE NO REASON TO STOP.

And they’re still not running out of stupid ideas we can see through:

UPDATE 3: OCTOBER 17 2021:

TOLD YA!

Guess who has a vaccine in works for it

Oh, look who pushes the fear! Exactly who I would’ve expected:

Later update: In the meantime I’ve learned that Marburg (an Ebola relative) and Xinjiang fever, a Chinese relative of the Yellow Fever virus, are also top candidates, and that goes in line with the Fauci e-mails I highlighted below. I will be back with more details shortly. Almost certainly it will be some form of hemorrhagic fever, most likely to cover for injections side-effects on the blood stream.

UPDATE 2:

One month later, they’re starting to catch up and it’s still not too late to un-play it if this goes BOOM NOW!



By the end of last century, The Military has abandoned you and has joined Pharmafia and the super-rich elites in a plan to govern you with bioweapons and psy-ops. As I’ve said many times, Big Pharma and Big Tech are long gone, The Military BioTech Complex has been running the show for quite a while.
This is just a chapter from that book, more to come if we get some love.

WHAT YOU NEED TO KNOW:

INDIA BLACKLISTED US CDC FOR SECRETLY FUNDING BIOWEAPONS RESEARCH IN MANIPAL – Silview.media

Government pulls up U.S. agency for work on Nipah virus – The Hindu

NIPAH IS ONE OF THREE VIRUSES MODIFIED BY WUHAN LAB AT NIAD’S REQUEST, FAUCI E-MAIL REVEAL – Silview.media

SOURCE

Canadian lab’s shipment of Ebola, Henipah viruses to China raises questions

  • Henipah and Nipah are interchangeable

Scientists at the National Microbiology Lab sent live Ebola and Henipah viruses to Beijing on an Air Canada flight March 31, and while the Public Health Agency of Canada says all federal policies were followed, there are questions about whether that shipment is part of an ongoing RCMP investigation.

Ebola and Henipah are Level 4 pathogens, meaning they’re some of the deadliest viruses in the world. They must be contained in a lab with the highest level of biosafety control, such as the one in Winnipeg. 

Two months after that shipment, on May 24, the Public Health Agency of Canada (PHAC) referred an “administrative matter” to RCMP that resulted in the removal of two Chinese research scientists — Xiangguo Qiu and Keding Cheng — and several international students on July 5. 

Both agencies have said repeatedly that public safety has not been at risk. 

PHAC will not confirm if the March 31 shipment is part of the RCMP investigation.

Strict protocols

Several sources, who have asked to remain anonymous because they fear for their jobs, say the pathogens may have been shipped to the Chinese Academy of Sciences in a way that circumvented the lab’s operating procedures, and without a document protecting Canada’s intellectual property rights.

Researchers working at the National Microbiology Lab on cutting-edge, high-containment research are not allowed to send anything to other countries or labs without the intellectual property office negotiating and having a material transfer agreement in place, in case the material sent leads to a notable discovery.

A PHAC spokesperson did not confirm if this shipment included such an agreement.

However, Eric Morrissette said it’s “routine” for the lab to share samples of pathogens and toxins with partners in other countries to advance scientific work worldwide.

The transfers follow strict protocols, including requirements under the Human Pathogens and Toxins Act(HPTA), the Transportation of Dangerous Goods Act, theCanadian Biosafety Standard and the lab’s standard operating procedures, Morrisette added.

“All transfers of Risk Group 4 samples follow strict transportation requirements and are authorized by senior officials at the lab and the NML tracks and keeps electronic records of all shipments of samples in accordance with the HPTA. Agreements for the transfer of materials are determined on a case-by-case basis,” Morrisette wrote in an email statement.

“On the specific shipments to China earlier this year, we can confirm that we have all records pertaining to the shipment, and that all protocols were followed as directed by the above Acts and Standards.”

Sources say Xiangguo Qiu and her husband, Keding Cheng, were escorted from the National Microbiology Lab in Winnipeg on July 5. (Governor General’s Innovation Awards)

Xiangguo Qiu is head of the National Microbiology Lab’s Vaccine Development and Antiviral Therapies section in the Special Pathogens Program. She is responsible for the lab that works with Ebola. Her husband, Keding Cheng, is also a PHAC biologist. 

After their security clearance was revoked and they were escorted from the lab, the University of Manitoba also cut ties with them and re-assigned Qiu’s graduate students, pending the RCMP investigation. No charges have been laid.

Neither scientist has responded to requests for comment, although some of their former colleagues say Qiu is not just a world-renowned scientist who helped develop a treatment for Ebola, but also a researcher with ethics and integrity.

Case raises questions 

One question raised by this case is that of intellectual property protection, says Leah West, who practises, studies and publishes in the field of national security law and lectures at the Norman Paterson School of International Affairs.

“If China was leveraging these scientists in Canada to gain access to a potentially valuable pathogen or to elements of a virus without having to license the patent  … it makes sense with the idea of China trying to gain access to valuable IP without paying for it,” she said.

Leah West says she hopes the lab and Health Canada are doing an investigation in addition to the one the RCMP is conducting. (Submitted by Leah West)

West accepts PHAC’s assertion that public safety is not an issue, even though the viruses were transported on a commercial Air Canada flight.

However, she says the fact the RCMP is involved means there’s a legitimate concern.

“You don’t send a policy breach, a bureaucratic policy breach, to the RCMP to investigate unless you believe that that policy breach has resulted in a criminal offence or could have resulted in a criminal offence. So what is the criminal offence potentially here?” West said.

She said she hopes the lab and Health Canada are also doing an internal investigation.

“I think there will need to be an inquiry into the scientists to potentially see whether or not they were compromised or any elements of their work were compromised and that China gained illegal or improper access to Canadian intellectual property … to see what China may have gained access to without knowledge, prior to this incident,” West says.

Don’t ‘jump into any conclusions too quickly’

However, the deputy director of the University of Alberta’s China Institute is urging caution when it comes to making assumptions. 

Jia Wang doesn’t dispute China has been involved in the past in espionage and intellectual property theft, but she says that country is making big investments in developing STEM (science, technology, engineering and mathematics) scholars and then putting that into innovation.

China has its own reasons to protect intellectual property because many new ideas are coming from there, Wang says.

She’s waiting to see what comes of the RCMP investigation of the lab in Winnipeg.

“As China observers, we’d like to perhaps gently remind people not to jump into any conclusions too quickly,” she said.

“It will be good to get to the bottom of this and see what might have gone wrong and what was the oversight and how can the procedures be improved or people involved can be reminded of how to adhere to the policies better.”

Jia Wang, deputy director of the University of Alberta’s China Institute, is advising caution about making assumptions concerning the case. (Submitted by Jia Wang)

The shipment of the viruses took place at a time when relations between Canada and China have been strained over the arrest of a Huawei executive, at the request of the United States. 

In retaliation, China has detained two Canadians and is boycotting Canadian canola and pork.

Because of the strained relationship between the two countries, and this case at the lab, Chinese-Canadian researchers and academics are starting to worry they may be singled out and targeted, Wang said.

“Certain assumptions are made or their loyalty to Canada is questioned in any way. And as multicultural as we are in Canada, we don’t want to see that.”  – CBC, 2019

SOURCE

On December 19, 2019, the U.S. Food and Drug Administration announced the approval of Ervebo to prevent EVD caused by Zaire ebolavirus in individuals 18 years of age and older. This report, published by the U.S. CDC on January 8, 2021, summarizes the Advisory Committee on Immunization Practices (ACIP) recommendations for using the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the USA.

On July 1, 2020, the European Medicines Agency granted Johnson & Johnson Janssen’s Zabdeno and Mvabea Ebola vaccine therapy, a prime-boost vaccination approach for preventing infectious diseases. Janssen’s Ebola vaccine regimen is specifically designed to induce long-term immunity against the Ebola virus in adults and children aged one year and above.

CanSino Biologics’s Ad5-EBOV Ebola vaccine received approval in China in October 2017. Ad5-EBOV is an adenovirus type 5 vector-based Ebola virus disease vaccine that protects against Ebola by relying on the recombinant replication-defective human adenovirus type-5 vector immune response. In addition, Ad5-EBOV is manufactured as a lyophilized powder, highly stable, and does not require storage at ultra-low temperatures. This feature renders it viable for use in resource-limited tropical areas.

The WHO published the revised Ebola Vaccine FAQ on January 11, 2020.

In 2019, World’s deadliest viruses were ‘shipped to Wuhan ‘leak lab’ from Canada by rogue scientists linked to Chinese military’ – The Sun

Experts Say Nipah Virus Has Potential To Be Another Pandemic — With A Higher Death Toll – Yahoo

What is Henipavirus?

Henipaviruses belong to the family of paramyxoviruses. Two species have been identified to be zoonotic, causing disease in animals. These are the Hendra virus (HeV) and the Nipah virus (NiV). They produce severe and often fatal illness in humans and horses.

News-Medical.net

THAT IS TO SAY ‘NIPAH’, ‘HENIPAH’ AND ‘HENIPAVIRUS’ ARE INTERCHANGEABLE HERE

Samples from early Wuhan COVID-19 patients show the presence of genetically modified Henipah virus, an American scientist has found.

Henipah was one of the two types of viruses sent to China by Chinese-born scientists from a Canadian laboratory at the centre of a controversy over the firing of the scientists and collaboration with Chinese military researchers. It is not clear whether the virus found in the Chinese samples is related to the samples sent by the Canadian lab, which were shipped in late March 2019.

The finding was confirmed for The Epoch Times by another qualified scientist.

The evidence was first found by Dr. Steven Quay, a Seattle-based physician-scientist and former faculty member at the Stanford University School of Medicine, who looked at early COVID-19 samples uploaded by scientists at the Wuhan Institute of Virology (WIV) shortly after China informed the World Health Organization about the SARS-CoV-2 outbreak.

Epoch Times Photo
Chinese virologist Shi Zhengli is seen inside the P4 laboratory in Wuhan, China, on Feb. 23, 2017. (Johannes Eisele/AFP via Getty Images)

The samples from the patients, who reportedly were found to have the “unknown pneumonia” in December 2019, were uploaded to the genetic sequence database, GenBank, on the website of the U.S. National Institute of Health (NIH).

Quay says that while other scientists around the world were mostly interested in examining the genome of SARS-CoV-2 in the samples uploaded by the WIV scientists, he wanted to see what else was in the samples collected from the patients.

So he collaborated with a few other scientists to analyze sequences from the samples.

“We started fishing inside for weird things,” Quay told The Epoch Times.

What they found, he says, are the results of what could likely be contamination from different experiments in the lab making their way into the samples, as well as evidence of Henipah virus.

“We found genetic manipulation of the Nipah virus, which is more lethal than Ebola.” Nipah is a type of Henipah virus.

The Epoch Times asked Joe Wang, PhD, who formerly spearheaded a vaccine development program for SARS in Canada with one of the world’s leading pharmaceutical companies, to verify the finding. Wang is currently the president of NTD Television Canada, the sister company of The Epoch Times in Canada.

After examining the evidence, Wang said he was able to replicate Quay’s findings on the Henipah virus. He explains that the genetic manipulation of the virus was likely for the purposes of vaccine development.

Winnipeg Lab

The firing of Chinese-born scientist Xiangguo Qiu and her husband, Keding Cheng, from the National Microbiology laboratory (NML) in Winnipeg has been the subject of much controversy in Canada, with opposition parties pressing the government for more details on the case, and the government refusing to release information citing national security and privacy concerns.

Qiu and Cheng along with several Chinese students were escorted out of NML, Canada’s only Level 4 lab, in July 2019, amid a police investigation. The two scientists were formally fired in January 2021.

The Public Health Agency of Canada (PHAC), which is in charge of NML, said the termination was the result of an “administrative matter” and “possible breaches of security protocols,” but has declined to provide further details, citing security and privacy concerns.

Epoch Times Photo
House Speaker Anthony Rota admonishes Public Health Agency of Canada President Iain Stewart in the House of Commons on June 21, 2021, for failing to provide documents related to the firing of two scientists from the National Microbiology Laboratory in Winnipeg. (The Canadian Press/Sean Kilpatrick)

During her time at NML, Qiu travelled several times in an official capacity to WIV, helping train personnel on Level 4 safety. The Globe and Mail later reported that scientists at NML have been collaborating with Chinese military researchers on deadly pathogens, and that one of the Chinese military researchers worked at the high-security Winnipeg lab for a period of time.

Documents and emails released by PHAC show that the shipment of Henipah and Ebola samples was done with the permission of NML authorities.

In one of the emails sent in September 2018, David Safronetz, chief of special pathogens at PHAC, informs then-head of NML Matthew Gilmour and other lab administrators about the request from WIV for the shipment of the samples, saying “I trust the lab.”

In response, Gilmour asks about the nature of the work that will be done at the Wuhan lab, and why the lab doesn’t get the material from “other, more local labs.” He also tells Safronetz that it’s “good to know that you trust this group,” asking how NML was connected with them.

In his reply, Safronetz doesn’t specifically say what the samples will be used for in China, but notes they will only be sent once all paperwork and certification is completed. He also says the WIV is requesting the material from NML “due to collaboration” with Qiu.

He adds, “Historically, it’s also been easier to obtain material from us as opposed to US labs. I don’t think other, closer labs have the ability to ship these materials.”

Gilmour resigned from his position at NML in May 2020 and joined a UK-based bioresearch company.

MPs have asked NML management why shipment of the samples was allowed and whether they knew if China performs any Gain of Function (GoF) research at WIV. GoF research involves increasing the lethal level (virulence) or transmissibility of pathogens.

NML’s acting scientific director general Guillaume Poliquin told MPs during a parliamentary committee meeting on March 22 that the lab only sent the samples to WIV after receiving assurance that no GoF research would take place.

Conservative MP John Williamson pressed for more answers, saying the word of the state-run Chinese lab can’t be trusted as the Chinese regime “has a history of theft and lies.”

The issue of GoF research at WIV has been a point of contention in the United States between lawmakers and Dr. Anthony Fauci, NIH’s head of the National Institute of Allergy and Infectious Diseases, whose organization has funded research (through EcoHealth Alliance) on coronaviruses at the Wuhan lab. U.S. Sen. Rand Paul says published work from WIV on coronaviruses shows the lab is conducting GoF research, a charge Fauci denies.

Epoch Times Photo
The P4 laboratory on the campus of the Wuhan Institute of Virology in Wuhan, China, on May 13, 2020. (Hector Retamal/AFP via Getty Images)

The Epoch Times sought comment from PHAC, including as to how the agency addressed issues of intellectual property and the development of any products such as vaccines with WIV, but didn’t hear back by time of publication.

Despite repeated requests by opposition parties for more details related to the firing of the two NML scientists, the Liberal government has refused to provide records, saying there are national security and privacy concerns.

After the House of Commons issued an order for the government to disclose the information, the government took the Speaker of the House to court to obtain confirmation from a judge that it can withhold the documents. The government later dropped its court case once Prime Minister Justin Trudeau called an election and Parliament was dissolved. – Epoch Times

LATER UPDATE: JUST LEARNED NIPAH WAS THE INSPIRATION FOR ANOTHER DRILL VERY SIMILAR TO EVENT201 – CLADE-X

NOTEWORTHY: Germany is the epicenter of this psyop, in their scenario

‘For the next pandemic, we’ll have gigantic mRNA factories in India’ – Bill Gates

The next pandemic: Nipah virus? – Bill Gates’ GAVI

SOURCE

Oh, look, a Dutch NGO on Taiwan TV pushing Nipah fearporn to WHO as early as February 2021:

SOURCE

India fighting to contain Nipah, a virus deadlier than COVID-19 – NY Post

Experimental drug by Gilead completely effective against Nipah virus infection in monkeys – NIH

ALSO IN 2019, INDIA CONDUCTS NIPAH OUTBREAK DRILLS. OFFICIALS SAY THEY HOPE FOR FULL PREPAREDNESS BY 2022:

ECO-HEALTH ALLIANCE INVOLVED AGAIN!

Remember the host?

THERE ARE SEVERAL PATENTS FOR NIPAH DRUGS AND SOME ARE mRNA GENE THERAPIES REGISTERED AS VACCINES

SOURCE
SOURCE
SOURCE

UPDATE 3: I FOUND CREDIBLE SOURCES FOR MOST OF DR. ARYANA LOVE’S EXPLOSIVE CLAIMS BELOW:

I didn’t have an in depth look at all her sources, I can’t have a final 100% verdict, but I did more than a glance and no lies detected. You can review her blog post yourself HERE.
This might be the closure to this report and the start for another.

OBAMA: EBOLA RESPONSE A TRIAL RUN FOR A POTENTIAL AIRBORNE VIRUS THAT MIGHT HIT SOON (2014)

BONUS

This is from 2014, but the story goes a way long back. And forward. Let’s not forget Putin is a Davos regular since before he became such a literal czar.

‘Contagion’ Reality Check: CDC Experts Explore Some of the Film’s Scenarios – PBS

WE ARE BEING PRIMED FOR THE DARKEST WINTER

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Right off the bat:

Detection and comparative analysis of persistent measles virus infection in Crohn’s disease by immunogold electron microscopy
Daszak, Peter, Purcell, Matthew, Lewin, Jackie, Dhillon, Amar P, Pounder, Roy E and Wakefield, Andrew J (1997) Detection and comparative analysis of persistent measles virus infection in Crohn’s disease by immunogold electron microscopy. Journal of Clinical Pathology, 50(4), pp. 299-304. ISSN (print) 0021-9746
Official URL: http://www.ncbi.nlm.nih.gov/pubmed/9215145

AFTER THAT, HE GOT 77 NOBEL PRIZES AND 31 MEDICAL ASSOCIATIONS TO BACK HIS AND FAUCI’S GAIN-OF-FUNCTION RESEARCH

BONUS BOMBSHELL: CLICK HERE TO WATCH DASZAK AND HIS WUHAN TEAM ADMITTING THEY WENT THERE FOR COLLABORATION, NOT INSPECTION

Peter Daszak – who donated to Hillary Clinton 13 times in 2016 – serves as the president of EcoHealth Alliance, a research organization that has partnered with the Wuhan Institue of Virology (WIV) – the very same lab many count as the source of COVID-19.

The type of research conducted by the group in tandem with the WIV prompted concern among National Institutes of Health officials for its role in COVID-related research, as outlined in a letter by NIH’s Deputy Director for Extramural Research Dr. Michael Lauer.

Dr. Lauer announced the suspension of NIH grants to the group, which saw its studies engineer the “highly specific doorway into the human body” as COVID-19, as a response:

“It is our understanding that one of the sub-recipients of the grant funds is the Wuhan Institute of Virology (‘WIV’). It is our understanding that WIV studies the interaction between corona viruses and bats. The scientific community believes that the coronavirus causing COVID-19 jumped from bats to humans likely in Wuhan where the COVID-19 pandemic began. There are now allegations that the current crisis was precipitated by the release from WIV of the coronavirus responsible for COVID-19. Given these concerns, we are pursuing suspension of WIV from participation in Federal programs.”

Chinese State Media.

While speaking at a conference sponsored by state-run media outlet China Global Television Network (CGTN), Daszak also revealed that he was a recipient of Chinese Communist Party cash.

He revealed he “has been working in China in collaboration with Chinese scientists and the government of China for over 15 years supported by federal funding from the U.S. and federal funding from China.”

Daszak has praised and attended the Beijing-based World Conference on Science Literacy, which is sponsored by the scientific group China Association for Science and Technology (CAST) that “serves as a bridge that links the Communist Party of China and the Chinese government to the country’s science and technology community.”

He has also appeared on panels at a CGTN-sponsored conference in cooperation with the Chinese Society for Science and Technology Journalism, a subsidiary of CAST.
.

The zoologist obtained his Ph.D. in parasitic infectious diseases from the University of East London – a college ranked 116th of 130 in the country. 

He has repeatedly appeared on CGTN, including praising the network as “fantastic” and “great” and defending scientific collaboration with the Chinese Communist Party as “important”

EcoHealth Alliance, Daszak’s nonprofit group, routed $600,000 in taxpayer funds to the WIV in form of subgrants as part of a project to study bat-based coronaviruses in China, funding that was terminated by the National Institutes of Health in May 2020.

From the onset of the pandemic, Daszak has denied he has a conflict of interest with the WIV, a claim that Rutgers University professor of chemical biology Richard H. Ebright said in April was a “brazen lie.

The WHO has defended its decision to appoint Daszak to the investigation of its COVID-9 origins despite accusations that his involvement mires the probe with major conflict of interests.

The WHO investigative panel shelved plans last week to release an interim report detailing how it concluded that it was “extremely unlikely” that COVID-19 could have accidentally leaked from the WIV. ”

Despite working at the onset of the pandemic to suppress debate on the lab leak theory, Daszak said former White House strategist Steve Bannon and the Chinese Falun Gong religious sect, which financially backs the Epoch Times newspaper and faces persecution from the Chinese Communist Party, are the ones responsible for China’s decision to block an outside investigation of the pandemic’s origins for over a year after the initial outbreak.

“I’ve seen incredible efforts from everything from Falun Gong to … Steve Bannon’s group pushing the conspiracy theories around China,” Daszak said during Wednesday’s panel discussion. “It’s useful to them. They’re funding it and pushing it and science has been to some extent caught up in that to other instances absolutely crushed by it.”

“We’ve not had access to work in China on the origins for the last 12 months, which is ironic because we could have been on the ground there working with our Chinese colleagues and by now we could have found some really important answers,” he said. “The rhetoric has held that up.”

Life is good when you share the bill with both Wakefield and Fauci

MORE RESOURCES:

TRIPLE-BOMBSHELL ON #WUHAN: #FAUCI, #WHO AND #CCP INVOLVED IN GAIN-OF-FUNCTION RESEARCH JUST PRIOR TO “PANDEMIC”

CCP-Linked Peter Daszak Has Long-Standing Relationship With “Incomparable” Dr. Fauci.

Trump Critic Doctor Donated To Hillary Clinton 13 Times In TWO MONTHS

WHO Investigator Peter Daszak Authored Over 20 CCP-Funded, Linked Studies.

NIH awards $7.5 million grant to EcoHealth Alliance, months after uproar over political interference

US Researcher With Chinese Ties Admits He Convinced WHO Team That Missing Wuhan Lab Data Was Irrelevant

Nobel laureates and science groups demand NIH review decision to kill coronavirus grant

By Science News Staff May. 21, 2020 , 6:40 PM

Science’s COVID-19 reporting is supported by the Pulitzer Center.

Seventy-seven U.S. scientists who have won a Nobel Prize today asked Francis Collins, director of the National Institutes of Health, and Alex Azar, secretary of Health and Human Services, to “act urgently” to review a controversial NIH decision to terminate a grant that supported research into bat coronaviruses in China. NIH’s explanation for killing the grant was “preposterous,” the laureates write.

Thirty-one scientific societies have also written to Collins, calling on NIH “to be transparent about their decision-making process on this matter. … The action taken by the NIH must be immediately reconsidered.”

On 24 April, NIH informed the nonprofit EcoHealth Alliance, led by wildlife disease specialist Peter Daszak, that it was ending a grant, first awarded in 2014 and renewed in 2019 because it no longer aligned with the agency’s priorities. The move came after Conservative U.S. politicians and media suggested—without evidence—that the coronavirus causing the pandemic escaped from a laboratory in Wuhan, China, that employs a Chinese virologist who had received funding from the grant. The termination also came 1 week after President Donald Trump, when asked about the project at a press conference, said: “We will end that grant very quickly.”

In their letter, the Nobel laureates say they “are gravely concerned” about that decision. “We believe that this action sets a dangerous precedent by interfering in the conduct of science and jeopardizes public trust in the process of awarding federal funds for research. … Now is precisely the time when we need to support this kind of research if we aim to control the pandemic and prevent subsequent ones.”

They write that “despite the high relevance of the studies to the current pandemic, and despite the very high priority score that his application for renewal had received during peer review, the NIH informed Dr. Daszak and his colleagues that the grant was being terminated because ‘NIH does not believe that the current project outcomes align with the program goals and agency priorities.’ Such explanations are preposterous under the circumstances.”

Azar and Collins should, they write, “act urgently to conduct and release a thorough review of the actions that led to the decision to terminate the grant, and that, following this review … take appropriate steps to rectify the injustices that may have been committed in revoking it.”

The signers of the letter include researchers who won a Nobel Prize as recently as 2019, and as long ago as 1975.

The letter from the scientific societies was organized by the American Society for Biochemistry and Molecular Biology (ASBMB). “Our aim with this effort is to stand up for a scientific enterprise that should be free of political influence on sound scientific research,” said Benjamin Corb, public affairs director for ASBMB, in a statement. “The continued politicization of science during this pandemic crisis is an alarming trend that is risking not only the integrity of science, but also the lives of citizens.

The Honorable Francis S. Collins
Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892
May 20, 2020
Director Francis Collins:
We, the undersigned scientific organizations representing tens of thousands of members of the American biomedical research enterprise, are alarmed by the National Institutes of Health’s revocation of a peer-reviewed research grant for studies of coronaviruses by EcoHealth Alliance. Not only is this decision counterintuitive, given the urgent need to better understand the virus that causes COVID-19 and identify drugs that will save lives, but it politicizes science at a time when, if we are to stamp out this scourge, we need the public to trust
experts and to take collective action.
The foundation of the American biomedical research enterprise rests on two principles: international collaboration and a robust peer-review process. Both must be vigilantly upheld. The abrupt revocation of the NIH grant for the EcoHealth Alliance concerns us for two primary reasons:
First, the decision seems to be a reaction to a theory about the origins of the COVID-19 virus that the intelligence community itself has publicly repudiated. EcoHealth Alliance at one point collaborated with a lab in Wuhan, China, which has recently been at the center of rumors about the origin of the pandemic. The overall goal of EcoHealth Alliance’s research project is to study coronavirus transmission from species to species. But the purpose of the research project has been conflated with these rumors. This is worrisome. International collaboration has propelled the American research enterprise to achieve vital innovations and discoveries; it is the gold standard for the scientific community. The United States is a beacon for the best and brightest minds, consistently attracting top scientists from around the world. However, with this incident, international
collaboration is being portrayed as a threat. The scientific enterprise requires diversity, and American scientists depend on their international colleagues to pool resources, expertise, and ultimately make scientific breakthroughs.
Second, the decision sets a dangerous precedent by revoking a grant that was awarded based upon scientific merit without a justifiable rationale such as issues related to scientific or financial fraud or misconduct. This grant is highly and uniquely relevant to all NIAID priorities to address the current COVID-19 pandemic. Most extramural research funds are awarded through a robust peer-review process. Scientists, not politicians, determine the merit of grant applications, and grant recipients are expected to be careful stewards of taxpayer
dollars. Throughout the lifetime of a grant, each recipient communicates regularly with scientific review officers at the funding agency and produces progress reports providing evidence that the work remains valuable and on
track. This has been the norm and until April 24, 2020 was applied to the now terminated grant. That has now been breached and this action must not become the norm going forward.
The scientific community urges federal funding agencies and policymakers to ensure the transparency, openness, and collaborative nature of the American biomedical research enterprise. We call on the NIH to be transparent about their decision-making process on this matter. We urge federal funding agencies to safeguard the American biomedical research enterprise. The action taken by the NIH must be immediately reconsidered.
Respectfully,
The American Society for Biochemistry and Molecular Biology
The Academy for Radiology and Biomedical Imaging Research
The American Association for Anatomy
The American Institute of Biological Sciences
The American Physiological Society
The American Psychological Association
The American Society for Investigative Pathology
The American Society for Virology
The American Society of Ichthyologists and Herpetologists
The Association of Anatomy, Cell Biology and Neurobiology Chairs
The Association of Biomolecular Resource Facilities
The Association of Medical and Graduate Departments of Biochemistry
The Association of Schools and Programs of Public Health
The Biophysical Society
The Botanical Society of America
The Conference Board of Mathematical Sciences
The Endocrine Society
The Entomological Society of America
The Federation of American Societies for Experimental Biology
The Genetics Society of America
The HIV Medicine Association
The Infectious Diseases Society of America
The Natural Science Collections Alliance
The North American Vascular Biology Organization
The Shock Society
The Society for Freshwater Science
The Society for the Study of Amphibians and Reptiles
The Society for the Study of Reproduction
The Society of Toxicology

Download original PDF

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

You’ve likely heard of IG Farben, but have you ever heard of American IG and the follow up story?

This is a follow up to an earlier report you should check first.

Imagine that the brutal experiments at Auschwitz were better concealed and the prisoners were drugged and brainwashed to believe that’s the best world out there for them. Then find out that the management has never stopped winning, expanding and perfecting their business model, up to today’s Great Reset.

This report is a video presentation

good stuff that i had to leave out the video documentary:

Rockefellers brought the Nazi doctors and researchers to the US

SOURCE

ANSCO

Founded in Binghamton, New York, in 1901, Ansco was a manufacturer of photographic products and film. Ansco was originally founded through the merger of E. Anthony & Company and Scovill Manufacturing. In 1928, Ansco merged with Agfa to form Agfa-Ansco. The new corporation was a division of General Aniline and Film (GAF) Corporation, which was controlled by the German chemical cartel IG Farben. After Germany declared war on the United States in 1941, the United States Government seized the assets of GAF, including Agfa-Ansco. In 1943, the company removed “Agfa” from its name, once again becoming Ansco. The United States Justice Department oversaw Ansco’s operation until 1965, when government-held stock in GAF was sold to the public. In 1977, GAF eliminated its line of consumer photography products, including those manufactured by Ansco at the Binghamton facility. GAF also sold the Ansco trademark to Haking Enterprises. GAF continued to manufacture film at the Binghamton plant for industrial and medical use until 1981, when it sold the plant to Anitec Image Corporation. Over the next two decades, the former Ansco facility was sold several times, and in 2000, it was demolished.

Prior to the late 1970s, dozens of asbestos-containing materials were utilized in the construction and maintenance of buildings at Ansco’s Binghamton facility, including fireproof insulation, pipe covering and insulating cement. Inhaling dust from the application and removal of asbestos-containing materials placed workers at risk for developing an asbestos-related disease, such as mesothelioma or lung cancer.

Fireproof insulation was applied to structural steel during the construction of buildings at Ansco. Fireproofing materials were manufactured as a dry mixture of asbestos, linen and cement, packaged in fifty-pound paper bags. The dry mixture was mixed with water and sprayed onto the structural steel using a hose. Pouring, mixing and spraying fireproof insulation created clouds of asbestos-containing dust. After the fireproofing material was applied, it was typical for tradesmen, such as electricians or pipefitters, to scrape the fireproofing material from structural steel in order to install pipes and conduits. When the fireproof insulation was disturbed, asbestos fibers and dust became airborne.

Workers applied asbestos-containing pipe covering to pipes at the Binghamton Ansco facility. Pipe covering was applied to numerous piping systems in order to maintain stable internal temperatures and to protect pipes from damage. When pipe covering was applied, asbestos fibers were emitted. Insulating cement was also applied to pumps, valves and other equipment. It was manufactured as a powder and mixed with water to prepare it for application. Mixing insulating cement caused asbestos-containing dust to become airborne.

source:

What’s Bayer been up to lately?
We find out from their website:

The Bio Revolution is redefining innovation in the life sciences. How this might be a game changer.

The life sciences have made great advances in the past years. Biology, life sciences and the megatrend of digitization are growing closer together, enabling new inventions that impact our daily lives in a scope that we speak of a Bio Revolution. This revolution is reinforced by rapid increases in computing power and the emergence of new capabilities in AI, automation, and data analytics. These trends are further accelerating the pace of innovation and the potential for higher R&D productivity in the life sciences.

All this has led to new ways to understand and explore biology. The range of life forms on earth is incredibly complex and diverse. However, the methods to analyze them can be remarkably similar. Technologies and methods are transcending disciplinary boundaries even faster.

The implications across the life sciences can be enormous:

For human health, for example, a deeper understanding of the relationship between genetics and disease has led to the emergence of precision medicine, which can potentially be more effective than the one-size-fits-all therapies of the past. In the future, new technologies could help the healthcare industry not only treat, but cure or even prevent diseases. New gene and cell therapies, for example, aim to cure genetic diseases, potentially enabling sustainable organ replacement or reversing autoimmune diseases.

The Bio Revolution has the potential to help address some of the most critical global challenges, from climate change to pandemics, chronic diseases, and worldwide food security. Experts estimate that a significant portion of the economic impact of biological applications will be in health care, agriculture, and consumer products.3 Already today, the Bio Revolution with its convergence of science and technology has created an explosion of research projects in science and business. Each year, the amount of Intellectual Property related to the Bio Revolution is increasing.4 This can be seen, for example, by the number of patents in CrispR or plant biotech. In short: the revolution is gaining momentum and holds a great promise for health and food alike.

Total number of CRISPR patent applications worldwide per year from 1984 to 2018.

Quote symbolFueled by digitalization, growing connectivity, and falling costs, important advances in biotechnology are intertwined with more systemic shift in how bio-innovation is undertaken and who is involved. Microbiome technologies, advanced genomics, gene editing and synthetic biology are among key enabling technologies that have the potential to change the face of bio-innovation. This broader redefinition of bio-innovation creates new prospects to help address important nutrition, environmental and development needs.

World Economic Forum, Bio-Innovation Dialogue Initiative

.At the Forefront of the Bio Revolution

As a leading life science company, Bayer is aligned with the long-term market trends in health and nutrition and offers innovative and sustainable solutions to tackle some of the key challenges for humanity. Bayer brings to the table an extensive knowledge of human and plant science, supported by its expertise in regulatory processes and an impressive global footprint to ultimately bring innovations from labs to market. https://www.youtube-nocookie.com/embed/EYE1gya7XiM?autoplay=1&start=0&rel=0

The Bio Revolution marks the beginning of a new era: Innovations enabled by the convergence of biology and technology have the potential to significantly improve our lives, our nutrition, and our health.

Did you know that Bayer is at the forefront of the wave of innovation coming from the Bio Revolution?

The Bio Revolution is expected to transform healthcare and agriculture over the next decades – but the revolution is already happening now. With its newly established cell and gene therapy platform in Pharmaceuticals and innovative gene-editing tools such as CRISPR, Bayer operates at the core of the Bio Revolution and has tremendous opportunities to improve health and nutrition.

In Pharma, Bayer’s new Cell & Gene Therapy (CGT) platform steers our strategy in the area and orchestrates our activities along the value chain providing an innovation ecosystem for the companies – including BlueRock Therapeutics and Asklepios BioPharmaceutical (AskBio), which are fully owned by Bayer but operate autonomously. These therapies hold the potential to significantly impact patients’ lives by moving from treating symptoms to potentially curative approaches.

Bayer’s development portfolio of cell and gene therapies already comprises eight advanced assets in different stages of clinical development. These are applicable in multiple therapeutic areas with high unmet need, such as neurodegenerative, neuromuscular and cardiovascular indications, with programs in Pompe disease, Parkinson’s disease, hemophilia A, and congestive heart failure. With over 15 preclinical assets in the cell and gene therapy field, the pipeline is expected to grow steadily year by year.

Yet Bayer is not only using biotechnology to advance health – the promise for agriculture is just as inspiring. In the Crop Science Division, for example, tools like CRISPR can make changes to plant DNA with more precision than ever before and make plants more weather- or disease-resistant, enabling farmers to grow more or better-quality products under changing conditions.

Advancing genetic solutions for a sustainable future (1)PreviousNext

Did you know that Leaps by Bayer invests into potentially disruptive technologies to tackle some of the largest, unsolved challenges in the life sciences?

With Leaps by Bayer – our impact investment approach utilizing venture capital – we are constantly scanning for additional potential breakthroughs that hold promise to either cure or treat people from diseases or help feed a growing population with less impact on the environment.

$1 Billion

Since 2015, Leaps by Bayer has invested over $1 billion in ventures that tackle fundamental breakthroughs and shift core paradigms in our industries.

Leaps by Bayer has an investment focus on potentially disruptive solutions in the fields of healthcare and agriculture. The Leaps investment approach is remarkable: It aims to invest into or build up new innovative companies. Bayer supports those companies by enabling the exchange of proprietary assets, which can include sharing own patents or providing access to the Bayer network’s technical capabilities and 150 years of expertise. The companies remain autonomous with respect to decision making, while Leaps facilitates and supports them in a so-called active incubation process. Experienced team members actively engage in the young companies’ development by providing resources and helping them to steer the initial strategic direction. Today, the investment portfolio includes more than 35 companies advancing potential breakthrough technologies.

Quote symbolLeaps is our way of thinking big.

Werner Baumann, CEO of Bayer AG

Many Leaps ventures have made significant progress towards unlocking the potential of new technology platforms with a promising and transformative potential. BlueRock Therapeutics, for example, started as a Leaps investment and is now an integral part of Bayer’s CGT platform and just received clearance to proceed with a phase I trial in Parkinson’s disease.

Other companies, like the biopharmaceutical player Triumvira, are specialized on next generation immuno-oncology treatments. Triumvira focuses on novel T-cell therapies that aim to be safer and more efficacious than current cell therapy cancer treatments. Treating, curing and preventing cancer is one of the focus areas of Leaps by Bayer, since this group of diseases still represents one of today’s biggest health challenges with limited curative or preventative therapies available.

Quote symbolWe face a huge disease burden, and the way we produce food isn’t sustainable for the planet. I believe the Bio Revolution can help us overcome these issues.

Jürgen Eckhardt, Head of Leaps by Bayer

Leaps is also investing in the development of sustainable biotechnological solutions in the field of agriculture. One of the ventures in this field is Joyn Bio, a company that aims to significantly reduce the environmental impact of synthetic nitrogen fertilizers through a technology that fixes nitrogen into the soil. Nitrogen is one of the most important nutrients essential for every plant to grow, however, its use and production as a fertilizer is estimated to contribute 3-5% to all global greenhouse gas emissions. Joyn Bio is working on an engineered microbe that enables cereal crops like corn, wheat, and rice to convert nitrogen from the air into a form they can use to grow. This technology may have the potential to help farmers use nitrogen in new ways, and as a result, reduce agriculture’s environmental footprint.

Leaps portfolio

The Leaps by Bayer investment portfolio includes more than 35 companies.

At least that’s what Bayer says. All I know is that they’re still running the show.

Ex-Standard Oil

HERE WE GO AGAIN:

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We gave up on our profit shares from masks, if you want to help us, please use the donation button!
We think frequent mask use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness.
Get it here!

DNA harvesting, mRNA technologies, mind-reading and more – this was the official race start signal at the Transhumanist Olympics, all the way back in 2013

The vision for the BRAIN Initiative is to combine these areas of research into a coherent, integrated science of cells, circuits, brain and behavior.

  • Generate a census of brain cell types
  • Create structural maps of the brain
  • Develop new, large-scale neural network recording capabilities
  • Develop a suite of tools for neural circuit manipulation
  • Link neuronal activity to behavior
  • Integrate theory, modeling, statistics and computation with neuroscience experiments
  • Delineate mechanisms underlying human brain imaging technologies
  • Create mechanisms to enable collection of human data for scientific research
  • Disseminate knowledge and training

Source: NIH

You mean THIS DARPA?
Yeah, this one…
  • Not often mentioned, IARPA is CIA’s DARPA, an even more secretive, dark and psychopathic agency.

How The BRAIN Initiative® workS 

Given the ambitious scope of this pioneering endeavor, it was vital that planning be informed by a wide range of expertise and experience. Therefore, NIH established a high level working group of the Advisory Committee to the NIH Director (ACD) to help shape this new initiative.

This working group, co-chaired by Dr. Cornelia “Cori” Bargmann (The Rockefeller University) and Dr. William Newsome (Stanford University) sought broad input from the scientific community, patient advocates, and the general public. Their report, BRAIN 2025: A Scientific Vision, released in June 2014 and enthusiastically endorsed by the ACD, articulated the scientific goals of The BRAIN Initiative® and developed a multi-year scientific plan for achieving these goals, including timetables, milestones, and cost estimates.

Of course, a goal this audacious will require ideas from the best scientists and engineers across many diverse disciplines and sectors. Therefore, NIH is working in close collaboration with other government agencies, including the Defense Advanced Research Projects Agency (DARPA), National Science Foundation (NSF), the U.S. Food and Drug Administration (FDA) and Intelligence Advanced Research Projects Activity (IARPA). Private partners are also committed to ensuring success through investment in The BRAIN Initiative®.

Five years ago a project such as this would have been considered impossible. Five years from now will be too late. While the goals are profoundly ambitious, the time is right to inspire a new generation of neuroscientists to undertake the most groundbreaking approach ever contemplated to understanding how the brain works, and how disease occurs.
Source: NIH

The White House Office of the Press Secretary, For Immediate Release, April 02, 2013

Remarks by the President on the BRAIN Initiative and American Innovation

East Room  10:04 A.M. EDT 

THE PRESIDENT:  

Thank you so much.  (Applause.)  

Thank you, everybody.  Please have a seat.  Well, first of all, let me thank Dr. Collins not just for the introduction but for his incredible leadership at NIH.  Those of you who know Francis also know that he’s quite a gifted singer and musician.  So I was asking whether he was going to be willing to sing the introduction — (laughter) — and he declined. But his leadership has been extraordinary.  And I’m glad I’ve been promoted Scientist-in-Chief.  (Laughter.)

 Given my grades in physics, I’m not sure it’s deserving.  But I hold science in proper esteem, so maybe that gives me a little credit. Today I’ve invited some of the smartest people in the country, some of the most imaginative and effective researchers in the country — some very smart people to talk about the challenge that I issued in my State of the Union address:  to grow our economy, to create new jobs, to reignite a rising, thriving middle class by investing in one of our core strengths, and that’s American innovation.  Ideas are what power our economy.  It’s what sets us apart.  It’s what America has been all about.  We have been a nation of dreamers and risk-takers; people who see what nobody else sees sooner than anybody else sees it.  We do innovation better than anybody else — and that makes our economy stronger.  

When we invest in the best ideas before anybody else does, our businesses and our workers can make the best products and deliver the best services before anybody else.   And because of that incredible dynamism, we don’t just attract the best scientists or the best entrepreneurs — we also continually invest in their success.  We support labs and universities to help them learn and explore.  And we fund grants to help them turn a dream into a reality.  And we have a patent system to protect their inventions.  And we offer loans to help them turn those inventions into successful businesses.   

And the investments don’t always pay off.  But when they do, they change our lives in ways that we could never have imagined.  Computer chips and GPS technology, the Internet — all these things grew out of government investments in basic research.  And sometimes, in fact, some of the best products and services spin off completely from unintended research that nobody expected to have certain applications.  

Businesses then used that technology to create countless new jobs. 

So the founders of Google got their early support from the National Science Foundation.  The Apollo project that put a man on the moon also gave us eventually CAT scans.  And every dollar we spent to map the human genome has returned $140 to our economy — $1 of investment, $140 in return.

 Dr. Collins helped lead that genome effort, and that’s why we thought it was appropriate to have him here to announce the next great American project, and that’s what we’re calling the BRAIN Initiative.   

As humans, we can identify galaxies light years away, we can study particles smaller than an atom.  But we still haven’t unlocked the mystery of the three pounds of matter that sits between our ears.  (Laughter.)  But today, scientists possess the capability to study individual neurons and figure out the main functions of certain areas of the brain.  But a human brain contains almost 100 billion neurons making trillions of connections.  

So Dr. Collins says it’s like listening to the strings section and trying to figure out what the whole orchestra sounds like.  So as a result, we’re still unable to cure diseases like Alzheimer’s or autism, or fully reverse the effects of a stroke.  And the most powerful computer in the world isn’t nearly as intuitive as the one we’re born with. So there is this enormous mystery waiting to be unlocked, and the BRAIN Initiative will change that by giving scientists the tools they need to get a dynamic picture of the brain in action and better understand how we think and how we learn and how we remember.  And that knowledge could be — will be — transformative.   In the budget I will send to Congress next week, I will propose a significant investment by the National Institutes of Health, DARPA, and the National Science Foundation to help get this project off the ground.

 I’m directing my bioethics commission to make sure all of the research is being done in a responsible way.  And we’re also partnering with the private sector, including leading companies and foundations and research institutions, to tap the nation’s brightest minds to help us reach our goal. And of course, none of this will be easy.  If it was, we would already know everything there was about how the brain works, and presumably my life would be simpler here.  (Laughter.)  It could explain all kinds of things that go on in Washington.  (Laughter.)  We could prescribe something.  (Laughter.)  

So it won’t be easy.  But think about what we could do once we do crack this code.  Imagine if no family had to feel helpless watching a loved one disappear behind the mask of Parkinson’s or struggle in the grip of epilepsy.  Imagine if we could reverse traumatic brain injury or PTSD for our veterans who are coming home.  Imagine if someone with a prosthetic limb can now play the piano or throw a baseball as well as anybody else, because the wiring from the brain to that prosthetic is direct and triggered by what’s already happening in the patient’s mind.  What if computers could respond to our thoughts or our language barriers could come tumbling down.  Or if millions of Americans were suddenly finding new jobs in these fields — jobs we haven’t even dreamt up yet — because we chose to invest in this project. That’s the future we’re imagining.  That’s what we’re hoping for.  That’s why the BRAIN Initiative is so absolutely important.  And that’s why it’s so important that we think about basic research generally as a driver of growth and that we replace the across-the-board budget cuts that are threatening to set us back before we even get started.  

A few weeks ago, the directors of some of our national laboratories said that the sequester — these arbitrary, across-the-board cuts that have gone into place — are so severe, so poorly designed that they will hold back a generation of young scientists.  When our leading thinkers wonder if it still makes sense to encourage young people to get involved in science in the first place because they’re not sure whether the research funding and the grants will be there to cultivate an entire new generation of scientists, that’s something we should worry about.  We can’t afford to miss these opportunities while the rest of the world races ahead.  We have to seize them.  I don’t want the next job-creating discoveries to happen in China or India or Germany.  I want them to happen right here, in the United States of America.   And that’s part of what this BRAIN Initiative is about.  That’s why we’re pursuing other “grand challenges” like making solar energy as cheap as coal or making electric vehicles as affordable as the ones that run on gas.  They’re ambitious goals, but they’re achievable.  And we’re encouraging companies and research universities and other organizations to get involved and help us make progress. We have a chance to improve the lives of not just millions, but billions of people on this planet through the research that’s done in this BRAIN Initiative alone.  

But it’s going to require a serious effort, a sustained effort.  And it’s going to require us as a country to embody and embrace that spirit of discovery that is what made America, America. They year before I was born, an American company came out with one of the earliest mini-computers.  It was a revolutionary machine, didn’t require its own air conditioning system.  That was a big deal.  It took only one person to operate, but each computer was eight feet tall, weighed 1,200 pounds, and cost more than $100,000.  And today, most of the people in this room, including the person whose cell phone just rang — (laughter) — have a far more powerful computer in their pocket.  Computers have become so small, so universal, so ubiquitous, most of us can’t imagine life without them — certainly, my kids can’t.   And, as a consequence, millions of Americans work in fields that didn’t exist before their parents were born.  Watson, the computer that won “Jeopardy,” is now being used in hospitals across the country to diagnose diseases like cancer.  That’s how much progress has been made in my lifetime and in many of yours.  That’s how fast we can move when we make the investments.   

But we can’t predict what that next big thing will be.  We don’t know what life will be like 20 years from now, or 50 years, or 100 years down the road.  What we do know is if we keep investing in the most prominent, promising solutions to our toughest problems, then things will get better. I don’t want our children or grandchildren to look back on this day and wish we had done more to keep America at the cutting edge.  I want them to look back and be proud that we took some risks, that we seized this opportunity.  That’s what the American story is about.  That’s who we are.  

That’s why this BRAIN Initiative is so important.  And if we keep taking bold steps like the one we’re talking about to learn about the brain, then I’m confident America will continue to lead the world in the next frontiers of human understanding.  And all of you are going to help us get there. 

So I’m very excited about this project.  Francis, let’s get to work.  God bless you and God bless the United States of America.  Thank you.  (Applause.)  

A LITTLE EARLIER, AT DARPA’S

DARPA Fold F(x) Program to Advance Synthetic Biomedical Polymers

by Global Biodefense StaffJanuary 21, 2014

The Defense Advanced Research Projects Agency (DARPA) is soliciting proposals for advancing “Folded Non-Natural Polymers with Biological Function” under a new Broad Agency Announcement for the Fold F(x) program.

While the biopharmaceutical industry has realized many outstanding protein and oligonucleotide reagents and medicines by screening large biopolymer libraries for desired function, significant technical gaps remain to rapidly address the full suite of existing and anticipated national security threats in DoD medicine (e.g., diagnostics and remediation strategies for chemical/biological warfare agents and infectious disease threats).

The objective of Fold F(x) is to develop processes enabling the rapid synthesis, screening, sequencing and scale-up of folded, non-natural, sequence-defined polymers with expanded functionality. The program will specifically address the development of non-natural affinity reagents that can bind and respond to a selected target, as well as catalytic systems that can either synthesize or degrade a desired target.

While non-natural folding polymers (e.g., foldamers) are known, broad utilization of these systems is currently limited because there is no available approach for rapidly developing and screening large non-natural polymer libraries. Fold F(x) will address this technical gap to create new molecular entities that will become future critical reagents in sensor and diagnostic applications, novel medicine leads against viral and bacterial threats, and new polymeric materials for future material science applications.

DARPA anticipates that successful efforts will include (1) novel synthetic approaches that yield large libraries (>109 members) of non-natural sequence-defined polymers; (2) flexible screening strategies that enable the selection of high affinity/specificity binders and high activity/selectivity catalysts from the non-natural libraries; (3) demonstration that the screening approach can rapidly (<4 days) yield affinity reagents or catalysts against targets of interest to the DoD; and (4) demonstration of scalability and transferability to the DoD scientific community.

DARPA seeks proposals that significantly advance the area of non-natural polymer synthesis, screening and sequencing for DoD-relevant threats. Proposals that simply provide evolutionary improvements in state-of-the-art technology will not be considered.

A Proposers’ Day Webinar for the Fold F(x) Program will be held on January 28, 2014. Further details are available under Solicitation Number: DARPA-BAA-14-13. White papers are due by February 6, 2014.

Source: FBO.gov

They deleted this from their website, but not from Internet

FOLDED NON-NATURAL POLYMERS WITH BIOLOGICAL FUNCTION (FOLD F(X))

Health threats often evolve more quickly than health solutions. Despite ongoing research in the government and the biopharmaceutical industry to identify new therapies, the Department of Defense currently lacks the tools to address the full spectrum of chemical, biological, and disease threats that could impact the readiness of U.S. forces. DARPA created the Folded Non-Natural Polymers with Biological Function program (Fold F(x)) to give DoD medical researchers new tools to develop medicines, sensors, and diagnostics using new libraries of synthetic polymers.

The human body contains natural, folded polymers such as DNA, RNA, and proteins. These are made up of strings of specific biological molecules, or monomers, with the potential for massive variation in sequence, structure, and function. The body’s library of natural polymers is massive, but ultimately limited by the number of naturally present monomers. Through Fold F(x), DARPA is looking to expand the body’s biomolecular arsenal using non-natural, sequence-dictated polymers built from lab-created monomers.

Broad use of folded, non-natural polymers has been limited because no approach yet exists for rapidly developing large libraries of such sequence-dictated polymers. However, recent advances in the theory for predicting folds in polymer structure enable a more targeted search for polymers with specific attributes. Additionally, new, high-throughput analytical chemistry tools may enable researchers to efficiently screen massive subsets of polymers to essentially find the needle in the haystack to confront a given health threat. Finally, recently developed tools for determining polymer structure, function, and in vivo effects can further accelerate the characterization of promising non-natural polymers once they have been identified.

To achieve its objective, Fold F(x) seeks to develop the following capabilities: 1) processes that enable rapid, high-fidelity synthesis of monomers and polymer libraries at scale; 2) automated screening of polymers against a target; and 3) automated sequencing and characterization of successful polymers. The capabilities developed will need to be generalized and extendable so they can be applied to a broad range of potential applications.

If Fold F(x) is successful, synthetic polymers, produced at low cost in libraries containing trillions of combinations, would give scientists vastly more molecules to work with in the search for new health solutions and greatly increase the likelihood that a molecule can be found to combat a given health threat. Synthetic polymers would also offer other benefits over natural polymers including greater lifetime in the blood and less immunogenicity.

LATER…

DOES THIS REMIND YOU OF ANY PARTICULAR IMPLANT: SRI Biosciences DARPA Fold F(X) Synthetic Polymers Contract

by CBRNE CENTRAL STAFF, February 11, 2015, 11:33

SRI Biosciences, a division of SRI International, has been awarded a $10 million contract under a Defense Advanced Research Projects Agency (DARPA) program to reimagine how proteins are constructed and to develop novel medicines and diagnostics as countermeasures to chemical and biological threats.

The new contract is part of DARPA’s Folded Non-Natural Polymers with Biological Function program, known as Fold F(x). The initial goal of the program will be to develop biologically active non-natural polymers that are structurally similar to naturally occurring proteins, but without their limitations, such as sensitivity to heat denaturation or chemical degradation.

To develop the new polymers, SRI is combining its expertise in medicinal chemistry and biopolymer design with a breakthrough approach to screening vast numbers of compounds. The novel polymers are being made from entirely new types of monomer structures based on drug-like scaffolds with high functional group densities.

SRI’s compound screening innovation is based on its proprietary Fiber-Optic Array Scanning Technology (FASTcell™). Originally developed to identify circulating tumor cells in a blood sample, FASTcell can distinguish a single tumor cell among tens of millions of healthy ones in a few minutes.

With DARPA support, SRI is expanding this technology to screen 25 million compounds in just one minute.

“Our goal is to develop a method that can enable rapid, large-scale responses to a bioterrorism threat or an infectious disease epidemic,” said Peter Madrid, Ph.D., program director in SRI Biosciences’ Center for Chemical Biology and co-principal investigator and leader of the chemistry effort of the project. “We are looking for non-natural polymers to detect or neutralize identified chemical or biological threats. Once we find potent molecules, we will be able to produce them at mass scale.”

The overall goal of the Fold F(x) program is to expand on the utility of proteins and DNA, and to overcome their limitations by re-engineering their polymer backbones and side chain diversity—creating new molecules with improved functionality such as stability, potency and catalytic function in environments usually hostile for biopolymers.

The knowledge to design new functional molecules from first principles doesn’t exist yet. The alternative is to synthesize enormous libraries of non-natural polymers and screen for sequences that have a desired action. Finding a single effective compound, such as one that can block a virus, may require screening hundreds of millions of compounds.

“We are taking a full departure from how nature does things to come up with new ways of mimicking protein function in a highly tailored and controlled way,” said Nathan Collins, Ph.D., executive director of SRI Biosciences’ Discovery Sciences Section and principal investigator of SRI’s Fold F(x) project. “Our breakthrough has been to adapt SRI’s FASTcell technology to screen libraries of non-natural polymers. It’s very exciting to be doing such novel research.”

Initially the program will focus on screening massive numbers of non-natural polymers for potential uses against security threats.

As a proof of concept, the team will design, synthesize and screen chemically unique libraries of 100 million non-natural polymers for activity against a variety of agents, including toxins such as ricin and viruses such as the H1N1 bird flu strain of influenza.

As the program evolves it may progress to include a range of possibilities, such as how to synthesize molecules to fold such that they emit light, have enhanced levels of strength or elasticity, or store power.

Sources: SRI International, DARPA

Stargate Project

From Wikipedia, the free encyclopedia

Stargate Project was the 1991 code name for a secret U.S. Army unit established in 1978 at Fort MeadeMaryland, by the Defense Intelligence Agency (DIA) and SRI International (a California contractor) to investigate the potential for psychic phenomena in military and domestic intelligence applications. The Project, and its precursors and sister projects, originally went by various code names—GONDOLA WISH, GRILL FLAME, CENTER LANE, PROJECT CF, SUN STREAK, SCANATE—until 1991 when they were consolidated and rechristened as “Stargate Project”.

Stargate Project work primarily involved remote viewing, the purported ability to psychically “see” events, sites, or information from a great distance.[1] The project was overseen until 1987 by Lt. Frederick Holmes “Skip” Atwater, an aide and “psychic headhunter” to Maj. Gen. Albert Stubblebine, and later president of the Monroe Institute.[2] The unit was small-scale, comprising about 15 to 20 individuals, and was run out of “an old, leaky wooden barracks”.[3]

The Stargate Project was terminated and declassified in 1995 after a CIA report concluded that it was never useful in any intelligence operation. Information provided by the program was vague and included irrelevant and erroneous data, and there was reason to suspect that its project managers had changed the reports so they would fit background cues.[4] The program was featured in the 2004 book and 2009 film, both titled The Men Who Stare at Goats,[5][6][7][8] although neither mentions it by name.

THE LIST OF RESEARCHES THEY FUNDED MIGHT BLOW YOUR BRAIN

FULL LIST HERE

THEIR REPORT BELOW SEEMS TO CONFIRM OUR EARLIER REPORT THAT MRNA IS A GATEWAY TO THE BRAIN AND BEHAVIOURS

SOURCE

READ: Yes, they CAN vaccinate us through nasal test swabs AND target the brain (Biohacking P.1)

Private Sector Partners

Key private sector partners have made important commitments to support the BRAIN Initiative, including:

  • The Allen Institute for Brain Science:  The Allen Institute, a nonprofit medical research organization, is a leader in large-scale brain research and public sharing of data and tools. In March 2012, the Allen Institute for Brain Science embarked upon a ten-year project to understand the neural code: how brain activity leads to perception, decision making, and ultimately action. The Allen Institute’s expansion, with a $300M investment from philanthropist Paul G. Allen in the first four years, was based on the recent unprecedented advances in technologies for recording the brain’s activity and mapping its interconnections.  More than $60M annually will be spent to support Allen Institute projects related to the BRAIN Initiative.
  • Howard Hughes Medical Institute:  HHMI is the Nation’s largest nongovernmental funder of basic biomedical research and has a long history of supporting basic neuroscience research.  HHMI’s Janelia Farm Research Campus in Virginia was opened in 2006 with the goal of developing new imaging technologies and understanding how information is stored and processed in neural networks. It will spend at least $30 million annually to support projects related to this initiative. 
  • Kavli Foundation:  The Kavli Foundation anticipates supporting activities that are related to this project with approximately $4 million dollars per year over the next ten years.  This figure includes a portion of the expected annual income from the endowments of existing Kavli Institutes and endowment gifts to establish new Kavli Institutes over the coming decade. This figure also includes the Foundation’s continuing commitment to supporting project meetings and selected other activities.
  • Salk Institute for Biological Studies:  The Salk Institute, under its Dynamic Brain Initiative, will dedicate over $28 million to work across traditional boundaries of neuroscience, producing a sophisticated understanding of the brain, from individual genes to neuronal circuits to behavior. To truly understand how the brain operates in both healthy and diseased states, scientists will map out the brain’s neural networks and unravel how they interrelate. To stave off or reverse diseases such as Alzheimer’s and Parkinson’s, scientists will explore the changes that occur in the brain as we age, laying the groundwork for prevention and treatment of age-related neurological diseases.

Source: The White House

Kavli are just Rockefeller proxies and partners

“National Institutes of Health chief Francis Collins says the brain initiative builds on recent advances in attaching electronic implants to brain cells. That was demonstrated last year in dramatic scenes of fully paralyzed patients manipulating robot arms to sip coffee and grasp rubber balls. And through increased computer power, scientists are now better able to collect data from the 86 billion vastly interconnected cells within the 3-pound human brain.”

USA Today

White House pitches brain mapping project

April 2, 2013, 12:00 PM CESTBy Peter Alexander and Alastair Jamieson, NBC News and Maggie Fox, Senior Writer

President Obama pitched a human brain research initiative on Tuesday that he likened to the Human Genome Project to map all the human DNA, and said it will not only help find cures for diseases such as Alzheimer’s and autism, but create jobs and drive economic growth…

It’s not clear just what the initiative will do. Obama and collins said they’d appointed a “dream team” of experts to lay out the agenda — they should report back before the end of the summer. They are led by neurobiologists Cori Bargmann of Rockefeller University and William Newsome of Stanford University.

The public-private initiative, with money from groups such as the Howard Hughes Medical Institute and Microsoft co-founder Paul Allen’s brain mapping project, aims to find a way to take pictures of the brain in action in real time.

“We want to understand the brain to know how we reason, how we memorize, how we learn, how we move, how our emotions work. These abilities define us, yet we hardly understand any of it,” said Miyoung Chun, vice president of science programs at The Kavli Foundation, which is taking part in the initiative and which funds basic research in neuroscience and physics.

The project has some big money and some big science to build on. Allen pumped another $300 million into his institute’s brain mapping initiative a year ago, and has published freely available maps of the human and mouse brains. The Howard Hughes Medical Institute built a whole research campus devoted to brain science, called Janelia Farm, in Virginia.

Arati Prabhakar, director of the Defense Advanced Research Projects Agency (DARPA) pointed to a project that allowed a quadriplegic woman to control a robot arm with her thoughts alone.

“There is nothing like a project to inspire people to go to that next level,” Collins told a telephone briefing.

Not everybody is happy about a centralized, administration-led project. Michael Eisen, a biologist at the University of California at Berkeley, said earlier this year that grand projects in biology such as Project ENCODE for DNA analysis were emerging as the “greatest threat” to individual discovery-driven science.

“It’s one thing to fund neuroscience, another to have a centralized 10-year project to ‘solve the brain,'” Eisen wrote in a Twitter update in February.

“It’s great to see the president supporting basic neuroscience research. And the amount of money is enough to seed new initiatives, which is the way to start something,” 

Neuroscientist Cori Bargmann of The Rockefeller University in New York, BRAIN co-chair

Who Will Pay for Obama’s Ambitious Brain Project?

By Stephanie Pappas April 02, 2013, Science Direct

An MRI scan reveals the gross anatomical structure of the human brain. (Image credit: Courtesy FONAR Corporation)

The initial funding for a major new brain research initiative will come largely from the National Institutes of Health and the Defense Advanced Research Projects Agency (DARPA), with contributions from the National Science Foundation and private foundations, officials said today (April 2).

After President Obama announced the launch of the BRAIN Initiative this morning, the directors of the National Institutes of Health (NIH) and DARPA took public questions via the Internet about specific plans for the project and who will pay. The agencies expect about $100 million in 2014 to start the initiative.

BRAIN stands for Brain Research through Advancing Innovative Neurotechnologies. In it’s planning stages, the project was called the Brain Activity Map, because the goal is to understand how neural networks function. Currently, researchers can detect the activities of single brain cells; they can also measure brain activity on the macro level using technology such as functional magnetic resonance imaging. But the middle level — the actions of hundreds and thousands of neurons working together in circuits — remains largely mysterious.

“This initiative is an idea whose time has come,” NIH director Francis Collins said in the White House Q&A session. He called the human brain the “greatest scientific frontier you could think of.” [Gallery: Slicing Through the Brain]

Funding the brain map

President Obama announced this morning that the Fiscal Year 2014 budget would include about $100 million in seed funding for the BRAIN Initiative. Collins broke those numbers down: The NIH will provide about $40 million, much of that from the Neuroscience Blueprint, an NIH collaboration with a rolling investment fund for nervous system research. Some NIH discretionary funds will also go toward the project, Collins said.

The National Science Foundation will provide about $20 million in funding, Collins said, and DARPA will contribute about $50 million. Private foundations, including the Howard Hughes Medical Institute, the Salk Institute for Biological Studies and the Kavli Institute, will also provide funds.

DARPA’s interest in the project stems largely from concerns about “wounded warriors,” said director Arati Prabhakar. The agency hopes the BRAIN Initiative will provide answers about how to treat post-traumatic stress disorder, brain injuries and other neurological problems for injured soldiers. The project may also inspire new computing processes as scientists learn how the brain works and use that as inspiration for artificial circuits, Prabhakar said.

Bumps ahead?

Federal funding for research has been flat in recent years, and the federal budget sequester has further squeezed agencies such as the NIH and NSF with 9 percent cuts across the board. The BRAIN Initiative is projected to last more than a decade, with no guarantee the fiscal situation will bounce back. Some neuroscience researchers, including Donald Stein of the Emory School of Medicine, have argued that funding is a “zero-sum game” and that the BRAIN Initiative will take resources from other worthy brain research causes. 

Collins acknowledged the budget challenge.

“One might well ask, ‘Is this the wrong time to be starting something new and innovative?'” he said.

But with the technology needed to measure large neural networks just coming into its own, delaying would be counterproductive, Collins argued.

“If you could see the opportunity for the next big advance … it would be very hard to say we’re going to hunker down for awhile and wait until the budget gets better,” he said.

2019: Around min 11, they present the tech that they hope to develop into a brain recording implant for humans
Magnetic nanoparticles used to make massive advancements in brain imaging.

A $4.5 Billion Price Tag for the BRAIN Initiative?

By Emily Underwood, Jun. 5, 2014 , 6:00 PM, Science Mag

The price of President Barack Obama’s BRAIN may have just skyrocketed. Last year, the White House unveiled a bold project to map the human brain in action, the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, and commanded several federal agencies to quickly develop plans to make it reality. To kick-start the project, the president allocated about $100 million this year to BRAIN, spread over the National Institutes of Health (NIH), the National Science Foundation, and the Defense Advanced Research Projects Agency.

Now, after more than a year of meetings and deliberations, an NIH-convened working group has fleshed out some of the goals and aspirations of BRAIN and tried to offer a more realistic appraisal of the funding needed for the agency’s share of the project: $4.5 billion over the course of a decade.

Neuroscientist Cornelia Bargmann, of Rockefeller University in New York City, who led the working group, sought to put that cost in perspective at a press conference today, saying it amounted to “about one six-pack of beer for each American over the entire 12 years of the program.”

NIH, which provides $40 million of BRAIN’s current funding, doesn’t have a plan in place for where to get extra money called for in the new report, NIH Director Francis Collins told reporters. “It won’t be fast, it won’t be easy, and it won’t be cheap,” he says. Regardless, Collins, who commissioned the new report to guide his agency’s role in the initiative, embraced the plan wholeheartedly:

86 billion neurons take note: I’ve accepted a scientific vision for #BRAINI that will transform neuroscience: http://t.co/12xluad54U #NIH

— Francis S. Collins (@NIHDirector) June 5, 2014

The report lays out a 10- to 12-year plan for investing $300 million to $500 million per year to develop new tools to monitor and map brain activity and structure, beginning in fiscal year 2016. It suggests focusing on tool development for the first 5 to 6 years, then ramping up funding as new techniques come online. A key goal is to produce cheaper, more accessible tools that all researchers can use without needing special training, so that the overall cost of doing neuroscience research goes down over time, Bargmann says.

The panel acknowledges the uncertainty of their cost estimate. “While we did not conduct a detailed cost analysis, we considered the scope of the questions to be addressed by the initiative, and the cost of programs that have developed in related areas over recent years. Thus our budget estimates, while provisional, are informed by the costs of real neuroscience at this technological level,” the group writes.

The first round of requests for NIH grant applications already went out last fall, and awardees will be announced in September, according to Collins. Additional opportunities to apply for NIH funding will open up by fall, based on this new, more detailed report, he says. Researchers planning to apply “may now consider that [the report] is a blueprint of where we want to go,” Collins added.

*Correction, 10 June, 12:17 p.m.: This article has been corrected to reflect that the $4.5 billion proposed price tag for the BRAIN initiative refers only to NIH’s portion of the project, not all funding. – Science Mag.

Advisory Committee to the Director, Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative Working Group

The National Institutes of Health (NIH) convened a BRAIN Working Group of the Advisory Committee to the Director, NIH, to develop a rigorous plan for achieving this scientific vision. This report presents the findings and recommendations of the working group, including the scientific background and rationale for The BRAIN Initiative® as a whole and for each of seven major goals articulated in the report. In addition, we include specific deliverables, timelines, and cost estimates for these goals as requested by the NIH Director. Read more in the BRAIN 2025 Report.

As the NIH BRAIN Initiative rapidly approached its halfway point, the ACD BRAIN Initiative Working Group 2.0 was asked to assess BRAIN’s progress and advances within the context of the original BRAIN 2025 report, identify key opportunities to apply new and emerging tools to revolutionize our understanding of brain circuits, and designate valuable areas of continued technology development. Alongside, the BRAIN Neuroethics Subgroup was tasked with considering the ethical implications of ongoing research and forecasting what the future of BRAIN advancements might entail, crafting a neuroethics “roadmap” for the Initiative. Read more in the BRAIN 2.0 companion reports (BRAIN Initiative 2.0 report and Neuroethics report).

2020, mid-epidemic

Brain-to-brain communication demo receives DARPA funding

JADE BOYD – JANUARY 25, 2021

Wireless linkage of brains may soon go to human testing

Wireless communication directly between brains is one step closer to reality thanks to $8 million in Department of Defense follow-up funding for Rice University neuroengineers.

The Defense Advanced Research Projects Agency (DARPA), which funded the team’s proof-of-principle research toward a wireless brain link in 2018, has asked for a preclinical demonstration of the technology that could set the stage for human tests as early as 2022.

“We started this in a very exploratory phase,” said Rice’s Jacob Robinson, lead investigator on the MOANA Project, which ultimately hopes to create a dual-function, wireless headset capable of both “reading” and “writing” brain activity to help restore lost sensory function, all without the need for surgery.

MOANA, which is short for “magnetic, optical and acoustic neural access,” will use light to decode neural activity in one brain and magnetic fields to encode that activity in another brain, all in less than one-twentieth of a second.

“We spent the last year trying to see if the physics works, if we could actually transmit enough information through a skull to detect and stimulate activity in brain cells grown in a dish,” said Robinson, an associate professor of electrical and computer engineering and core faculty member of the Rice Neuroengineering Initiative.

Jacob Robinson (Photo by Tommy LaVergne/Rice University)

“What we’ve shown is that there is promise,” he said. “With the little bit of light that we are able to collect through the skull, we were able to reconstruct the activity of cells that were grown in the lab. Similarly, we showed we could stimulate lab-grown cells in a very precise way with magnetic fields and magnetic nanoparticles.”

Robinson, who’s orchestrating the efforts of 16 research groups from four states, said the second round of DARPA funding will allow the team to “develop this further into a system and to demonstrate that this system can work in a real brain, beginning with rodents.”

If the demonstrations are successful, he said the team could begin working with human patients within two years.

Ethics in a void of regulation? No probs, we self regulate, we’re used to that, we’re the Government!

“Most immediately, we’re thinking about ways we can help patients who are blind,” Robinson said. “In individuals who have lost the ability to see, scientists have shown that stimulating parts of the brain associated with vision can give those patients a sense of vision, even though their eyes no longer work.”

The MOANA team includes 15 co-investigators from Rice, Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Duke University, Columbia University, the Massachusetts Institute of Technology and Yale’s John B. Pierce Laboratory.

The project is funded through DARPA’s Next-Generation Nonsurgical Neurotechnology (N3) program. – RICE University

The BRAIN Initiative has never been concluded. We’re living it now.

Silview.media

UPDATE JULY 25, 2021

My conclusion above just got fully confirmed a few days ago, more so, BRAIN went woke, if you can imagine that:

Comments turned off on this video LMAO

SPOOKY FIBERS IN MAKS AND TEST SWABS? WAIT ’TIL YOU READ THE SCIENCE!

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We gave up on our profit shares from masks, if you want to help us, please use the donation button!
We think frequent mask use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness.
Get it here!

UPDATE: LATER JOSH ROGIN APPEARANCE ON JOE ROGAN’S PODCAST

Washington Post’s Josh Rogin Calls Out Media for Ignoring Fauci’s Potential Connection to Wuhan Lab

Rudy Takala  April 25, 2021


Washington Post columnist Josh Rogin lamented the media’s refusal to discuss aspects of the Covid-19 pandemic, including Dr. Anthony Fauci’s potential connection to a Wuhan lab, in an interview with Megyn Kelly.

a man wearing a suit and tie: Anthony Fauci Tasos Katopodis/Getty Images© Provided by Mediaite Anthony Fauci Tasos Katopodis/Getty Images

“This body of research, this gain-of-function research, the whole world of virologists … it’s very insular,” Rogin said in an interview on Kelly’s podcast. “I often talk to scientists who say the same thing, who say, ‘Listen, we really want to speak out about this, but we can’t do it.’ Why can’t we do it? Well, We get all of our funding from NIH, or NIAID, which is run by Dr. Fauci. … And so we can’t say anything like ‘Oh, gain-of-function research might be dangerous, or it might have come from a lab, because we’re going to lose our careers, we’re going to lose our funding, we’re not going to be able to do our work.’

“Gain-of-function” research focuses on artificially enhancing the transmissibility of pathogens. In the five years prior to the coronavirus pandemic, that research was spearheaded in China by the Wuhan Institute of Virology. The U.S. National Institute of Allergy and Infectious Diseases, which Fauci has led since 1984, oversees funding for most of the related research in America. The agency falls under the National Institutes of Health, which Rogin referenced.

“The head of the funding, the head of the entire field, really, is Anthony Fauci,” Rogin said. “He’s the godfather of gain-of-function research as we know it. That, what I said right there, is too hot for TV, because people don’t want to think about the fact that our hero of the pandemic … might also have been connected to this research, which might also have been connected to the outbreak.

“The problem is not that they were doing something wrong or illegal,” he noted. “The problem is that nobody knows what this legal stuff was that was going on. And now, all of a sudden, we have to take a look at it.”

Fauci has inspired critics in some quarters for his role in approving a $3.7 million grant to the Wuhan lab in 2015 to engage in related research, which came just a year after the Obama administration issued a moratorium on conducting such research in the U.S.

Rogin claimed in a book published last month that sources informed him China engaged in that research more aggressively than was previously understood, arguing that it contributed to evidence the Covid-19 pandemic stemmed from the lab in Wuhan.

“The Wuhan Institute of Virology had openly participated in gain-of-function research in partnership with U.S. universities and institutions,” Rogin noted in the book. “But [an] official told me the U.S. government had evidence that Chinese labs were performing gain-of-function research on a much larger scale than was publicly disclosed, meaning they were taking more risks in more labs than anyone outside China was aware of. This insight, in turn, fed into the lab-accident hypothesis in a new and troubling way.”

Rogin expanded on that statement in his interview with Kelly, saying, “Dr. Fauci, the hero of the pandemic, might also have had a role in the research that may have caused the pandemic.”

“People can’t get it through their heads, but that’s the reality,” he added, before lamenting that the topic was largely absent from public dialogue. “We don’t have a media environment where we can have that kind of discussion.”

Listen above via The Megyn Kelly Show.
The post Washington Post’s Josh Rogin Calls Out Media for Ignoring Fauci’s Potential Connection to Wuhan Lab first appeared on Mediaite, but we picked it up from Microsoft News.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them